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Thesis overview 
 
The concept that gut derived factors can influence pancreatic secretions was known 
for more than 100 years. These factors later named as “incretins” were only 
discovered many decades later. Glucose Dependent Insulinotropic Polypeptide 
(GIP) previously known as gastric inhibitory peptide was the first incretin hormone 
to be identified in the early 1970’s followed by glucagon like peptide-1(GLP-1) in 
the late 1980’s. Both these hormones are potent stimulators of insulin secretion after 
nutrient ingestion and regulate postprandial glucose metabolism. It was nearly 20 
years later, that the first incretin based drug in the form of GLP-1 receptor agonist 
was used in the treatment of type 2 diabetes mellitus (T2DM). In contrast, GIP could 
not be used as a therapeutic agent due to its inability to secrete insulin in individuals 
with T2DM.  
 
For many years, the significance of GIP was overshadowed by the expansion in 
physiological actions and therapeutics of GLP-1. Emerging evidence in the recent 
years suggest that GIP has biological actions in multiple peripheral tissues and a 
prominent role in promoting fat deposition in adipose tissue. GIP appears to be a 
hormone of evolutionary importance which facilitates energy storage by fat 
deposition into adipose tissue from the nutrition derived through dietary sources. 
However, in the current times of over-nutrition, this physiological action of GIP 
may have become a maladaptive response leading to undesired fat storage. 
Interestingly, GIP also appears to have beneficial effects in other tissues such as 
improving cognitive function in the brain and in prevention of bone resorption. 
Understanding various physiological actions of GIP would help to explore its 
biological significance beyond the insulinotropic action in the pancreas. 
 
Obesity is a major risk factor for type 2 diabetes (T2DM). In the current era of the 
obesity pandemic and the alarming rise in the prevalence of T2DM, evidence 
accumulating on the pro-adipogenic properties of GIP opens a new therapeutic 
avenue in the treatment of obesity and obesity related diabetes. Nevertheless, it is 
vital to understand the effects of GIP on various tissues and its significance in 
humans before envisaging any therapeutic role. 
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The focus of my research is to understand the biological actions of GIP in adipose 
tissue metabolism in humans and to study if these effects differed in healthy subjects 
and in individuals with obesity and type 2 diabetes mellitus (T2DM). In my first 
study, we conducted experiments to evaluate the effects of acute GIP infusions on 
insulin secretion and adipose tissue metabolism in normoglycaemic men (lean and 
obese) and in obese individuals with impaired glucose regulation and T2DM. I was 
also interested in understanding the effects of commonly used hypoglycaemic agents 
in T2DM on the incretin system.  Hence, we studied the effects of metformin 
treatment (most commonly used drug in T2DM) on the incretin system in my second 
research study described in this thesis.  
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Abstract 
The role of Glucose dependent Insulinotropic Polypeptide (GIP) and 
other gut hormones in glucose regulation and adipose tissue metabolism 
in obesity and type 2 diabetes 
 
Aims and hypothesis: Beyond the insulinotropic effects, glucose-dependent 
insulinotropic polypeptide (GIP) may regulate post-prandial lipid metabolism by 
promoting fat deposition and inflammation in adipose tissue after high fat diets. We 
hypothesised that GIP would have an anabolic action in subcutaneous adipose tissue 
(SAT) promoting non-esterified fatty acid (NEFA) re-esterification. We speculated 
these effects may be mediated by changes to the expression of key lipid metabolism 
enzymes and that GIP may promote inflammation by affecting the expression of key 
adipokines in SAT. We postulated that these effects may be different according to 
obesity status or glucose tolerance. Incretins and other gut hormones are affected by 
medications used in the treatment of T2DM. We hypothesised that metformin, a 
commonly used drug in T2DM, may influence the secretion of incretin and other gut 
hormones which may contribute to its pleotropic effects in glucose metabolism. 
Subjects/Methods: We recruited 31 participants, for 2 different studies. In the first 
study, 23 men in four categories, normoglycaemic lean (n=6), normoglycaemic 
obese, (n=6), obese with impaired glucose regulation (IGR) (n=6) and obese, T2DM 
(n=5) participated in a double-blind, randomised, crossover study involving a 
hyperglycaemic clamp with a 4-hour infusion of GIP or placebo (normal saline). 
Serum insulin, plasma NEFA concentrations, SAT triacylglycerol (TAG) content 
and gene expression of key lipid metabolism enzymes, lipoprotein lipase (LPL), 
adipose tissue triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) and 
adipokine gene expression (TNF-α, MCP-1, osteopontin and adiponectin) in SAT 
were determined before and after the GIP/placebo infusions.  
In the second study, eight subjects (6 male and 2 female) were studied on two 
occasions for 6 hours following a standard mixed meal, before and after metformin 
monotherapy for at least 3 months. Blood samples were taken in the fasted state and 
at multiple time points after the mixed meal for measuring incretin hormone, 
glucagon like peptide (GLP-1), ghrelin (appetite regulatory gut hormone) and 
dipeptidyl peptidase –IV (DPP-IV) activity.   
Results: Study-1 The insulinotropic effect of GIP vs. placebo was greater in lean, 
obese and obese IGR groups with no significant effect in obese T2DM. In contrast, 
GIP lowered NEFA concentrations in obese T2DM concomitantly increasing the 
SAT-TAG content. Such effects were not observed in other groups. There was no 
change in gene expression of LPL, ATGL and HSL with GIP or placebo infusions. 
The gene expression of TNF-α was significantly higher in obese T2DM group and 
the expression of MCP-1 was higher in lean and obese subjects.  
Study-2 Metformin monotherapy in obese patients with T2DM was associated with 
significantly increased postprandial active GLP-1 concentrations. 
Conclusion: In T2DM, although the insulinotropic effect of GIP is impaired, the 
ability of GIP to promote fat storage seems intact lowering NEFA concentrations 
and increasing SAT lipid deposition which may further exacerbate obesity and 
insulin resistance. Oral hypoglycaemic agent metformin influences the incretin 
system by increasing GLP-1 concentrations and this may represent another 
important mechanism of its glucose-lowering effect. 
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1.1 Historical aspects of incretin hormones                                        
	
Incretin hormones are gut derived peptides secreted by the intestinal mucosa in 
response to nutrient ingestion. These hormones stimulate insulin release from the 
endocrine pancreas and reduce blood glucose levels. The possible role of gut derived 
factors on the secretion of pancreatic juice was first described in 19021. It was first 
reported in 1906 that treating patients with diabetes mellitus with the extracts of 
duodenal mucous membrane resolved glycosuria2. These factors were initially 
named “secretins”. Later in 1929, Zunz and LaBarre purified these glucose lowering 
factors from gut extracts and  named them as “incretins,” a term coined  to indicate 
their origin and function (INtestinal seCRETion INsulin)3. The introduction of 
radioimmunoassay for measurement of insulin in the 1960’s improved the 
understanding of communication between the intestine and the endocrine pancreas 
on insulin secretion4. The term “entero-insular axis” coined by Unger and Eisentraut 
in 1969 defines the concept of gut hormones influencing the islets of Langerhans to 
secrete insulin and glucagon5. An interesting observation to support this concept was 
that the oral administration of glucose was associated with much greater increase in 
plasma insulin compared to the intravenous route for the same level of plasma 
glucose concentration6,7. This phenomenon was later known as the “incretin effect” 
(Figure 1.1) which is defined as the difference in b-cell insulin secretory response to 
oral glucose load versus intravenous glucose stimuli8-10. 
	
In search of novel gastrointestinal hormones in the late 1960s, Brown and Pederson 
observed a crude preparation of porcine cholecystokinin to inhibit stomach acid 
secretion in dogs and later named it as “Gastric Inhibitory Peptide” (GIP)11,12. 
Discovery of GIP relates to period between 1969 to 197113. The amino acid 
sequence of GIP was first reported in 197114. In the later years, highly purified 
preparations of GIP administered in physiological doses along with intravenous 
glucose resulted in significant increases in insulin secretion and improvement in 
glucose tolerance15. Inhibition of gastric acid was only seen at pharmacological 
doses of GIP but insulin secretory action occurred at physiological concentrations. 
Thus, GIP was renamed as “Glucose-dependent Insulinotropic Polypeptide”, 
retaining its acronym and was the first incretin hormone to be identified16.  
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The incretin effect however could not be fully explained by the action of GIP alone. 
Immuno-neutralisation of GIP in a study did not eliminate the incretin effect. 
Surgical resection of the ileum was associated with reduced incretin effect despite 
preserved GIP levels which suggested the presence of another incretin hormone 
secreted from the lower gastro intestinal tract17.  Another important observation was 
that the intravenous administration of GIP and glucose produced only 40% of the 
insulin response that occurred after oral glucose administration, strengthening the 
concept of additional insulinotropic factors being released with nutrient ingestion18. 
Subsequently a second incretin hormone was identified as a potent stimulator of 
insulin secretion and named as glucagon like peptide -1 (GLP-1) due to its structural 
similarities with glucagon19,20. GIP is secreted from the K cells of duodenum and 
proximal jejunum whereas GLP-1 is secreted from the L cells of the distal ileum. 
Both the incretin hormones are secreted in response to nutrient ingestion and 
potentiate glucose induced insulin secretion playing an essential role in glucose 
homeostasis. In addition to insulin secretory action, both these hormones are thought 
to play an essential role in enhancing insulin biosynthesis, beta cell proliferation and 
reducing beta cell apoptosis21. 
 
1.2 Incretin hormones and diabetes mellitus 
 
1.2.1 Type 2 Diabetes mellitus (T2DM) 
Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycaemia 
with disturbances of carbohydrate, fat and protein metabolism resulting from defects 
in insulin secretion, insulin action or both22. Chronic uncontrolled hyperglycaemia 
leads to cardiovascular complications and death. The prevalence of diabetes is 
rapidly rising; a recent report from the World Health Organization (WHO) indicates 
the current prevalence to be 8.5 % in the adult population and this has doubled since 
1980 (4.7%). This is expected to rise to 9.9% by 2030 which is predominantly due 
to increasing number of patients with type 2 diabetes (T2DM)23. WHO estimated 
that 422 million people in the world were living with diabetes in 2014 compared to 
180 million people in 198024. The majority of these people (> 80%) have type 2 
diabetes (previously known as non-insulin dependent diabetes). 
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Type 1 diabetes (previously known as insulin dependent diabetes) results purely 
from deficient insulin production. The exact causes of type 1 diabetes (T1DM) are 
not completely understood and this condition is not preventable. Pathogenesis of 
T2DM involves interplay of genetic and metabolic elements. It results from the 
inability of the individual to effectively use insulin and is associated with defects in 
insulin secretion from the endocrine pancreas. T2DM is strongly associated with 
risk factors such as obesity, insulin resistance and ethnicity, family history of 
diabetes, older age group, poor dietary habits and inactive life style. This condition 
is preventable and reversible by modifying the risk factors. Although insulin 
resistance and pancreatic beta cell dysfunction are the key pathogenic elements, 
significantly diminished incretin effect also contributes to the impaired postprandial 
glucose homeostasis in T2DM25. 
 
1.2.2 Incretin concentrations in T2DM 
In healthy individuals, the incretin effect from the two incretin hormones (GLP-1 
and GIP) is thought to contribute to 50- 70% of postprandial insulin response10. 
Whereas in individuals with type 2 diabetes the incretin effect is significantly 
reduced (Figure 1.1) and may only contribute to < 20% of post prandial insulin 
secretion9. Postprandial concentrations of incretin hormones are an important 
determinant of the incretin effect. The concentrations of GLP-1 were reported to be 
consistently reduced in T2DM in most studies26-29. In contrast to GLP-1, many 
studies reported higher or unchanged postprandial GIP concentrations in T2DM29-32. 
A meta-analysis concluded that GIP secretion in response to oral glucose and meal 
tests is persevered in T2DM and also suggested higher BMI to be associated with 
higher GIP levels but people in older age groups and those with higher glycated 
hemoglobin (HbA1c) had reduced GIP secretion33.   
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Figure 1.1 Comparison of incretin effect (vertical arrow) in healthy subjects and patients with type 2 diabetes mellitus (T2DM) 
Figure re-drawn with data taken from Nauck M et al. Diabetologia 1986 9
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1.2.3 Incretin based therapies in type 2 diabetes (T2DM)  
T2DM is a progressive disease, intensification of glycemic control with insulin and 
most hypoglycemic agents causes weight gain as evident in some of the major 
studies like UKPDS, ACCORD and DCCT34-36. It is also important to recognise that 
patients with diabetes may be on other drugs for various co-morbidities that can also 
induce weight gain. Physiological changes during treatment account for lower 
protein catabolism, decreased calories excreted in urine and reduced energy 
expenditure to compensate for weight loss37. Obesity and progressive weight gain 
are therefore the major hurdles in optimising therapy and controlling cardiovascular 
risk factors in T2DM. Therefore, pharmacotherapy to improve glycaemic control 
which is either weight neutral or assists with weight reduction is more beneficial in 
treating an obese patient with T2DM.  
 
Advent of incretin based therapies is a breakthrough in the pharmacotherapeutics of 
T2DM. The first one of this class is a GLP-1receptor agonist. These agents enhance 
the incretin effect in T2DM, improve glycaemic control and have also thought to 
have beneficial effects on preserving b cell function.  Additionally, the weight loss 
induced by GLP-1 receptor agonists (described later in this section) has positioned 
them distinctly in the treatment of obese patient with T2DM. Details of these 
therapeutic agents are described below.  
 
GLP-1 receptor agonists (GLP-1RAs) 
GLP-1 although reduced in T2DM, retains its insulinotropic activity when given 
exogenously38-40. Pharmacological substitution of GLP-1 in the treatment of T2DM 
is therefore a logical therapeutic approach. Stable (GLP-1RAs) have been developed 
in the last decade which are now available as self-administered subcutaneous 
injections. The first GLP-1RA to be used is exenatide (twice daily injection) 
followed by commonly used once daily preparations in the UK such as liraglutide 
and lixisenatide. Longer acting preparations of exenatide and semaglutide are now 
available in the U.K that can be given once a week. All GLP-1R agonists are widely 
in use and proved to be effective in the treatment of T2DM associated with 
obesity41.   
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In addition to the glucose lowering properties, GLP-1 receptor agonists (GLP-1RAs) 
induce weight loss which  is thought to be due to multiple mechanisms involving  
reduced calorie intake, delayed gastric emptying and increased satiety levels by 
centrally mediated mechanisms through neuronal transmission at hypothalamic 
regions that regulate food intake42. GLP-1R agonists remain at the forefront of 
T2DM and cardiovascular research. Previous clinical trials of GLP-1R agonists had 
indicated no increased cardiovascular risk in long term use but now there is clear 
evidence of cardiovascular benefit with liraglutide43 and semaglutide44 . 
 
DPP-IV inhibitors 
Both GLP-1 and GIP are rapidly degraded by the enzyme Dipeptidyl peptidase-IV 
(DPP-IV) expressed in multiple tissues including intestines, kidneys and liver45. 
Stable inhibitors of this enzyme were developed more than 10 years ago and have 
been in therapeutic use around the same time as GLP-1RAs. These agents decrease 
serum DPP-IV activity by more than 80% with some degree of inhibition sustained 
for 24 hours making them suitable for once daily treatment dose46. Several DPP-IV 
inhibitors are now widely used in the treatment of type 2 diabetes (sitagliptin, 
vildagliptin saxagliptin, linagliptin and alogliptin). These drugs are safe and 
effective as monotherapy or as an add on therapy to other commonly used drugs 
such as metformin and sulphonylureas47,48.  
 
GIP agonists 
GIP, although the first incretin to be identified, could not be used as a therapeutic 
agent as its incretin activity is blunted in T2DM and even exogenous infusion of 
GIP does not have insulinotropic activity38. In contrast to GLP-1 levels, GIP 
concentrations are normal or increased in patients with T2DM. The mechanisms 
behind the loss of insulinotropic activity of GIP in patients with T2DM remain 
unclear and therefore a major obstacle for its therapeutic use. Potent GIP agonists 
were developed by amino acid modifications to GIP molecule49-51.  However, 
unfavourable pharmacokinetics and rapid degradation of GIP by dipeptidyl-
peptidase-IV (DPP- IV) were potential limitations for development of a stable 
agonist52. Longer-acting N terminal modified GIP agonists that are DPP IV resistant 
have also been developed53,54. Truncated GIP analogues D-Ala(2)-GIP(1-30) and  
(D-GIP(1-30)) were shown to improve glucose tolerance and insulin secretion in 
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diabetic Zuker fatty rats55. Although these GIP agonists have shown glucose 
lowering effects in mice they have not been tested in humans. GIP antagonists have 
also been developed and these are discussed sections 1.4.   
 
1.3 The link between obesity and type 2 diabetes mellitus 
 
Obesity is a major risk factor for type 2 diabetes; the alarming increase in the global 
incidence of type 2 diabetes parallels the rise in obesity and strong epidemiological 
and pathophysiological evidence support a causal link. The national statistics for 
obesity in England suggest that approximately 25% of the adult population in 
England are obese. The prevalence of diabetes in the UK is estimated to be 4.5% of 
which T2DM constitutes about 90% of cases. More than 80% of patients with type 2 
diabetes are either obese or overweight at the time of diagnosis56. The risk of 
developing diabetes substantially increases even with modest weight gain during 
adulthood57. Insulin resistance is an important precursor to T2DM, visceral and liver 
adiposity strongly correlate with insulin resistance independent of subcutaneous 
fat58,59.  
 
Subcutaneous and visceral fat are a major source of plasma non-esterified fatty acids 
(NEFA) and chronic elevations of NEFAs interfere with insulin signalling, 
inhibiting glucose uptake and glycogen synthesis60,61. Recent research suggests that 
adipose tissue is an endocrine organ that secretes several adipokines (for example 
leptin, adiponectin, resistin) and pro-inflammatory cytokines (for example TNF-α 
and IL-6) that may modify insulin resistance. Prolonged exposure to these 
inflammatory agents and excess NEFAs from excess visceral and ectopic fat 
interferes with insulin signalling in skeletal muscle and liver62. Management of 
obesity is therefore the crucial step in reducing the global impact of T2DM. 
Sustained weight reduction through diet and life style alone is a major challenge for 
most patients. It is a continuous combat against strong human instinct and 
exceptionally efficient mechanisms of energy homeostasis to retain body weight. 
Treatment therefore requires a multidisciplinary approach with lifestyle intervention, 
behaviour modification and pharmacotherapy. 
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1.4 Pharmacotherapy targeting specific pathways in obesity 
 
Although weight loss through non-pharmacological approaches is more desirable, it 
may not be achieved in many patients as body weight tends to reach a plateau and 
weight regain is common. Pharmacotherapy is therefore an important adjunct to 
lifestyle modification before considering bariatric surgery which is usually a last 
resort in many cases.  The rapidly growing prevalence of obesity has led to several 
drugs being developed but the history of pharmacotherapy has undergone a 
troublesome phase with failures and withdrawals of weight loss drugs due to their 
side effects. An example to this is the suspension of sibutramine (a centrally acting 
agent) in January 2010. This was based on evidence suggestive of increased risk of 
non-fatal heart attacks and strokes in older patients with diabetes and pre-existing 
cardiovascular disease (a contraindication to the use of sibutramine) in a 
cardiovascular outcomes trial63.  Prior to this was the withdrawal of rimonabant in 
October 2008 due to increased incidence of depression. This cannabinoid receptor 
antagonist was shown to reduce weight and improve glucose regulation64.  
 
Currently there are very few potent therapeutic agents for weight loss and their use 
is very much limited by side-effects. Pharmacological intervention through gut 
hormones has opened a new avenue in the treatment of obesity with a GLP-1RA 
now approved as a potent weight loss medication. Several new and combination of 
old agents are currently being researched as anti- obesity drugs. Pharmacotherapy 
targeting specific pathways in obesity are described below.  
 
1.4.1 Targeting gut hormones  
GLP-RA. GLP-1 receptor agonists (GLP-1RAs) used predominantly for glycaemic 
control in T2DM have additional benefits of weight reduction as described in the 
previous section. Liraglutide, a (GLP-1 RA) marketed as Saxenda given at a higher 
dose of 3mg (compared to 1.8mg in T2DM) was approved as an anti-obesity drug by 
FDA and European Medicines agency (EMA) in March 2015 for the treatment of 
obesity. In the SCALE study (Satiety and Clinical Adiposity Liraglutide Evidence in 
Non-diabetic and diabetic people), a randomised control trial with 3 mg liraglutide, 
63% of patients in the liraglutide group lost at least 5% of their body weight 
 27 
compared to placebo group and 33% had lost more than 10% body weight compared 
to 10.6% with placebo65. These results are very encouraging for future use of 
liraglutide in the UK as an anti-obesity drug. 
 
GIP antagonists Modification to amino acids and truncations in the GIP molecule 
has led to development of several GIP antagonists66-69 but none of these were shown 
to act effectively in human physiological conditions. Recent studies showed that the 
most potent GIP antagonists were GIP(3–30)NH2 and GIP(5–30)NH2 which were 
developed by truncating amino acids at N-terminal of GIP and excluding                   
C-terminal70. Previously developed (Pro3) GIP as an antagonist in mice71 was 
shown to have agonist properties in human GIPR72. The effects of GIP antagonist in 
prevention of diet induced obesity and improved insulin sensitivity in animal models 
is discussed in detail in section 1.10. 
Ghrelin antagonists Ghrelin is a potent appetite regulatory hormone. It is 
synthesised and secreted by gastric oxyntic cells of the gastric fundus and plays an 
important role in the hypothalamic regulation of energy homeostasis73-75. Ghrelin 
also previously known as ‘hunger hormone’ demonstrates circadian variation with 
meal times76. Ghrelin acts by binding to the receptor known as “Growth Hormone 
Secretagogue Receptor–1a (GHSR-1a) making this a potential target for 
therapeutics. Desensitisation and down regulation of this receptor have been 
considered for appetite modulation therapies however, heterogeneity of GHSR-1a 
and blood brain barrier are a limitation to development of drugs. Synthetic ghrelin 
ligands and centrally penetrant GHSR-1a antagonists are currently being researched 
in animal models77. 
 
Other gut hormones Stable analogues of other gut hormones such as amylin, 
pancreatic peptide YY (PYY), cholecystokinin-I, pancreatic polypeptide, 
oxyntomodulin are being researched as potential therapeutic agents78. Pramlintide 
(amylin analogue) is available in the United States for treatment of diabetes79. A 
combination of pramlintide and metreleptin (leptin analogue) as a weight loss 
medication is in development80. PYY analogue (PYY3-36) was also shown to 
reduce weight in animal studies81,82.  
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1.4.2 Targeting fat absorption in the gut 
Orlistat is a potent inhibitor of pancreatic and other intestinal lipases such as gastric 
lipase and carboxyl ester lipase. It acts by inhibiting the absorption of dietary of 
triacylglycerols (30%) Orlistat marketed as Xenical is the only drug commonly used 
in the UK for the treatment of obesity. Studies have shown 3 to 6% of initial body 
weight reduction and 37% relative risk reduction for development of T2DM in 
patients with impaired glucose tolerance83,84. Compliance with this drug is poor in 
patients and particularly so when not adhering to a strict fat free diet due to gastro-
intestinal side effects.  Because of fat excretion, commonly experienced side effects 
are abdominal bloating, flatus with discharge, steatorrhea and faecal urgency.  
 
1.4.3 Targeting appetite regulation  
Some of these drugs act by increasing satiety, reduction in food consumption and 
stimulating energy expenditure. Mysimba, Locaserin, Qsymia and liraglutide 
(Saxenda) are the new anti-obesity drugs approved by US Food and Drug 
Administration (FDA) but these are not currently marketed in the UK85. Mysimba is 
a combination of Naltraxone (opioid antagonist) and bupropion (dopamine and 
noradrenaline re-uptake inhibitor) that targets appetite regulatory centres in the 
brain. Lorcaserin is a selective 5-HT2C receptor (serotonin) agonist which activates 
pro-opiomelanocortin production to increase satiety. Qsymia is a combination of 
topiramate and phentermine which acts as an appetite suppressant by stimulating 
synaptic noradrenaline dopamine and serotonin release. These drugs are effective in 
achieving at least 5% of weight loss86. 
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1.5 Link between GIP and adiposity 
  
The evidence to suggest a link between GIP and adiposity although existed for many 
years appears to have gained importance in the last decade. Animal studies have 
shown GIP receptor mediated effects to be the key link in the consumption of high 
fat energy rich diet and development of obesity and insulin resistance.  Several 
important findings support the concept of GIP as a pro-adiposity hormone87. 
Ingestion of food with high fat content is the most potent stimulator of GIP secretion 
in humans88. A high fat diet has been shown to induce K cell hyperplasia and 
increase GIP gene expression89. Raised concentrations of GIP were observed in 
mice with hyperinsulinaemia and metabolic abnormalities of the obesity-
diabetes syndromes90. At the adipocyte level GIP was shown to significantly 
enhance lipoprotein lipase (LPL) activity supporting its role in clearance of 
triglyceride rich lipo-proteins and chylomicrons from the circulation and assisting in 
lipid storage91. The presence of functional GIP receptors on adipocytes also suggests 
that it has an important role in lipid metabolism92. GIP could therefore play a key 
role in diet induced obesity. It is now well recognised that obesity is a major risk 
factor for insulin resistance and T2DM. Higher GIP concentrations in patients with 
T2DM may further worsen obesity and insulin resistance because of high fat diet 
leading to a vicious cycle. 
 
It is crucial to understand the effects of GIP on various tissues in humans before 
envisaging its therapeutic role. Very few studies so far have investigated the in-vivo 
effects of GIP on human adipose tissue. The focus of our research is the effects of 
GIP on non-esterified fatty acid (NEFA) incorporation in the human subcutaneous 
adipose tissue metabolism and inflammation in adipose tissue. In the coming 
sections, I have discussed the structure and biological actions of GIP and elaborated 
on its role in lipid metabolism. 
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1.6 Glucose dependent Insulinotropic Polypeptide (GIP)  
 
1.6.1 Structure and biosynthesis  
Bioactive human GIP is a 42-amino acid peptide. It is derived through a post-
translational cleavage of a larger 153 amino acid proGIP protein precursor. ProGIP 
consists of three main domains of which the middle one corresponds to active GIP 
with NH2 and COOH terminals on either side (Figure 1.2).  Prohormone convertase 
1/3 (PC1/3) is essential for cleavage of active GIP from its pro GIP precursor.93 
Human gene for encoding GIP sequences is present in the long arm of chromosome 
19. GIP in humans, mouse, rat, and porcine and bovine species exhibit more than 
90% amino-acid sequence identity21. The N terminus is crucial for binding to GIP 
receptor and GIP agonist activity. The C terminus has little impact on binding of 
GIP to receptor and may have some intrinsic agonistic properties. However, absence 
of C terminus with preserved N terminus creates a naturally occurring potent GIP 
antagonist70. 
 
 
 
 
Figure 1.2: Bioactive GIP with 42 amino acid structure is derived from cleavage of 
its precursor proGIP mediated by enzyme prohormone convertase 1/3 (PC 1/3). 
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1.6.2 Secretion and metabolism  
GIP is synthesized and secreted from enteroendocrine K cells primarily located in 
the duodenum and proximal jejunum, whereas GLP-1 is secreted from L cell located 
predominantly in the terminal ileum (Figure 1.3A).  GIP mRNA has also been 
detected in the a cells of human islets and both a and b cells of mice islets94,95. The 
role of GIP synthesis in islets is not clearly understood. GIP secretion increases after 
nutrient ingestion and the major stimulus for GIP secretion is fat and carbohydrate 
reaching the duodenum88,96-98. The rate of absorption and content of nutrition 
regulates GIP secretion and this appears to differ between species as fat is the most 
potent stimulator of GIP secretion in humans compared to carbohydrates in rodents 
and pigs99. The mechanisms of fat induced GIP secretion is thought to involve a 
transcription regulatory factor X6(Rfx6) which is solely expressed in K cells. 
Expression of Rfx6 was increased in K cells of high fat fed mice and knock down of 
Rfx6 reduced mRNA of GIP suggesting an important role for this transcription 
factor in GIP hypersecretion with high fat diet100.  
 
Both the incretin hormones (GIP and GLP-1) are actively degraded by the enzyme 
dipeptidyl peptidase IV (DPP-IV), a serine protease enzyme that is responsible for 
N-terminal cleavage and inactivation of the endogenous incretin hormones. DPP-IV 
is expressed in multiple organs such as kidney, lung, adrenal gland, liver, intestine, 
spleen, pancreas and central nervous system. DPP-IV cleaves the first two              
N-terminal amino acids (Tyr1-Ala2) of GIP, resulting in the truncated metabolite 
GIP(3-42). Most radio-immunoassays measure the total GIP plasma concentrations 
which include the active component intact GIP(1-42) and the non-insulinotropic    
N-terminally truncated metabolites. Newer assays specific to the N-terminus 
measure only the biologically active intact GIP101. In healthy individuals, basal 
concentration of total GIP is ~10pmol/l reaching concentrations of 70-150 pmol/l 
between 30-60 minutes after meal ingestion depending on meal size. The plasma 
concentration of intact GIP is much lower ~30 pmol/l after a meal as shown in a 
study with a meal containing 250Kcal (55% carbohydrate, 30% fat and 15% 
protein)102 (Figure 1.3B). The half-life of GIP is approximately 7 minutes in healthy 
and 5 minutes in subjects with T2DM101GIP clearance is predominantly through the 
kidneys and increased levels of GIP may be seen in patients with renal failure. 
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GIP secretion 
 
 
                        
     
          
 
Figure 1.3: A Site of gut hormone secretion from gastro-intestinal tract and insulin and 
glucagon secretion from endocrine pancreas. B Graph showing concentrations of total GIP 
versus the active component intact GIP in a study with healthy volunteers after ingestion of 
a mixed meal102. 
 
Ghrelin 
Insulin	&	
glucagon 
GIP 
GLP-
1
A	
B	
 33 
1.6.3 GIP receptor biology 
The metabolic effects of GIP are mediated by binding to its specific plasma 
membrane receptor. GIP receptor was first cloned in rats 1993103 and subsequently 
in hamsters104 and humans105. Human GIPR gene is localised to chromosome 19106. 
GIP receptor (GIPR) is a member of the secretin-vasoactive intestinal polypeptide 
family of G-protein-coupled receptors. GIPR has a large  N terminal with  sequence 
for N-glycosylation and C-terminal which is abundant in threonine and serine for 
phosphorylation sites107. 
 
Like all the G protein coupled receptors, GIPR shares a common molecular structure 
with seven transmembrane helices and a common signalling mechanisms through   
G- protein dependent pathways. The N terminus of GIP binds to a specific site in the 
transmembrane helices of GIPR108.  The specific amino acid domains involved in 
ligand binding site and in interaction pathways between GIPR and G-protein have 
been identified109. GIP hormone binds to GIPR and triggers cyclic AMP mediated 
by G protein complex and subsequent signalling cascades leads to increase in 
intracellular calcium and insulin release which is described in detail in section 1.6. 
 
GIPR mRNA is widely expressed in the pancreas, gut, adipose tissue, heart, 
pituitary, and inner layers of the adrenal cortex.  It is also present in the cerebral 
cortex, hippocampus, and olfactory bulb, but not found in kidney, spleen, or liver.  
Such extensive expression suggests that GIP may have multiple unidentified actions 
in different organs. Importantly, the presence of functional GIP receptors in 
adipocytes lays emphasis on the role of GIP in adipocyte metabolism. GIPR was in 
was first identified in 1998 in rat adipocytes and differentiated mouse 3T3 cell107. 
Ten years later it was demonstrated that GIPR is also expressed in well 
differentiated human adipocytes but not in pre-adipocytes. This indicates the GIPR 
expression increases as the adipocytes mature and begin to accumulate in lipid 
droplets favouring the concept of GIP induced lipid accumulation related to over 
nutrition110. GIPR expression is reduced in mice and humans with diabetes which 
may explain the lack of insulinotropic activity for GIP in T2DM111,112. 
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1.7 Biological actions of GIP 
 
1.7.1 Insulinotropic effects on β cells of pancreas 
GIP as an incretin hormone has a primary physiological role in glucose dependent 
insulin secretion. GIP is also known to enhance  β cell insulin gene transcription and 
insulin biosynthesis, increase  β cell proliferation and reduce apoptosis21. Both GIP 
and GLP-1 share the same signalling pathways. Binding of GIP to GIPR on 
pancreatic β cell increases in intracellular cyclic AMP mediated by G-protein 
complex leading to activation of protein kinase A and inactivation of voltage-
dependent potassium channel (Kv) which are ATP sensitive and also known as KATP 
channels113. These mechanisms are tightly linked to glucose and amino acid influx 
into cells that leads to ATP generation which inactivate Kv channels causing 
potassium efflux out of the β cell. This causes membrane depolarisation on 
pancreatic β cell which activates the voltage gated calcium channels (VGCC) which 
subsequently leads to calcium influx followed by release of insulin granules25. The 
cascade of events leading to insulin secretion is shown in Figure 1.4.  
 
Complex signalling pathways of insulin secretion by GIP have been unravelled in 
recent years. GIP is also shown to independently regulate the voltage-dependent 
potassium (Kv) channels on the cell surface expression which is an important step in 
insulin release pathway114. Activation of protein kinase A (PKA) and exchange 
protein directly mediated by cyclic adenosine monophosphate (EPAC2) were shown 
to play a key  role in GIP signalling and post-translational modification of Kv 
channels that contributes to β cell survival115. Inhibition of β-cell apoptosis by GIP 
is mediated through pathways involving Akt-dependent inhibition of apoptosis 
signal-regulating kinase-1, that antagonises the pro-apoptotic actions of p38 mitogen 
activated protein kinase (MAPK) and Jun N-terminal kinase (JNK)116. Studies have 
also shown that GIP inhibits apoptosis signal-regulating kinase1 (ASK1) causing 
reduction in mitochondria-induced apoptosis in β-cells through protein kinase B 
(PKB)-mediated pathways117. Additionally, GIP has effects on a cells by increasing 
glucagon secretion during fasting and hypoglycaemic conditions but not during 
hyperglycaemia118,119. 
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Insulin secretion pathway for GIP and GLP-1  
in β cells of pancreas 
 
 
 
 
 
 
 
Figure: 1.4 Schematic presentation on insulin secretion pathway for both incretin 
hormones (GIP and GLP-1) in the pancreatic β cell involving cAMP, and protein 
kinase A (PKA). Please see content in text for details on insulin secretion pathway.                              
Figure taken with permission from Meier JJ, Nauck MA, Diabetes 201025 
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1.7.2 Effects on the central nervous system 
GIPR is expressed in several regions of the brain and GIP was demonstrated in adult 
rat hippocampus120. Distinct GIP immunoreactivity was also seen in the cerebral 
cortex, amygdala, substantia nigra, lateral septal nucleus and in several nuclei in the 
thalamus, hypothalamus and brainstem. The exact mechanism of GIP action in the 
brain is yet unclear  however the neuronal distribution of GIP may suggest its role in 
neural progenitor cell proliferation and as a neuromodulator121. There is now new 
evidence in animal studies that chronic treatment with stable GIP analogues may be 
neuroprotective. Chronic treatment with the GIP analogue, D-Ala2-GIP-glu-PAL in 
mice was shown to prevent dopaminergic neuronal loss in the substantia nigra pars 
compacta and inhibit the MTPT induced parkinsonism like motor disorders122,123. 
Protease resistant long acting GIP analogues showed protective effects in animal 
models of Parkinson’s and Alzheimer’s disease124. Studies using a dual GLP-1 and 
GIP antagonist treatments were shown to protect against neurodegeneration125,126.  
 
1.7.3 Effects on bone and other tissues 
GIP has biological actions in multiple peripheral tissues (Figure 1.5) GIP mRNA is 
expressed in normal bone and GIP receptors are present in osteoblasts. GIPR is 
expressed in osteoblasts and osteoclasts127-129. GIP treatment increased lysyl oxidase 
activities, collagen maturity and enzymatic collagen cross linking through cAMP 
dependent pathways leading to intra-cellular calcium influx129,130. GIP is thought to 
stimulate osteoblastic activity and increase new bone formation128. GIP was also 
found to inhibit osteoclast function and therefore reduced bone resorption129,131. 
GIPR expression was also seen in bone marrow stromal cells (BMSCs) in mice and 
this expression decreased in an age-dependent manner. Stimulation of BMSCs with 
GIP increased osteoblastic differentiation suggesting a role of GIP in prevention of 
age related bone loss132. GIP may have protective effects in bone by preventing 
apoptosis in human bone marrow derived mesenchymal stem cells and osteoblastic 
cells133. GIPR was also shown to be expressed in adrenal cortex and vascular 
endothelium, where GIP induced glucocorticoid secretion in rats134 and increased 
intracellular calcium influx in endothelium21. The effects of GIP in these tissues 
remain to be further elucidated.         
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Biological actions of GIP 
 
 
 
 
 
 
 
 
Figure 1.5 Biological actions of GIP on various tissues including pancreas, bone, 
brain, adipose tissue and blood vessels.  
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1.7.4 Effects of GIP on appetite and energy expenditure 
The effects of GIP on energy expenditure was studied by Miyawaki et al.135 using 
GIPR knockout (Gipr–/–) mice. In addition to the lack of weight gain in Gipr–/– mice 
with high fat feed, the oxygen consumption had increased and respiratory quotient 
decreased compared to WT mice, suggesting increased energy expenditure in Gipr–/– 
mice135. This occurred predominantly in the light phase when mice had low 
spontaneous motor activity indicating that energy expenditure was in the basal state. 
There was no significant difference in the dark phase (increased motor activity) in 
both groups. These experiments suggest inhibition or lack of GIPR prevents fat 
accumulation and promotes basal energy expenditure perhaps using fat as the 
preferred source of energy. A previous study from our research unit investigated the 
role of GIP in energy expenditure, appetite and energy intake in healthy subjects and 
those with obesity and T2DM136. Energy expenditure (EE) was measured throughout 
the experiment with indirect calorimetry and subjects were given a series of visual 
analogue scales to rate hourly their hunger, fullness, urge to eat and prospective 
consumption of food. During GIP infusion (at 2 pmol/kg/min for 4 hours) there was 
a trend for healthy subjects to report higher hunger scores and a reduction in their 
EE was recorded when compared with placebo. These parameters remained 
unchanged in patients with T2DM. 
 
1.7.5 Effects on adipose tissue 
The insulinotropic actions of GIP have been well characterised, but its effects on 
lipid metabolism and adipose tissue had received far less attention previously. 
Identification of functional GIP receptors in animal and human adipocytes 92,110 
along with emerging data from studies in animal models and in cultured human 
adipocytes strongly support a physiological role for GIP in the adipose tissue 
metabolism in response to chronic exposure to nutritional excess. Several 
observations demonstrate that GIP exerts physiologically relevant actions critical not 
only for glucose but also lipid metabolism and enhance our understanding of the role 
of GIP receptor signalling in energy homeostasis. In the sections below, I have 
discussed in detail the role of GIP relevant to adipose tissue metabolism and its role 
in lipogenesis and lipolysis. 
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1.8 Adipose tissue metabolism in humans 
 
Adipose tissue has an important role in energy balance. High calorie food intake and 
reduced physical activity leads to excess energy storage in the form of 
triacylglycerols (also referred as triglycerides) within the adipocytes. During times 
of energy demand (starvation, exercise and physical stress), triacylglycerols within 
the adipose tissue are broken down into glycerol and non-esterified fatty acids 
(NEFAs) to meet the energy requirements. The process of fat storage and 
mobilisation into the circulation is regulated by hormones such as insulin, 
catecholamines, growth hormone and glucocorticoids137. The balance between 
energy storage and breakdown usually exists during eu-caloric states, but is 
dysregulated in hyper-caloric states with reduced energy expenditure which in the 
long term leads to adiposity.  
 
1.8.1 Lipid storage in adipose tissue (Lipogenesis) 
Human adipocytes unlike liver cells have reduced capacity for de novo 
lipogenesis138,139. Triglyceride rich lipoproteins and chylomicrons from the 
circulation are hydrolysed into NEFA by the enzyme lipoprotein lipase (LPL) in the 
adipose tissue capillary endothelium. A large proportion of these NEFAs are taken 
up by the adipocyte and re-esterified into glycerol 3 phosphates (triacylglycerols). 
Insulin enhances the activity of LPL and the process of esterification140-142. 
Triacylglycerols are stored as lipid droplets coated with a protective layer of protein 
known as perilipin within the adipocyte (Figure 1.6). Although triacylglycerol 
deposition in the adipose tissue is largely mediated by LPL, the process can still 
occur to a certain extent in the absence of LPL and this was shown to be through 
upregulation of de novo fatty acid synthesis in mice143. 
 
Lipoprotein lipase (LPL) 
LPL is a member of the triglyceride lipase protein family and it is the major enzyme 
responsible for triacylglycerol hydrolysis. It is synthesised in the adipose tissue, 
cardiac muscle, skeletal muscle, islets and macrophages and transported to the 
luminal surface of the vascular endothelium. It is bound to the endothelial wall by 
ion interaction with heparin sulphate proteoglycans (HSPG) and glycosyl-
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phosphatidylinositol and is displaced from these sites by heparin. Several factors 
including the position of LPL on the endothelial lumen, apolipoprotein composition 
of the particles and the size of the lipoproteins influence the hydrolytic action of 
LPL144. It is a multifunctional enzyme and in the absence of hydrolysis it anchors 
lipoproteins to the vessel wall and assists the uptake into the cells. Apart from 
hydrolysis, LPL mediates the conversion of very low density lipoproteins (VLDL) 
into intermediate density lipoproteins (IDL) and contributes to the transfer of surface 
lipid to high density lipoprotein (HDL) after lipolysis145.  
 
Adipose tissue LPL activity is enhanced by nutrient ingestion and insulin which 
increases fatty acid uptake and esterification by adipose tissue. This subsequently 
leads to fat accretion within the adipose tissue146,147. However, in skeletal muscle 
insulin does not stimulate LPL activity. The LPL hydrolysis products, NEFAs and 
monoacylglycerols are taken up differentially in adipose tissue and muscle. They are 
stored as cholesteryl esters in cardiac and skeletal muscle or oxidised to meet the 
energy requirements. NEFAs meet >70% of the cardiac energy demands145. Growth 
hormone, testosterone and oestrogen inhibit LPL activity in adipose tissue leading to 
fat mobilisation but enhance its activity in heart and skeletal muscle148. 
 
1.8.2 Adipose tissue lipolysis 
Triacylglycerols in the adipose tissue are composed of 3 fatty acids bound to a 
glycerol molecule and these are broken down in a stepwise manner during high 
energy requirement states. Majority of lipolysis in adipose tissue is mediated by the 
enzymes hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL)149. 
For the conversion of triacylglycerol (TAG) to diacylglycerol (DAG), the first step 
is largely mediated by ATGL and to a lesser extent by HSL which is thought to be 
the rate limiting step in lipolysis. The chief function of HSL is to convert 
diacylglycerol (DAG) to monoacylglycerol (MAG). Monoaclyglycerol lipase further 
converts MAG into NEFAs when released into circulation are utilised during high 
energy demands (Figure 1.6 and 1.7).  
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Lipogenesis and lipolysis pathways in adipose tissue 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 A schematic diagram showing lipogenesis pathway in the left half and 
lipolysis pathway in the right half of the figure with various enzymes and hormones 
involved in lipid metabolism. Please refer to text for more details on the pathways.  
Figure re-drawn inspired from Frayn K et al. IJO 2003137.  
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Hormone sensitive lipase (HSL) 
HSL is an intracellular neutral lipase with isoforms expressed predominantly in 
adipose tissue and other cholesterol storing tissues such as testes, ovaries and 
adrenal cortex. It plays an important role in metabolism of cholesterol esters and 
steroidogenesis150. As the name implies, HSL is regulated by hormones such as 
catecholamines and insulin. In adipose tissue, catecholamines stimulate lipolysis 
through β adrenergic pathways by activating cyclic adenosine monophosphate 
(cAMP) and protein kinase A (PKA) which results in phosphorylation of HSL and 
perilipin (protective layer of lipid droplet). Phosphorylation is a key step in lipolysis 
which enables translocation of HSL from adipocyte cytoplasm to the surface of lipid 
droplet to initiate its lipase activity137. Lipolysis is modulated by several hormones. 
Acute increases in catecholamines, natriuretic peptides, growth hormone and 
cortisol (stress response hormones) enhance lipolytic activity whereas insulin 
inhibits lipolysis. The effects of chronic exposure to glucocorticoids, although  
unclear may have anti-lipolytic effects and increase lipid accumulation in adipose 
tissue151. 
 
Resistance to catecholamine-induced lipolysis in subcutaneous adipose tissue has 
been demonstrated in obese adults and children152,153 and has been attributed to 
alterations and impaired expression of lipolytic b2- and anti-lipolytic a2-
adrenoceptors154,155 along with decreased expression of HSL156.  The existence of a 
positive relationship between lipolytic activity in human fat cells and HSL 
expression157 and the presence of decreased expression of HSL in obese first-degree 
relatives of normal weight subjects158 underscore the importance of this HSL 
defect159. Moreover, from comparison of obese and non-obese subjects it has been 
demonstrated that the obese phenotype in humans is associated with a decreased 
HSL expression in mature fat cells and in differentiated pre-adipocytes159 and a 
decreased catecholamine-induced lipolysis, supporting a possible role of a low HSL 
as a primary defect in obesity. 
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Adipose tissue triglyceride lipase (ATGL) 
Until recently, HSL was the only enzyme known to play a key role in lipolysis. 
However, diacylglycerols (DAGs) were shown to accumulate in the adipose tissue 
of HSL knock-out mice suggesting the first step in TAG hydrolysis to DAG was 
predominantly mediated by another enzyme identified later and named as ATGL160. 
ATGL belongs to a gene family characterised by presence of patatin, a protein found 
abundantly in potato tuber. This enzyme has nearly 10-fold higher affinity for TAG 
than DAG and selectively hydrolyses TAGs.  Unlike HSL, ATGL it is not under 
hormonal control and is not activated by PKA mediated phosphorylation. Its  
activity may be regulated by a protein known as  comparative gene identification -58 
(CGI-58)149. Phosphorylation of perilipin is thought to be associated with release of 
CGI-58  which increases the lipolytic activity of ATGL161.  
 
 
 
 
 
 
 
Figure 1.7.  Enzymes mediating lipolysis pathway in adipose tissue.  
                     Figure adapted from Peckett A.J et al 2011  
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1.9 Role of GIP in adipose tissue metabolism 
 
GIP secretion from the K-cells of the duodenum and proximal jejunum is stimulated 
by glucose, fat and amino acids162,163. Amongst the various stimuli, fat ingestion was 
shown to be the most potent stimulator of GIP secretion97,99. Falko et.al showed that 
ingestion of emulsified corn oil in healthy humans significantly increased 
endogenous GIP secretion from baseline fasting level by 30 minutes compared to 
placebo88. Diurnal variation of endogenous GIP concentration in healthy humans 
was shown to parallel serum triacylglycerol concentrations for most of the day 
suggesting its role in metabolism of ingested fat164. GIP is proposed to modulate 
other adipose tissue depots, and that excessive GIP secretion may underlie excessive 
visceral and liver fat deposition165,166.  A cross sectional study with large number of 
Danish subjects (ADDITION-PRO study) suggested that higher fasting GIP levels 
were associated with better low density plasma lipoprotein clearance but an 
unhealthy fat distribution independent of insulin. This effect on obesity varied 
between men and women167.  
 
GIP concentrations increased significantly in plasma and intestines of obese 
hyperglycaemic mice after eight weeks of high fat diet compared to high 
carbohydrate diet. The density of GIP secreting K cells although increased on both 
diets was higher in high fat fed mice indicating chronic fat consumption can cause 
hyperplasia of intestinal K cells89. Similar findings on K cell hyperplasia were 
observed in another study on Wistar rats after 60 days of high fat diet168. Although 
several studies demonstrated increased GIP concentrations after fat ingestion and 
speculated its role in lipid metabolism, it was unclear as to how GIP exerted its 
metabolic effects on adipose tissue. Identification of functional GIP receptors 
(GIPR) on rat adipocytes and mouse 3T3 cells in the late 1990s improved the 
understanding that  GIP had a direct metabolic effect on adipose tissue through its 
own receptor92. Later it was shown that functional expression of GIPR in human 
adipocytes was seen in differentiated adipocytes but not in pre-adipocytes. GIPR 
expression increased as the differentiating adipocytes start to accumulate in lipid 
droplets, a process of lipid storage from nutrition110 supporting the role of GIP in 
obesity related to over-nutrition. 
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1.9.1 Effects of GIP on Lipoprotein Lipase (LPL) 
Insulin regulates the activity of LPL a key enzyme in hydrolysis of triacylglycerols 
that facilitates lipid storage in adipocytes169. A similar regulatory role of GIP on 
LPL was investigated by incubating cultured pre-adipocytes with GIP for 2 hours 
and the release of LPL and total activity were measured.  GIP in pre-cultured 
adipocytes was shown to enhance LPL activity significantly supporting its role in 
clearance of triglyceride rich proteins and chylomicrons from the circulation and 
assisting in lipid storage91. Furthermore, GIP was shown to have a direct influence 
on LPL activity in explants of rat epididymal adipose tissue and when combined 
with insulin the LPL activity is significantly greater than either hormone alone 
suggesting GIP compliments insulin in enhancing triacylglycerol clearance. Similar 
effects were not observed with the other incretin hormone  GLP-1170. In another 
study GIP was shown to enhance LPL activity in 3T3-L1 cells in a dose dependent 
manner135. The effects of GIP on LPL and other enzymes in different studies are 
shown in Table 1.1. 
 
The mechanism through which GIP stimulates LPL has been identified recently and 
the signal transduction pathway involves many serine/threonine protein kinases. GIP 
increases phosphorylation of protein kinase B (PKB) and decreases the 
phosphorylation of LKB1 and AMP-activated protein kinase (AMPK) that leads to 
activation of LPL and triacylglycerol accumulation in the adipocytes171. The 
lipogenic effects of GIP, in the presence of insulin was shown to be  partially 
mediated by up-regulation of adipocyte LPL gene transcription172. A study in lean 
and obese women with a carbohydrate meal alone or combined with intravenous 
infusion of octreotide to supress insulin did not show any change in LPL activity in 
both groups whilst insulin, GIP and GLP-1 were reduced in the group who were 
given octreotide infusion indicating that the effects GIP are only evident when 
combined with insulin173. 
 
1.9.2 Effects of GIP on other enzymes involved in lipolysis 
The evidence on the effects of GIP on other enzymes is very limited. GIP may 
increase lipolysis along with induction of inflammatory adipokines174-176.  These 
lipolytic effects of GIP may be enhanced with insulin deficiency177. GIP induced 
lipolysis in the absence of insulin was shown to be through phosphorylation of HSL 
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and this process was inhibited by insulin175. In another study GIP was shown to 
reduce glucagon stimulated lipolysis15. The effects of GIP on lipolytic enzymes HSL 
and ATGL are less well studied and therefore the role on adipose tissue lipolysis 
remains unclear. One study investigated the acute effects of GIP infusion on basal 
lipolysis and lipolytic enzymes in humans178. In this study, healthy obese men were 
administered GIP (2pmol/kg/min) or normal saline in a randomised manner for 240 
minutes and subcutaneous fat biopsies were taken before and after the infusion. 
NEFAs were significantly reduced in the circulation in a time dependent manner 
after GIP compared to saline infusion. GIP was shown to reduce mRNA expression 
and enzyme activity of 11β hydroxysteroid dehydrogenase type-1(11β HSD-1) an 
enzyme that converts inactive cortisone to active cortisone. Additionally, GIP was 
shown to reduce the activity of both HSL and ATGL. The experiments were 
conducted in a euglycaemic fasting state and therefore findings may differ in 
hyperglycaemic or postprandial states. Hence these effects may be better studied 
under hyperglycaemic clamp conditions. 
 
The above described study is the only human study to have evaluated the in-vivo 
effects of GIP on lipid metabolism enzymes178. In-vitro experiments by the same 
group using 3T3-L1 differentiated cells showed that GIP reduced activity and 
expression of 11β- HSD1 and lowered the expression of ATGL and HSL. This led 
the authors to speculate that GIP-induced effects on lipid metabolism are due to the 
alteration in active cortisol content within the adipose tissue which is regulated by 
the enzyme 11β-HSD1178. In contrary 11βHSD1 gene knock out mice on high fat 
feed were shown to have improved glucose tolerance, reduced weight and adiposity 
179. Another study showed that selective 11βHSD1 inhibitors reduced insulin 
resistance and lowered blood glucose levels in mouse models of T2DM180,181. It is 
therefore unclear at this stage weather a reduction or enhancement of 11β-HSD1 is 
likely to increase fat accumulation in the adipose tissue and the long-term changes in 
the metabolic parameters. 
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Table 1.1 Effects of GIP on enzymes involved in lipid metabolism 
 
Author, year Experimental 
subjects 
 
Methods Effects of GIP on lipid 
metabolism enzymes 
Eckel RH  
et al.197991 
cultured pre-
adipocytes 
Cultured pre-adipocytes 
were incubated for 2 hours 
with GIP 
­LPL activity 
Knapper JM   
et al. 1995170 
Explanted rat 
epididymal adipose 
tissue 
Explants incubated in the 
presence of both insulin (0.5 
nmol) and GIP (4 nmol/L)  
 
­LPL activity with each 
hormone 
­­ LPL with 
combination of both 
hormones 
Ranganath LR 
et al. 1999173 
Women, lean (n=6) 
and obese (n=6)  
340 kcal of carbohydrate 
alone or combined with IV 
infusion of octreotide to 
inhibit insulin 
¯ Insulin, GIP and 
GLP-1 concentrations 
No change in LPL 
activity in both groups 
Miyawaki et al. 
2002135 
 
3T3-L1 adipocytes  Cells incubated with GIP ­LPL activity in dose 
dependent manner 
Kim S.J et al. 
2007182 
VDF rats 
Differentiated 3T3-
L1 adipocytes 
Human adipocytes 
(subcutaneous) 
GIP infusions in VDF rats 
and epididymal fat were 
harvested. 
Adipocytes incubated with 
GIP and insulin  
­LPL activity 
­ TAG accumulation 
PKB pathway 
 
 
Kim S.J et al. 
2010 172 
Cell cultures from 
human adipocytes 
Overnight treatment with 
GIP in the presence of 
insulin 
Aimed for underlying 
mechanism of LPL 
activation by GIP 
­LPL gene expression 
­LPL activity through 
CREB and TORC  
No such effects were 
seen with GLP-1 
Szalowska E   
et al. 2011183 
Mice on high fat 
diet 
2 weeks of stable GIP 
analogue D-Ala (2)-GIP 
¯ LPL activity 
¯ body weight 
 
Gogebakan et al.  
2012178 
Healthy obese men  
(n=11) 
and 3T3-L1 
differentiated cells 
Euglycaemic fasting state. 
GIP (2pmol/kg/min) or 
normal saline (240 min) 
subcutaneous fat biopsies 
pre-and post-infusion 
¯ expression and 
enzyme activity of        
11β HSD1 
¯ ATGL and HSL 
Timper K et al. 
2013175  
human adipocytes 
(subcutaneous) 
Investigated GIP induced 
inflammation and lipolysis 
with and without insulin 
­ lipolysis with GIP in 
absence of insulin 
through 
phosphorylation of HSL 
Kim S.J   et al. 
2013184 
 
Adipocytes isolated 
from resistin 
knockout mice 
Cells treated with GIP and 
insulin 
­LPL activity 
Mediated by resistin 
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1.9.3 Effects of GIP on NEFA metabolism in adipose tissue  
GIP secreted after fat ingestion under normoglycaemic conditions is not 
insulinotropic. However, under normal physiological conditions where nutrient 
composition is a mixture of carbohydrate, fat and protein, GIP is secreted along with 
insulin. As insulin is the main hormone that regulates incorporation of NEFA into 
adipose tissue, presence of both these hormones at the same time causes difficulty in 
assessing the independent action of GIP on NEFA incorporation. Earlier studies in 
dogs with intravenous porcine GIP infusions showed increased clearance of plasma 
chylomicron triacylglycerols185. Beck et al. studied the influence of GIP on NEFA 
incorporation in rat epididymal fat pads in the presence or absence of insulin. 
Without insulin in the incubation medium NEFA incorporation was significantly 
lower compared to when both are present in the incubation medium suggesting that 
presence of insulin is necessary for GIP to exert its effects186. In another study, 
exogenous GIP infusions in rats during intra-duodenal infusion of a lipid meal 
showed a significant decrease in plasma triacylglycerol levels. The effect of 
endogenous GIP was assessed by neutralising with antiserum to GIP as rats pre-
treated with antiserum had significantly elevated plasma triacylglycerol levels after 
a fat meal suggesting an important role of GIP in clearance of triacylglycerols from 
the circulation by incorporating them into adipose tissue187. The studies showing the 
effects of GIP on NEFA and triacylglycerols are listed in Table 1.2. 
 
All in-vitro studies have shown that adipocytes incubated with combination of GIP 
and insulin had significantly increased NEFA incorporation. As the major 
physiological role of GIP was thought to be to enhance insulin secretion one could 
imply that GIP merely enhances NEFA incorporation through hyperinsulinaemia 
and does not have a direct role. However, the experiments form Miyawaki et al. with 
leptin gene mutant obese mice (Lepob/Lepob) has improved the understanding of this 
concept. Lepob/Lepob mice develop marked obesity due to hyperphagia and have 
gross hyperinsulinaemia. Double homozygous Lepob/Lepob and GIP receptor 
knockout mice (Gipr–/–) were shown to have 23% reduced body weight compared to 
Lepob/Lepob   alone mice at 35 weeks of age. Both these groups had similar level of 
hyperinsulinaemia suggesting that GIP action is not solely mediated through insulin 
and it has direct influence on adipose tissue deposition leading to obesity135. 
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Most of the studies using animal models have shown that GIP along with insulin 
plays an important role in regulation of LPL, enhances triacylglycerol clearance 
from circulation and promote fatty acid incorporation into adipose tissue. However, 
in humans, these metabolic effects of GIP are less well studied. Asmar et al. studied 
the effects of GIP on plasma concentrations of TAG and NEFAs in humans188. In 
this study, healthy human male subjects were given 20% intra-lipid (chylomicron 
like emulsion) through intravenous route over 1 hour and GIP (1.5 pmols/kg/min) or 
normal saline as a continuous infusion for a period of 300 minutes. The same 
experiments were repeated with glucose (25 g) infused over 30 minutes to mimic 
postprandial glucose excursions. There was no significant difference in TAG 
clearance in all the experiments with intra-lipid (IL) infusions. NEFA concentrations 
after IL infusion were lower with GIP compared to normal saline. In the 
experiments with co-infusion of IL+ glucose + GIP/saline, NEFA concentrations 
were significantly reduced compared to IL+GIP/saline. Insulin secretion due to 
glucose infusion was shown to be the most important factor in lowering NEFAs. 
Such reductions in NEFAs were also seen in the absence of GIP and therefore these 
results would suggest that GIP promotes NEFA re-esterification only through 
insulin stimulation and may not have a direct and independent effect.  
 
1.9.4 Effects of GIP on human adipose tissue blood flow  
Adipose tissue blood flow (ATBF) varies significantly during different 
physiological states (e.g. feeding, fasting and exercise). An increase in blood flow is 
an important marker of tissue metabolic activity 137. A study by Asmar et al. 
assessed abdominal subcutaneous adipose tissue activity in healthy lean subjects by 
measuring ATBF during GIP (1.5 pmoles/kg/min) or saline infusion under 
hyperinsulinaemic hyperglycaemic (HI-HG) clamp conditions for 5 hours189. Results 
from this study showed that GIP in combination with hyperglycaemia and 
hyperinsulinaemia increased ATBF significantly compared to saline under the same 
HI-HG clamp conditions (Figure 1.7.). Reduction in NEFA in circulation was 
similar in absence of GIP under hyperglycaemic clamp conditions. Within the 
adipose tissue, TAG hydrolysis, glucose uptake was higher and NEFA output was 
lower with GIP compared to placebo under same HI-HG clamp conditions. Authors 
concluded that GIP increased ATBF and TAG hydrolysis resulting in reduced output 
of NEFAs into circulation and therefore increased re-esterification of NEFA in 
 50 
adipose tissue. The insulin independent effects of GIP were difficult to tease out 
from these experiments but a recently published study by the same group with 
similar experiments and octreotide induced insulin inhibition showed that the effects 
of GIP may be insulin independent190. The same research group conducted similar 
experiments of GIP infusion in obese and impaired glucose tolerant subjects and did 
not  find an increase in ATBF or TAG deposition in adipose tissue compared to lean 
individuals191. Subsequent experiments showed this phenomenon was reversed in 
the same individuals when repeated after a programmed weight loss192. The effects 
of GIP on human adipose tissue metabolism do not appear to be the same in healthy, 
obese and diabetes states. 
 
1.9.5 Effects of GIP on glucose incorporation into adipose tissue  
Glucose incorporation into adipose tissue (GAIT) is the other major aspect of 
adipocyte metabolism influenced by insulin. The role of GIP in GAIT is 
controversial. Beck et al. reported that GIP enhanced insulin mediated fatty acid 
incorporation in to adipose tissue in dose dependent manner but had no additional 
effect on insulin stimulated GAIT except for very high doses193. These results 
suggest that GIP mainly enhances NEFA transport but not glucose across the 
adipocyte membrane under physiological conditions. Miyawaki et al. studied GIP 
dependent response of glucose uptake (2-deoxy-D-glucose) in 3T3-L1 adipocytes in 
the presence or absence of insulin. GIP was shown to stimulate 2-deoxy-D-glucose 
uptake in a dose dependent manner in the presence of 1nM insulin but no significant 
changes were observed in the absence of insulin135. Another study suggested an 
alternative direct action of GIP on Akt (a serine/threonine protein kinase) and 
glucose transporter-4 that play an important role in glucose metabolism. GIP was 
also shown to activate Akt in a dose dependent manner, increase glucose 
transporter-4 accumulation and promote glucose uptake into adipocytes194. A recent 
study suggested that GIP increased sensitivity of adipocytes to insulin through a 
novel signalling pathway without having insulin mimetic activities195. 
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Table 1.2 Effects of GIP on NEFA and plasma triacylglycerols  
	
Author, year Experimental 
subjects 
Methods Effects of GIP 
Wasada T et al. 
1981185 
Dogs Infusion of porcine GIP or saline  ¯ chylomicron 
triacylglycerols in 
circulation 
Beck B et al.  
1983186 
Rat epididymal 
fat pads 
Incubation of adipocytes with GIP ± 
insulin 
¯plasma NEFA  
­incorporation with 
GIP + insulin 
compared to GIP 
alone   
Ebert et al. 
1999187 
Rats Intra-duodenal infusion of lipid meal 
+ GIP infusions 
¯ plasma 
triacylglycerol level 
Asmar et al.  
2010196 
Healthy men 
(n=10) 
20% intra-lipid intravenously + GIP 
or normal saline  
 
20% intra-lipid +25g glucose + GIP 
or saline intravenously 
¯ NEFA with GIP 
compared to saline  
 
¯¯ NEFA 
Asmar et al.   
 2010189 
 
Healthy men 
(n=8) 
GIP (1.5pmols/kg/min) versus saline 
infusion with hyperinsulinaemic 
hyperglycaemic clamp for 5 hours 
¯ plasma NEFA  
­ Adipose tissue 
blood flow 
­ NEFA 
esterification with 
GIP infusion 
 
Gogebakan et al.  
2012178 
Healthy  
obese men 
(n=11) 
and  
3T3-L1 cells 
GIP (2pmol/kg/min) or normal saline 
(240 min) subcutaneous fat biopsies 
pre and post infusion during 
Euglycaemic fasting state 
 
¯ plasma NEFA  
 
Asmar et al. 
2016192 
Obese men, 
before and after 
weight loss 
(n=5) 
GIP (1.5pmols/kg/min) versus saline 
infusion with hyperinsulinaemic 
hyperglycaemic clamp 
After weight loss: 
¯plasma NEFA and 
glycerol 
­ Adipose tissue 
blood flow 
 
Asmar et al. 
2016190 
Healthy men 
(n=6) 
GIP (1.5pmols/kg/min) versus saline 
infusion with different types of 
euglycaemic and  
hyperglycaemic clamps 
 
Octreotide to inhibit insulin 
¯plasma NEFA and 
glycerol 
­ Adipose tissue 
blood flow 
Independent to 
insulin effect 
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1.10   Role of GIP in adipose tissue inflammation 
 
1.10.1 Adipokines in inflammation and insulin resistance 
Adipose tissue is an endocrine organ that secretes a variety of cytokines commonly 
referred to as adipokines or adipo-cytokines. These hormones act locally through 
their receptors as autocrine and paracrine factors rather than remotely acting 
endocrine factors197. Adipose tissue is a dynamic contributor to energy balance and 
glucose homeostasis198. Obesity is a state of low grade inflammation and the 
interaction between various adipokines and changes in balance between pro and 
anti-inflammatory adipokines is likely to contribute to the development of type 2 
diabetes199. Leptin was the first adipocyte derived hormone to be identified. Several 
other adipocyte-derived factors identified in the subsequent years include  
interleukin-6 (IL-6), tumour necrosis factor α (TNFα), adiponectin, and resistin137. 
More recently identified adipokines like omentin, visfatin and osteopontin also 
appear to have important roles in inflammation. There are many adipokines involved 
in adipose tissue inflammation but I have limited my discussion to only those 
adipokines which may be influenced by GIP. Various studies showing the effects of 
GIP on adipokines are listed in Table 1.3.  
 
1.10.2 Effects of GIP on adipokine expression 
Leptin and adiponectin 
Leptin is the best studied adipocyte hormone and established to have a regulatory 
role in food intake, energy balance and body weight200-202. Animals and humans 
with defects in leptin secretion or leptin receptors are obese. Leptin acts centrally on 
the hypothalamus to suppress food intake and increase energy expenditure. It has 
peripheral actions on glucose homeostasis through enhanced NEFA oxidation and 
increases insulin sensitivity in muscle and reduces intra-myocellular lipid content. 
Leptin inhibits hepatic triacylglycerol accumulation and improves insulin sensitivity 
in the liver198.  Leptin therapy promotes satiety and causes weight reduction in obese 
children with congenital leptin deficiency and improves insulin resistance in 
lipodystrophy. Its therapeutic use in obesity is limited by severe leptin resistance and 
existing high levels of endogenous leptin in obese subjects203. Randomised 
controlled trials with recombinant leptin injections have shown very limited efficacy 
in subjects with obesity and type 2 diabetes204,205. There are no studies evaluating 
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the direct effects of GIP on leptin gene expression. Leptin gene mutant obese mice 
(Lepob/Lepob) develop marked obesity due to hyperphagia and have gross 
hyperinsulinaemia.  Miyawaki et al  showed that double homozygous Lepob/Lepob 
and GIP receptor knockout mice  (Gipr–/–) were shown to have 23% reduced body 
weight compared to Lepob/Lepob alone mice at 35 weeks of age135. These 
experiments showed that GIP inhibition reduced body weight even in leptin 
deficient obese mice suggesting a role for factors other than leptin. 
 
Adiponectin was identified independently  by four groups and was given different 
names (Arcp30, AdipoQ, apM1, and GBP28)206.  Adiponectin is secreted 
exclusively from adipocytes and has multi-mer forms in the circulation (trimer, 
hexamer and a 12-18mer high molecular weight form). High concentrations of 
adiponectin are found in plasma and levels correlate inversely with body mass. High 
molecular weight adiponectin positively correlates with insulin sensitivity. Two 
forms of adiponectin receptors have been identified (AdipoR1 and AdipoR2). The 
interaction between adiponectin and its receptor are mediated through adenosine 
monophosphate activated protein kinase (AMPk), peroxisome proliferator-activator 
receptor alpha (PPARα) and P38 mitogen activated protein kinase (P 38 MAPK)207. 
High levels of adiponectin are thought to preserve β cell mass by inhibiting 
apoptosis and increasing β cell proliferation199. A study in mice evaluating the 
effects of GIP inhibition on adiponectin levels showed that fat oxidation, 
adiponectin expression in adipose tissue and adiponectin levels in circulation were 
significantly increased after 3 weeks of high fat feed in Gipr–/– mice208, suggesting a 
role of GIP in suppressing adiponectin. 
 
Increased adiponectin levels are considered to be protective against atherosclerosis 
and low levels are associated with development of coronary artery disease and type 
2 diabetes209,210. The other adipokines identified recently that have a protective role 
are omentin and visfatin. Similar to adiponectin, omentin levels are low in people 
with obesity, insulin resistance and higher levels are thought to be protective against 
metabolic syndrome209,211. Visfatin is thought to enhance insulin secretion and 
preserve  β cell function199. 
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TNFα and Interleukin 6 (IL6) 
TNFα is a pro-inflammatory cytokine present in high levels in obesity and insulin 
resistant states. It is thought to induce insulin resistance in obesity through multiple 
mechanisms that involve altered regulation of NEFA, Glut-4 proteins and defects in 
insulin receptor signalling212,213. It is also known to have an immune mediated role 
in β cell failure in type 1 diabetes199. TNFα suppresses adiponectin and induces 
several pro-inflammatory cytokines (MCP-1, PAI-1) and IL-6. TNFα reduces NEFA 
uptake by adipocytes through inhibition of LPL expression and activity214.  
 
IL-6 is structurally related to leptin, expressed in multiple tissues and has tissue 
specific function. Adipose tissue has higher concentrations of IL-6 compared to 
TNFα215,216. IL-6 worsens insulin resistance in adipose tissue and liver while 
improving insulin sensitivity in the muscle. IL-6 has similar effects to TNFα in 
suppressing adiponectin, visfatin and induces other pro-inflammatory cytokines. It is 
also thought to increase basal lipolysis in adipocytes197. Additionally, IL-6 appears 
to have anti-inflammatory effects on islet cells and enhances glucose stimulated 
insulin secretion217-219. 
 
One study showed that human subcutaneous pre-adipocytes treated with GIP 
induced mRNA expression of IL-6, IL-1β, and the IL-1 receptor antagonist (IL-
1Ra), but not TNFα expression. GIP induced IL-6 and IL-1Ra secretion was 
enhanced in the presence of lipopolysaccharides (LPS), IL-1β, and TNFα. Cytokine 
induction by GIP involved PKA and nuclear factor κB (NF-κB) pathways175. GIP 
was also shown to induce lipolysis by activating hormone-sensitive lipase involving 
similar pathways. Lipolysis releases NEFAs that are re-esterified in the presence of 
GIP and this vicious cycle of lipolysis and pro-inflammatory adipokine expression 
may contribute to insulin resistance in adipose tissue. Currently there is insufficient 
evidence in humans to suggest that GIP has any effect on secretion of TNFα or IL-6. 
In a previous study from our research unit, acute GIP infusions in obese individuals 
with type 2 diabetes did not have an effect on circulating adipokine levels, however 
IL-6 was suppressed with acute infusion of GLP-1220. 
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MCP-1 
Monocyte Chemoattractant Protein-1 (MCP-1) is an extensively studied chemokine. 
MCP-1 is a key regulator chemokine involved in migration and infiltration of 
monocytes and macrophages221. There are a number of studies that investigated its 
role in the aetiologies of obesity- and diabetes-related diseases222. Gene expression 
and plasma concentrations of MCP-1 are higher in obese adults221,223,224.   MCP-1 in 
circulation is higher in patients with type 2 diabetes225,226 and higher concentrations 
of MCP-1 are correlated with increased risk of cardiovascular disease and diabetic 
complications 222,227,228. These correlations are stronger in obese patients with T2DM 
than lean patients229. Intraperitoneal injections in mice increase MCP-1 and IL-6 
expression in adipose tissue. The only human study published recently also showed 
increase in MCP-1 and MCP-2 expression and increased plasma MCP-1 with GIP 
infusion230. 
 
Osteopontin 
Osteopontin (OPN) is another important pro-inflammatory cytokine expressed in 
adipocytes and other cells like osteoclasts, smooth muscle cells and hepatocytes. It 
is thought to increase macrophage accumulation that causes inflammation and leads 
to insulin resistance231. OPN is classified as a T helper-1 cytokine that exacerbates 
numerous chronic inflammatory conditions including cardiovascular disease and 
atherosclerosis232. Expression of OPN is higher in obesity and obesity related 
diabetes compared to lean individuals233,234. Studies in mice have shown that 
inhibiting OPN action through antibody neutralisation and OPN knockout protected 
against insulin resistance and hepatic steatosis despite high fat diet234,235. 
 
GIP was shown to enhance OPN expression in primary rodent adipocytes236. Similar 
effects of GIP on OPN expression was observed in human adipocytes. Experiments 
on adipocytes from humans with a genetic variant of GIPR with diminished 
function, showed reduced OPN levels and improved  insulin sensitivity237.  Given 
the pro-inflammatory effects of OPN in adipocytes, an enhanced expression by GIP 
may exacerbate insulin resistance in adipocytes. Increased OPN expression by GIP 
was also observed in pancreatic β cells although this function appears to be 
protective in preservation of  pancreatic β cell mass238. 
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Resistin 
Resistin belongs to cysteine rich resistin like molecules (RELMs). It was discovered 
as a product of mouse adipocytes that was suppressed by thiazolidinediones (anti-
diabetic drugs that activate PPAR γ) and proposed to induce insulin resistance in 
adipocytes239. In rodent models, resistin was shown to downregulate insulin receptor 
expression, induce insulin resistance in pancreatic islets and reduce glucose 
stimulated insulin secretion240,241. Resistin in humans is predominantly expressed by 
non-adipocyte inflammatory cells like macrophages and mononuclear cells242. 
Obese individuals have higher serum concentrations of resistin243. Recombinant 
human resistin increased pro-inflammatory cytokines such as TNFα and IL-6 in 
human subcutaneous adipocytes244. Overall resistin acts on multiple human tissues 
to promote inflammation, atherosclerosis and possibly insulin resistance245. Its 
effects on insulin resistance in humans still remain controversial246.  
 
Resistin is thought to play a key role in the mechanism of GIP induced enhancement 
of LPL activity. GIP through its receptor activates P38 MAPK and stress-activated 
protein kinase/Jun amino-terminal kinase (SAPK/JNK) pathways leading to resistin 
secretion. This in turn leads to increase in protein kinase B (PKB) phosphorylation 
and decreases liver kinase B1 (LKB1) and AMPK phosphorylation resulting in 
increased LPL activity247. Adipocytes of resistin knockout mice showed reduced 
GIPR expression, and GIP signalling pathways (PKB/LKB1/AMPK) that enhanced 
LPL activity were compromised184. LPL responsiveness to GIP was recovered after 
treatment with resistin suggesting an important link with GIP mediated actions on 
adipogenesis.  
 
In summary, there is evidence from studies in animals that GIP may enhance pro-
inflammatory adipokines which play a significant regulatory role in adipose tissue 
inflammation and development of insulin resistance and type 2 diabetes. There is 
very little evidence in humans of the effects of GIP on adipokines which requires 
further exploration. Studies showing the effects of GIP on adipokines are listed in 
Table 1.3.  
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Table 1.3 Effects of GIP on adipokines 
 
Author, year Experimental 
subjects 
Methods Effects of GIP on 
Adipokines  
Khales F et al. 
2016248 
C57BL/6j mice lipopolysaccharides 
(LPS) administration and 
injecting inflammatory 
cytokines 
GIP receptor antagonists 
­ LPS induced GIP secretion 
Blunted LPS induced TNF-
alfa and IL6 secretion  
Berglund LM et al.  
2016249 
Mice arteries GIP infusions ­ Osteopontin via endothelin 
-1 and activation of CREB 
Timper K et al. 
2016250 
Pancreatic islets 
of humans & mice 
In vitro incubation with 
GIP 
­ IL-6 by a cells 
­ GLP-1 & Insulin 
Nakamura et al. 
2016251 
Gastro intestinal 
mucosa in humans 
with tumours and 
inflammation 
Observational study ­ GIP mRNA expression in 
upper jejunum in group with 
inflammation compared to 
Control group  
Gogebakan et al. 
2015230 
Normoglycaemic 
obese men (n=17). 
Human and 
murine adipocyte 
/3T3 L1  
GIP 2pmol/kg/min with 
Hyperglycaemic clamp  
In-vitro GIP experiments 
with co-cultures 
­ Gene expression of MCP-
1, ­ MCP-2, IL-6 
­ Plasma MCP-1 
­ mRNA expression of 
MCP-1 
Chen S, et al. 
2015252 
Mice  Intraperitoneal GIP 
injections 
 ­ MCP-1, IL6 expression in    
    adipose tissue 
Timper K et al.  
2013175 
Human 
subcutaneous pre-
adipocytes 
In-vitro GIP cultures 
Chronic GIP Rx 
­Gene expression of IL-6,      
­ L-1β,  
¯Glucose uptake in 
adipocytes 
Ahlqvist E, et al. 
2013237 
Human adipocytes  Genetic variant of GIPR ¯ Osteopontin levels and        
  ­ insulin sensitivity 
Omar B, et al. 
2012236 
Isolated primary 
rodent adipocytes 
In-vitro incubation 
with GIP  
­ Gene expression of  
    osteopontin 
Nie Y et al. 
2012253 
3T3 adipocytes  Over expression of GIPR ­ IL6, TNF-alfa 
Lyssenko V et al. 
 2011238 
Human and mice 
Pancreatic β cells 
In-vitro GIP experiments  ­ Gene expression of  
    osteopontin 
Kim SJ, et al. 
2013184 
Mouse adipocytes Resistin Knockout ¯ GIPR expression 
Naitoh R, et al. 
2008208 
 
Gipr–/– mice GIPR knockout  ­ Adiponectin on high fat 
diet for 3 weeks. ­ fat 
oxidation 
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1.11 GIP antagonism in prevention of diet induced obesity 
There is substantial evidence from animal models that adipocyte GIPR activation 
plays a key role in GIP induced actions in adipocytes. Consumption of high fat diet 
leads to enhanced GIP secretion causing anabolic effects through excessive 
triacylglycerol accumulation in adipocytes, liver and muscle tissue. This may 
contribute to obesity and insulin resistance, the two key elements in the development 
of type 2 diabetes. Insulin resistance may lead to hyperinsulinaemia which causes 
further increase in fat deposition with increased nutrition leading to a vicious cycle 
of obesity. Such effects could be prevented in theory by inhibiting GIP signal to halt 
the process of diet induced obesity. Various experimental methods (Figure 1.8.) 
have been utilised to test this concept by GIP receptor knockout, GIPR antagonism 
and active immunisation of GIP and have studied the effects of blocking GIP 
signalling in rat models to assess the impact on their metabolic state and 
development of obesity52. 
 
         
 
Figure 1.8. Experimental methods of GIP inhibition in animal models 
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1.11.1 GIP signal inhibition 
 
GIPR Knockout in mice 
GIP receptor knock out in transgenic mice was shown to be an exceedingly useful 
method in understanding the effects of GIP signal blockade. GIPR knockout mice 
(Gipr–/–) were generated by replacing exons 4 and 5 of GIPR with the PGK-neo 
cassette254. Miyawaki et al. studied the effects of high fat diet and energy 
expenditure in Gipr–/– mice135. Wild type (WT) mice and Gipr–/– mice were fed on a 
high fat diet (45% fat) or a control diet (13% fat) for 43 weeks from the age of 7 
weeks.  The body weight of WT and Gipr–/– mice remained similar on control diet. 
WT on high fat diet had 35% body weight gain compared to no weight gain in Gipr–
/– mice on the same high fat diet by the end of 50 weeks (Figure 1.9). Visceral and 
subcutaneous fat mass and adipocyte size significantly increased in high fat fed WT 
mice with steatosis in liver sections but none of these were evident in high fat fed 
Gipr–/– mice other than a 10% increase in adipocyte size compared to controls. 
Blood glucose levels were higher in high fat fed WT mice compared to Gipr–/– mice 
on the same diet. These results showed that inhibition of GIP signal prevented 
insulin resistance and dietary induced obesity. 
 
A study investigated the role of triacylglycerol accumulation into adipocytes and fat 
oxidation in normal dietary conditions under diminished insulin action by disrupting 
the insulin receptor substrate protein (IRS-1–/–). These effects were compared in 
mice with Gipr–/–  and Gipr+/+.   Mice with IRS-1–/– Gipr–/–   exhibited lower 
respiratory quotient, higher fat oxidation, reduced fat accumulation in adipocytes 
and improved insulin sensitivity compared to   IRS-1–/– Gipr–+/+   mice255.  These 
results indicate an important role of GIP in triacylglycerol accumulation under 
diminished insulin action by switching from fat oxidation to fat accumulation and 
this role may otherwise be trivial in a state of normal insulin sensitivity. This study 
highlights the difference in GIP action in insulin sensitive and insulin deficient or 
resistant states. Although this was not demonstrated in humans, these findings may 
be of significance when evaluating the action of GIP in individuals with T2DM with 
some degree of  b cell dysfunction and insulin resistance. 
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Studies published in subsequent years on GIPR knockout mice showed similar 
beneficial effects on prevention in development of age related insulin resistance 256. 
Another study published recently showed that mice with adipose tissue specific 
receptor knockout had lower body weight, reduced insulin resistance and reduced 
hepatic steatosis 257. 
 
 
 
 
 
 
 
  
 
Figure 1.9:  Picture shows that Gipr–/– mice (left side) were protected from fat 
deposition on high fat diet compared to wild type (WT) mice (right side) with 
increased body weight and fat composition on same high fat diet. On control diet, 
there was no significant difference in fat deposition in the two groups. 
Picture adapted from Miyawaki, K et al 2002135 
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GIP receptor antagonism in mice models 
GIP receptor (GIPR) antagonists such as GIP (7-30)-NH2 (known as ANTGIP) were 
developed in the past 258,259. However, these agents were mainly used to evaluate the 
physiological role of GIP as a postprandial insulinotropic agent.  Subsequently 
Proline3 (Pro3) GIP was developed which is a stable and specific antagonist of the 
GIP receptor characterised by single proline substitution at Glu3 position260. Initial 
studies by Gault V et al. showed that acute administration of (Pro3) GIP  eliminated 
GIP stimulated insulin release in obese diabetic mice and worsened glycaemic and 
insulinotropic excursions to intra-peritoneal glucose260. These experiments helped to 
improve understanding of the relative contribution of GIP action to the entero–
insular axis.   
 
Acute (Pro3) GIP administration only abolished GIP but not GLP-1 stimulated 
insulin release261. Further experiments by the same group studied the effects of 
prolonged administration of GIPR antagonist that caused chemical ablation of GIPR. 
Daily intra-peritoneal injections of (Pro3) GIP over a 11 day period in young adult 
obese mice was shown to lower plasma glucose, and significantly  improved insulin 
sensitivity262.  Prolonged chemical ablation with intraperitoneal daily (Pro3) GIP 
injections for 8 to16 weeks in mice fed with high-fat diet, reduced body weight 
significantly, enhanced loco-motor activity, improved HbA1c, glucose tolerance and 
insulin sensitivity263,264. Similar experiments with a novel long acting GIP antagonist 
(Pro3) GIP mini-polyethylene glycol demonstrated prolonged antagonism compared 
to (Pro3) GIP265. 
 
In a study done recently, Gip signalling was inhibited by using two GIP analogues 
GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] derived from N terminal 
truncation of native GIP266. These GIP analogues were injected once daily for 21 
days in normal mice and obese diabetic high fat fed mice. Both these analogues 
reduced the body weight and improved glucose tolerance in both groups of mice 
indicating beneficial effects in compromising GIP signal. 
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GIP neutralisation in mice 
Active immunisation against GIP by specific neutralising antibodies is another 
interesting approach to inhibit GIP action. Vaccination using GIP peptides 
covalently attached to virus like particles (VLP-GIP) in mice induced high titres of 
specific antibodies and efficiently reduced body weight gain in animals fed a high 
fat diet  267. Another study showed that active immunisation against GIP for 56 days 
showed reduced plasma glucose concentrations and showed reduced trends in 
insulin levels in the circulation268.  
 
  Another method used for prolonged disruption of  GIP signalling was active 
immunization against (Pro3) GIP269. Immunisation was undertaken using GIP-
ovalbumin and a mixture of Freund’s adjuvant. Mice were injected with this GIP-
ovalbumin conjugate, transferred to high fat diet followed by further booster doses 
every 14 days until 98 days. This method of sub-chronic immunisation is intended to 
have a dual therapeutic effect with antibodies against (Pro3) GIP that neutralise 
native GIP and albumin bound (Pro3) GIP that serve as a long acting GIPR 
antagonist. Immunisation of mice against (Pro3) GIP on high fat diet reduced plasma 
glucose concentrations, insulin levels, liver triacylglycerol, pancreatic insulin and 
circulating LDL-cholesterol levels compared to non-immunised mice. There was no 
significant change in body weight or eating habits between immunised and non-
immunised mice.  
 
Another study compared the effects of sub-chronic immunisation against native GIP 
versus (Pro3) GIP using GIP-ovalbumin conjugates in mice.  Beneficial effects on 
the metabolic profile very similar to other studies were observed with immunisation 
of GIP or (Pro3) GIP270. There was no significant change in body weight, energy 
intake, energy expenditure and cognitive function between immunised and non- 
immunised mice. Lack of reduction in body weight appears to be a consistent 
finding in studies involving immunisation of GIP or (Pro3) GIP compared to studies 
that used GIPR antagonist or GIPR knockout methods. Overall there is adequate 
evidence from these animal studies to suggest that metabolic profile improves with 
inhibition of GIP signalling independent of the method used. 
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1.11.2 Metabolic effects of GIP signal inhibition 
GIP inhibition in animal models has shown to reduce insulin resistance and improve 
beta cell responsiveness and this occurs despite compromising its beneficial effects 
on insulin secretion. The negative effects of GIP inhibition are thought to be 
compensated by improved beta cell function and insulin sensitivity due to removal 
of triacylglycerols from pancreas, liver and muscle. Weight loss as a result of 
reduction in adiposity also ameliorates insulin resistance52. Inhibition of GIP 
signalling is therefore seen as a new avenue to treat diet induced obesity and related 
complications such as type 2 diabetes87,271. Potent GIP receptor antagonists have 
been developed in recent years to improve our understanding of the role of GIP in 
various tissues272. 
 
There is sufficient evidence to suggest GIP has an important role in lipid metabolism 
in animal models and inhibition of GIP signal prevents diet induced weight gain in 
mice. Although there is evidence to suggest a similar role of GIP in humans with 
very few studies available to date the effects of GIP antagonism have not been 
evaluated. Further studies in humans are required to help improve our understanding 
of its action on adipose tissue. GIP signal inhibition appears to be a potentially 
viable strategy for treatment of diet induced obesity in the future. However, the role 
of GIP on other tissues needs to be established before such therapeutic avenues 
could be ventured. 
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1.12 Effects of hypoglycaemic agents on incretins and gut hormones  
        in type 2 diabetes mellitus (T2DM) 
 
The incretin effect is known to be diminished in diabetes mellitus due to altered 
concentrations or reduced insulinotropic activity of incretin hormones (GLP-1 and 
GIP)25. Although unclear if this is the cause or consequence of onset of diabetes 
mellitus, restoration of normoglycaemia in T2DM with hypoglycaemic agents may 
partially reverse the diminished insulinotropic activity. Drugs known to have 
hypoglycaemic properties but not commonly used in the treatment of diabetes have 
been shown to alter incretin secretion in animal studies. Resveratrol is a stilbenoid, a 
type of natural phenol and phytoalexin produced by several plants. Resveratrol is a 
potent anti-diabetic agent when used in high doses. Administering resveratrol for 
five weeks in mice was shown to increase portal vein concentrations of both GLP-1, 
insulin and intestinal content of active GLP-1273. Berberine is an isoquinoline 
alkaloid that has effects on glucose and lipid metabolism. In streptozocin induced 
diabetes rats, 5 weeks of treatment with berberine was shown to increase pro-
glucagon mRNA expression and increased L cells in ileum that produce GLP-1274. 
 
Hypoglycaemic agents used for treatment of T2DM in humans may also have 
additional benefits on secretion and efficacy of incretin and other gut hormones 
involved in glucose homeostasis275. In obese patients with poorly controlled T2DM, 
near normalisation of blood glucose levels for 4 weeks with insulin treatment 
significantly improved insulin responses to both GLP-1 and GIP276. Although 
insulin per se does not influence the incretin secretion, the efficacy of incretins may 
be increased in patients with T2DM achieving near normoglycaemia with insulin 
treatment. Other hypoglycaemic agents that influence incretin system are described 
below. 
 
1.12.1 Effects of DPP-IV inhibitors on incretin system 
The newer class of oral hypoglycaemic drugs developed more than 10 years ago to 
enhance the incretin axis are known as dipeptidyl peptidase-IV (DPP-IV) inhibitors. 
DPP-IV inhibitors  enhance the incretin hormones by inhibiting the enzyme DPP-IV 
that rapidly degrades GLP-1 and GIP45. These agents decrease serum DPP-IV 
activity by more than 80% with some degree of inhibition sustained for 24 hours 
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making them suitable for once daily treatment dose46. Several DPP-IV inhibitors are 
now widely used in treatment of type 2 diabetes (sitagliptin, vildagliptin saxagliptin, 
linagliptin and alogliptin) as monotherapy or as an add on therapy to metformin as a 
second line treatment. 
 
1.12.2 Effects of metformin on incretins and gut hormones 
In the recent years, evidence has emerged which suggests that an established older 
drug, metformin may also have a significant influence on incretin hormone 
secretion277. Metformin is widely used as a first line drug in overweight and obese 
individuals with type 2 diabetes mellitus (T2DM). The glucose-lowering effect is 
mediated through reduced hepatic glucose output, increased peripheral glucose 
uptake and enhanced intestinal utilisation of glucose278-280. Studies in mice and in 
human cell lines have shown metformin to increase glucagon-like peptide-1(GLP-1) 
and its mRNA gene expression281-287. Studies on the effects of metformin in animals 
and cell cultures are shown in Table 1.4. Many human studies in non-diabetic obese 
subjects and in individuals with T2DM, have consistently shown increases in 
circulating GLP-1 concentration with metformin therapy277,288-299. Studies on the 
effects of metformin in humans are shown in Tables 1.5 and 1.6. 
 
In contrast, little evidence exists on changes in GIP secretion after metformin 
treatment293,296,298,300 (Table 1.5). One study reported an increase in both GIP and 
GLP-1 (AUC measure) during a glucose tolerance test in women with polycystic 
ovarian syndrome (PCOS) after 8 months of metformin treatment295. GLP-1 is 
rapidly degraded by the enzyme dipeptidyl peptidase-IV (DPP-IV) and 
administration of a single dose of metformin in patients with T2DM has been shown 
to inhibit DPP-IV activity which may be another important mechanism of metformin 
in enhancing GLP-1 concentrations301,302. Although the effects of metformin on the 
incretin system may not represent the principal mechanism underlying its glucose-
lowering action, it exemplifies the pleiotropic actions of this drug.  
 
Metformin improves glycaemic control with less weight gain compared to some of 
the other oral anti-hyperglycaemic treatments in patients with T2DM303. Although 
the mechanisms behind this are poorly understood, metformin has been shown to 
reduce food intake in obese subjects with and without diabetes mellitus304,305.   The 
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effects of metformin treatment on appetite regulatory hormones are less well 
studied.  Ghrelin is a potent orexigenic hormone secreted from the gastric fundus 
which plays an important role in the hypothalamic regulation of energy 
homeostasis73. The role of metformin on modulation of ghrelin levels in patients 
with T2DM remains unclear. Studies evaluating these effects of metformin on 
ghrelin have shown conflicting results306-309.  
 
In summary, two of the commonly used oral hypoglycaemic agents have effects on 
the incretin axis. Whilst DPP-IV inhibitors play a major role in enhancing both 
GLP-1 and GIP, there is good evidence to suggest that metformin treatment 
enhances total and active GLP-1 concentrations. Most the studies have shown no 
significant effect on GIP concentrations. Although metformin is thought to have 
effects on appetite regulation, currently there is little evidence available to support 
its effects on appetite regulatory hormones. 
 
 
 
 
 
 
 
 
 
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
Table 1.4 Effect of metformin on incretins in animal studies and in-vitro studies 
 
Author, year Study aims Methods Metformin effects on 
incretins and DPP-IV  
 
Kappe et al.  
(2014)285 
To determine if high fat 
diet (HFD) and 
metformin in mice 
lowers number of 
entero-endocrine L cells 
and/or GLP-1 plasma 
levels 
Mice received control/HFD 
for 12 weeks and oral 
metformin/ saline for last 14 
days. 
Immunohistochemistry used 
to quantify GLP-1 positive 
cells in intestinal cells. 
↓ GLP positive cells in HFD   
   mice  
↑Prandial plasma GLP-1 
Upregulation of Intestinal 
expression of GLP-1R 
mRNA  
 
 
Kappe et al. 
(2012)284 
To identify mechanisms 
involved in mediating 
lipotoxicity and 
metformin lipo-
protection in GLP-1 
secreting cells 
Murine GLUT ag cell line 
used. 
DNA-fragment assay, 
ELISA,  
RT-PCR  
 
Regulates GLP-1 receptor 
expression in pancreas. 
Protects GLP-1 cells against 
lipo-apoptosis. 
↑ secretion of pre-
proglucagon 
Mulherin et 
al. (2011)287 
 
To assess direct effects 
of metformin on GLP-1 
secretion from intestinal 
L cells and assess 
indirect actions that 
increase plasma GLP-1. 
In vivo and in vitro studies 
using murine human NCI-
H716 and rat FRIC cells 
↑ GLP-1 in vivo only (M3 
muscarinic dependent 
effects) 
↑ total GLP-1 over 24 hours 
DPP-4 activity not affected 
 
Maida et al.  
(2011)286 
To assess if metformin 
exerts gluco-regulatory 
actions via modulation 
of the incretin axis  
Used GLP-1 and GIP 
receptor knock-out mice and 
obese hyperglycaemic wild-
type mice with or without 
GLP-1R antagonist 
(exendin) 
 
↑ GLP-1 levels in wild type 
mice 
No changes in GIP and PYY.  
Improved glucose tolerance 
in knock-out mice. 
↑ GLP-1R in INS-1β CELLS 
via PPAR-α dependent and 
AMPK independent 
pathways 
Green et al.  
(2006)282 
To evaluate the effect 
of metformin on DPP-
IV activity in normal 
and obese diabetic mice  
 
Radioimmunoassay using 
blood samples taken 30 
minutes post-intraperitoneal 
injection of glucose and 
GLP-1 or GLP-1+ 
metformin 
↑ circulating GLP-1 (7-36) 
amide in ↓ DPP-IV activity 
in-vivo in mice Improved 
glucose lowering and insulin 
release effects from 
exogenous GLP-1 
Hinke et al.   
(2002)283 
To Investigate whether 
metformin inhibits 
DPP-IV to increase 
GLP-1 in obese non-
diabetic patients 
 
In vitro analysis of 20% 
human serum, porcine 
kidney and recombinant 
human DPP-IV using mass 
spectrometry and surface 
plasma resonance 
↑ GLP-1 and glucagon 
secretion from pancreatic α 
cells and intestinal L cells  
Metformin does not act 
directly on DPP-IV  
 
Yasuda et al. 
(2002)310 
To elucidate 
mechanisms behind 
metformin’s ability to 
increase GLP-1 levels 
Plasma active GLP-1 
changes after metformin in 
fasting DPP-IV positive 
F344/Jcl rats using valine 
pyrrolide a DPP-IV 
inhibitor 
↑ GLP-1 dose dependently 
There was no direct 
inhibitory effect on DPP-IV 
activity 
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Table 1.5: The effect of metformin on incretins in recent human studies  
 
Author, year Study aims Methods, duration of 
treatment and number of 
subjects (N) 
Metformin effects on GLP-1, 
GIP DPP4 activity and gut 
hormones 
 
Priess D et.al  
(2016)277 
 
 
 
CAMERA study: 
Randomised double blind 
placebo controlled trial on 
effects of metformin on 
cardiovascular disease in 
patients without diabetes 
 
DIRECT study: Cross-
sectional study to identify 
predictive biomarkers of 
glycaemic deterioration 
deep phenotyping and 
drug response in patients 
recently diagnosed with 
T2DM 
CAMERA study: Fasting 
blood samples at 6 monthly 
visits after overnight fast. 
Duration: 18 months, n= 86 
(metformin), 87(life style). 
 
DIRECT study: Fasting blood 
samples after a 10 hr 
overnight fast and metformin 
stopped for 24 hours. 
Multiple time point blood 
samples over 2 hours after a 
mixed meal.  N = 270 
(metformin), 505 (life style). 
CAMERA study: ↑ Total 
fasting GLP-1 at 6, 12 and 18 
months 
↓ Leptin reduced with 
metformin 
   GIP was not measured 
 
DIRECT study: ↑ basal fasted 
GLP-1 (active and total) on 
metformin compared to those 
on lifestyle alone. There was 
no difference in 60-minute 
total GLP after mixed meal in 
both groups. GIP was not 
measured. 
DeFronzo R et al. 
(2016)299 
Investigated the effects of 
delayed release metformin 
on glucose lowering 
effects and gut hormone 
secretion 
Randomised, blinded cross 
over study using a delayed 
release metformin targeting 
the ileum 
Duration 5 days, n=24 
↑ GLP-1 ↑ PYY (AUC- 5 
days) 
Similar glucose lowering 
effects despite reduced 
systemic absorption. 
Otsuka Y et al. 
(2015)300 
Study assessed the effects 
of metformin vs 
sitagliptin (DPP-IV 
inhibitor) on insulin, 
glucagon and incretins in 
Japanese patients with 
T2DM 
 
Randomised parallel group 
study with hormone 
measurements after a meal 
challenge pre-and post-
treatment with metformin and 
sitagliptin. Duration:12 
weeks, n=25  
Metformin: No significant 
changes in GLP-1, GIP and 
glucagon. C-peptide levels 
were slightly increased.  
 
Sitagliptin:  ↑ active GLP-1 
and GIP 
Wu T et al.  
(2014)297 
Study of Caucasian 
T2DM men treated with 
placebo or metformin to 
investigate effects on 
DPP-IV and total intact 
GLP-1 
Crossover study with Intra-
duodenal glucose infusion on 
day 5 and day 8  
Duration: 2 X 7 days, n=12  
↓ Plasma fasting DPP-IV 
activity 
↑ Plasma intact GLP-1 
No significant difference in 
total GLP-1 
Napolitano et al. 
(2014)298 
Study of Caucasian 
subjects with T2DM on 
and off metformin to 
characterise gut based 
mechanisms 
Post-prandial incretins, gut 
hormones and bile acid 
measurements at 4 visits on 
metformin treatment and after 
withdrawal of treatment 
↓ GLP-1 after metformin 
withdrawal 
↑ GLP-1after re-starting 
metformin 
Similar changes in PYY 
No change in GIP 
Solis-Herrera et al. 
(2013)294 
Study assessing glucose 
lowering mechanisms of 
sitagliptin and/or 
metformin in patients with 
T2DM 
Cross-over study with meal 
tolerance testing and 
radioimmunoassay methods 
Duration: 4 X 6 weeks, n=16 
↑ GLP-1 secretion and β cell 
function in metformin and 
sitagliptin combined (2 to 3-
fold ↑ in basal plasma GLP-1 
concentration) 
No significant ↑ with 
metformin alone 
Vardarli et al. 
(2013)296 
Effect of metformin, 
sitagliptin or both on 
GLP-1 responses of 
overweight/obese patients 
with T2DM  
Cross-over study with oral 
glucose challenge on day 5 
and IV glucose infusion on 
day 6  
Duration: 4 X 6 days, n=20 
Metformin: ↑ fasting total 
GLP-1 by ↑ insulin secretory 
responses. No change in 
fasting total or intact GIP. 
Sitagliptin: ↑ plasma intact 
GLP-1 and GIP, but ↓ total 
GLP-1, GIP  
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Table 1.6: The effect of metformin on incretins in previous human studies  
 
 
 
 
 
 
 
 
 
 
 
 
 
Author, year Study aims Methods, duration of 
treatment and number of 
subjects (N) 
Metformin effects on GLP-1, 
GIP DPP4 activity and gut 
hormones 
 
Cuthbertson et al. 
(2011)291 
Acute effect of metformin 
and GLP-1 alone or in 
combination on DPP-4 
activity in overweight and 
obese patients with T2DM 
Blood samples after an 
overnight fast for DPP-4 
activity, insulin, GLP-1,  
Duration: 1 day, n=10 
DPP-4 only inhibited by 7% 
Insulin sensitizing effects 
important in glucose lowering 
by GLP-1 
 
Migoya et al. 
(2010)293 
 
Effect of metformin in 
healthy men and women 
Cross-over study including 
placebo and metformin 
interventions; Day 2 active 
and total GLP-1 and GIP and 
glucose plasma 
concentrations measured pre-
meal and post-meal 
Duration: 4 X 2 days, n=16 
↑ postprandial total GLP-1  
↑ postprandial active GLP-1  
No effect on total or active 
GIP  
No effect on postprandial 
DPP-4 activity  
Svendsen et al.  
(2009)295 
Effect of metformin on 
incretin hormones 
response during OGTT in 
women with polycystic 
ovarian syndrome (lease 
and obese PCOS) 
Uncontrolled interventional 
study with 180min oral 
glucose tolerance tests (75 g). 
Incretin response over 180 
mins was compared to 
baseline 
Duration: 8 months,  
n= 10 (lean), 12 (obese) 
 
Lean: ↑ GLP-1 and GIP AUC 
Obese ↑ trend in GLP-1 and 
GIP AUC 
with borderline statistical 
significance 
Mannucci et al. 
(2004)292 
Effect of metformin on 22 
obese T2DM versus 12 
placebo controls 
GLP-1 measured before and 
after 100g glucose load after 
4 weeks of 850mg metformin 
Duration: 4 weeks, n=34 
Single dose didn’t modify 
GLP-1 
Fasting GLP-1 ↑ after 4 weeks 
of metformin  
Mannucci et al.  
(2001)289 
Effect of metformin 
versus placebo on GLP-1 
and leptin in obese non-
diabetic men before and 
after 14 days of treatment 
GLP-1 measured using 
ELISA in fasting state and 
after oral glycaemic load 
during euglycaemic 
hyperinsulinaemic clamp 
Duration:14 days, n=10 
Significant GLP-1 ↑ at 30 and 
60 minutes after oral glucose 
load 
No changes in GLP-1 in 
control group 
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1.13 Effects of bariatric surgery on incretins and gut hormones    
        in T2DM 
 
1.13.1 Bariatric surgery in the treatment of type 2 diabetes 
Bariatric surgery is currently the most effective therapeutic modality for morbid 
obesity. Resolution of type 2 diabetes mellitus (T2DM) has been consistently 
observed as an additional benefit of surgical treatment of obesity. Normoglycaemia 
is restored in more than 95% of patients with diabetes undergoing bilio-pancreatic 
diversion (BPD), and in 80% of patients who are treated with the Roux-en-Y gastric 
bypass (RYGB) procedure311. RYGB is the most common gastric bypass procedure 
and is thought to be the gold standard procedure (Figure 1.10). Of considerable 
interest is the observation that normoglycaemia and normal insulin levels occur 
within days after surgery, long before any significant weight loss has occurred. The 
mechanisms underlying the dramatic effects of surgery on insulin sensitivity and β-
cell function are poorly understood. Many hypotheses have been proposed to 
explain this phenomenon. A foregut hypothesis lays emphasis on exclusion of 
duodenum and jejunum from the food tract as an important mechanism312. Whilst 
the hind gut hypothesis suggests that rapid delivery of nutrients to distal intestines 
may release GLP-1 and PYY which have insulinotropic and anorectic activity 
leading to improvement in metabolic profile313. 	 
 
1.13.2 Incretin hormone changes post bariatric surgery 
It was speculated that eliminating GIP secretion from the foregut (duodenum and 
proximal jejunum) in gastric bypass surgeries may lead to rapid improvement in 
insulin resistance314,315. A few studies demonstrated GIP levels to be significantly 
reduced along with improved insulin sensitivity within weeks after gastric bypass 
surgeries in obese patients with T2DM316-319. The foregut hypothesis could therefore 
possibly be a parallel concept of GIP inhibition in humans. However, some of the 
studies have shown contrasting results of increased post-prandial levels of GIP at 4 
to 6 weeks after gastric bypass surgeries in patients with T2DM320-322. The increased 
post meal GIP levels were shown to persist at one year and 3 years after gastric 
bypass surgery 323,324. Another study in non-diabetic obese patients showed elevated 
GLP-1 and GIP levels at 20 years after jejuno-ileal bypass (JIB) surgery325.  
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Overall the changes in GIP levels after bariatric surgery in various studies are 
inconsistent and contradictory. GLP-1 levels in contrast are consistently increased in 
all  the studies after a glucose tolerance test or a mixed test meal326. Increased GLP-
1, peptide YY (PYY), oxyntomodulin and changes in appetite regulatory hormones 
such as ghrelin are thought to play an important role in T2DM remission327,328. 
Based on current data, there is not enough evidence in humans to support the GIP 
inhibition concept through foregut exclusion in gastric bypass surgeries for 
resolution of diabetes. Although the exact mechanisms are unclear, favourable 
changes in incretin hormones, alteration in calorie intake, gastric emptying, nutrient 
absorption and sensing, bile acid metabolism, and microbiota may all play a 
significant role in remission of T2DM327. 
 
 
 
 
 
 
 
  Figure 1.10 Roux-en-Y Gastric Bypass (RYGB). The size of stomach is reduced to 
a small pouch of 30 mls. Small bowel is resected at the level of the distal jejunum 
and short intestinal roux limb is directly anastomosed to the small gastric pouch. 
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1.14  Overview of research studies in thesis 
 
 
1.14.1 Study-1  
 
The effects of acute GIP infusion on insulin secretion and adipose tissue metabolism 
in obesity and type 2 diabetes compared to lean controls 
 
Hypothesis 
• The effects of GIP on insulin secretion may diminish gradually from 
normoglycaemic to hyperglycaemic states which may explain the blunted 
effect of GIP in T2DM. 
• GIP would have an anabolic action in human subcutaneous adipose tissue 
(SAT) promoting NEFA re-esterification, which we speculated may be 
mediated either by enhancing lipoprotein lipase (LPL) expression/activity (a 
lipogenic enzyme) or by reducing adipose tissue triacylglycerol lipase 
(ATGL) and hormone sensitive lipase (HSL) expression/activity, two key 
lipolytic enzymes. We postulated that this effect may be different according 
to obesity status or glucose tolerance. 
• As demonstrated in animal models and in-vitro studies, GIP may increase the 
expression and secretion of some of the pro-inflammatory adipokines and 
reduce the expression and secretion of the anti-inflammatory cytokine, 
adiponectin in human SAT. 
 
Aims and objectives 
• To study the effects of acute GIP infusion versus placebo on serum insulin 
and plasma NEFA concentration under hyperglycaemic clamp conditions in 
lean, obese, obese subjects with impaired glucose regulation (IGR), and 
obese subjects with T2DM. 
• To determine the acute, in-vivo effects of intravenous GIP versus placebo on 
TAG content and gene expression of LPL, ATGL, and HSL in SAT, in the 
four groups of individuals as described above.  
• To investigate the effects of acute GIP infusions versus placebo on the gene 
expression and plasma concentrations of adipokines TNF-a, MCP-1, 
osteopontin and adiponectin in the above four groups of subjects.  
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1.14.2 Study-2 
 
Effects of treatment with metformin on incretin system and gut hormones in obese 
patients with T2DM  
 
Hypothesis 
Metformin the most commonly used treatment in T2DM may affect the incretin 
system by altering the incretin hormone concentrations in addition to its other 
glucose-lowering properties.  The previously reported anorectic effects of metformin 
that leads to improvement in glycaemic control and weight loss may be related to 
changes in ghrelin, an appetite regulatory hormone. 
 
Aims and objectives 
To study the effects of treatment with metformin (minimum 3 months) on 
endogenous GIP, GLP-1 concentrations, DPP-IV activity and active ghrelin levels in 
obese patients with T2DM. 
 
The two research studies undertaken for this thesis work, and an overview of 
chapters in this thesis are shown in Figure 1.11. General methods are discussed in 
detail in chapter 2. The study design and protocol for each study are described in 
individual results chapters; study 1 in chapter 3 and study 2 in chapter 6. 
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Figure 1.11: Overview of research studies in this thesis.  
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Chapter 2 
 
Methods 
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2.1 Approvals and sponsorship 
 
Ethical approval  
Ethical approval for research projects were obtained from the Northwest Research 
Ethics Committee, U.K (reference number: 08/H1001/20 and 05/Q1501/60). 
Research Sponsorship:  
Approvals were obtained from University of Liverpool to be the main sponsor and 
University Hospital Aintree as the co-sponsor for the research.                   
 
2.2 Participant recruitment 
Research projects were advertised on the websites of University of Liverpool and 
University Hospital Aintree and on the notice boards in outpatient clinics. We 
approached various departments in University Hospital Aintree to recruit healthy 
volunteers. Suitable subjects attending our Hospital diabetes clinics, weight 
management clinics and Lipid clinics were also approached for recruitment. Some 
of the subjects with impaired glucose regulation and treatment naïve diabetes were 
recruited from a local primary health care centre. Volunteers who expressed interest 
in participation were given detailed information on the purpose of the study and 
were provided with information leaflets on study protocol and procedures involved 
in the study. All subjects were recruited after informed and written consent. 
 
In study 1, we recruited 23 Caucasian male subjects into four groups: lean subjects 
with normoglycaemia (lean), obese subjects with normoglycaemia (obese), obese 
subjects with impaired glucose regulation (obese IGR) and obese subjects with type 
2 diabetes mellitus (obese T2DM) who are treatment naive and on diet control alone 
for diabetes. Lean were defined according to a BMI ≤25 kg/m2and obese with a BMI 
≥30 kg/m2 as per WHO criteria329. Allocation to glucose regulation categories was 
based on recent medical records combined with a fasting plasma glucose 
concentration. Fasting plasma glucose was measured in all subjects at the start of the 
study and 75gram oral glucose tolerance test (OGTT) was done in those with 
abnormal fasting glucose (> 6 mmol/L) and no previous diagnosis of IGR and 
T2DM. OGTT was not repeated in those with established diagnosis of IGR and 
T2DM through recent OGTT and HbA1c results within 6 months. 
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In study 1, subjects were recruited into four groups based on BMI and glucose 
parameters as in table 2.1.  Obese subjects allocated to the obese IGR group had one 
or more of the following: fasting hyperglycaemia defined as plasma glucose ≥ 6.1 to 
6.9 mmol/l or impaired glucose tolerance OGTT with 2-hour plasma glucose ≥ 7.8 
and < 11.1mmol/l or HbA1c in pre-diabetes range (42-47 mmol/mol or 6 to 6.4%). 
Obese subjects with a diagnosis of T2DM meeting World Health Organisation 
(WHO) diagnostic criteria330,331 and not on pharmacological treatment for T2DM, 
were allocated to obese T2DM group. WHO diagnostic criteria for diabetes are the 
same as shown in table 2 excluding the BMI measure. 
In study 2, we recruited 8 Caucasian subjects (6 male) with recent diagnosis of type 
2 diabetes as per WHO diagnostic criteria who were not on any pharmacological 
treatment for T2DM. 
 
 
 Lean 
normoglycaemia 
Obese 
normoglycaemia 
Obese  
(IGR) 
Obese  
T2DM 
 
BMI (kg/m2) 
 
≤25 
 
≥30 
 
≥30 
 
≥30 
 
 
Fasting plasma 
glucose (mmol/l) 
 
 
≤ 6.0 
 
≤ 6.0 
 
≥ 6.1 to 6.9 
 
≥ 7.0 
 
2-hour glucose on 
OGTT (mmol/l) 
 
 
≤ 7.8 
 
≤ 7.8 
 
≥ 7.8 and < 11.1 
 
≥ 11.1 
 
HbA1c 
(mmol/mol) 
 
 
≤ 42 
 
≤ 42 
 
≥ 42 and < 48 
 
≥ 48* 
 
HbA1c (%) 
 
 
≤ 6 % 
 
≤ 6 % 
 
6 to 6.4% 
 
≥ 6.5* % 
 
Table 2.1 Subject allocation to categories based on BMI and glucose parameters. 
Allocation under T2DM is based on WHO diabetes diagnostic criteria. 
*Asymptomatic patients with HbA1c ≥48 mmol/mol required a second result in 
similar range to confirm diagnosis of diabetes. 
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Exclusion criteria 
Subjects with following conditions were excluded from the studies: 
 
• History of severe cardiac, hepatic or renal disease 
• Poor diabetes control with HbA1c > 86 mmol/mol (10%) 
• Thyroid dysfunction (hyper-or hypothyroidism)  
• Hypoadrenalism or excess cortisol production 
• Other endocrine disturbance (acromegaly, growth hormone deficiency) 
• Current malignant disease 
• Known alcohol misuse 
• Major psychiatric disease (including current use of antidepressants) 
• History of major eating disorder (anorexia or bulimia nervosa) 
 
 
2.3 Conduct of study 
 
All experiments were performed in accordance with the principles of the Declaration 
of Helsinki. During each visit subjects attended the investigational unit at the 
Clinical Sciences Centre in University Hospital Aintree site between 8.00 to 08:30 
AM, after an overnight of at least 10 hours’ duration. All subjects were asked to 
refrain from alcohol and strenuous physical activity for at least 24 hours. At the first 
visit, eligibility was confirmed and written informed consent was obtained. A 
detailed history on medical conditions and the list of medication were obtained. 
 
Anthropometric assessments  
Height, weight, BMI, waist circumference, and blood pressure were recorded during 
each visit. Height was recorded with the subject standing barefoot against a standard 
stadiometer to the nearest 0.1 cm and weight was recorded digitally in kilograms 
(kg) to the nearest 0.1 Kg at each visit using the same Tanita scales. BMI was then 
calculated as weight (kg) / height2
 
(m). Blood pressure was recorded using an 
appropriate sized cuff, after at least 5 minutes of rest, in supine position. Percentage 
body fat estimation was determined by whole-body bioelectrical impedance analysis 
using a body composition analyser (Tanita Corporation, Tokyo, Japan). 
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Infusions and blood sampling  
In study 1, after initial assessments, two intravenous cannulae (one in each arm) 
were inserted in antecubital veins.  One cannula was used for collection of blood 
samples and the other for infusion of GIP/placebo and variable rate dextrose 
infusion for hyperglycaemic clamp (study 1).  Baseline (fasting) blood samples were 
taken prior to the initiation of hyperglycaemic clamp. Thirty minutes after initiation 
of hyperglycaemic clamp an intravenous infusion of either GIP (2 pmol.kg. -1min-1 
dissolved in 0.9% saline) or placebo (0.9% saline alone) was started and maintained 
until 240 minutes. Further blood samples (10 ml) were taken at 15, 30, 60, 120, 180 
and 240 minutes following the initiation of GIP/placebo infusion (study 1, details in 
chapter 3).  
 
In study 2, blood samples were taken in the fasted state and at further 11 time points 
after a standard mixed meal. There were no infusions given in this study. Blood 
samples were collected into plastic serum separator (SST), fluoride EDTA and 
lithium heparin tubes for later measurement of insulin, liver function, lipid profile, 
glucose, NEFAs, gut hormones and adipokines.  Blood samples collected into 
EDTA and lithium heparin tubes were pre-treated with 0.5 ml of aprotinin, to 
prevent degradation by dipeptidyl peptidase IV (DPP-IV) and other proteolytic 
enzymes. Serum samples (SST) were centrifuged (at -4°C) 15 minutes after 
collection whereas plasma samples were centrifuged immediately. All blood 
samples were stored at -80°C until further analysis.  
 
Appetite assessment 
In study 2, assessment of hunger and desire to eat were done using unipolar Visual 
Analogue Scale (VAS) ratings. This consist of a question accompanied by a 100mm 
unmarked scale, with descriptors of extreme state (e.g. not hungry at all at one end 
to extremely hungry at other end) Participants were asked to mark on the scale, in 
response to a question (using paper VAS) at fasting stage and at every hour after a 
mixed meal. An example of VAS is attached in Appendix D. 
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2.4 Subcutaneous Adipose tissue biopsy (SAT biopsy) 
 
In our first study, subcutaneous adipose tissue (SAT) biopsy was obtained at 
baseline (prior to initiation of hyperglycaemic clamp) and a second biopsy was 
obtained after 240 min of the GIP/placebo infusion from the contralateral side of 
abdomen on the same visit. Several adipose tissue biopsy techniques are described 
in the literature such as needle aspiration biopsy, Bergstrom’s technique and open 
incision biopsy techniques332-335.  I observed the open incision biopsy technique by 
Professor Tomlinson which was used in many of his research projects at the 
University of Birmingham, UK336. We adopted this open incision biopsy technique 
as it has advantages of having large adipose tissue blocks which can be stored intact 
at -80°C for later analysis of lipid content and gene expression.  
 
Volunteers were explained the procedure in detail. Subjects were placed in a supine 
position and the skin lateral to the umbilicus was cleaned with 3% chlorprep. The 
site is chosen at approximately 10 cm lateral to the umbilicus avoiding the small 
subcutaneous arteries that lie parallel to the midline by 2-4cm. A sterile drape is 
placed and the skin is anesthetized using less than 5 mls of 1% lidocaine with 
adrenaline of 1:200,000 concentrations, taking care not to infiltrate the subcutaneous 
or adipose tissue. An incision (0.75 to 1cm) was made through the skin and fascia 
using a sterile scalpel at this site. Skin is retracted and fat tissue tissues was incised 
using scalpel and Adson’s 15mm forceps. More passes were done to obtain the 
desired amount of tissue between 50-150 mg (Figure 2.1).  
                                                                                                                                                                                                                                                                                                         
Adipose tissue samples were cleaned with normal saline and immediately snap 
frozen in liquid nitrogen and stored at -80°C until further analysis. All biopsies were 
handled under sterile conditions. Following the biopsy procedure, pressure was 
applied at the site of incision. The skin was cleaned with sterile saline and site was 
closed with steri-strips (sterile tape). Biopsy site was dressed with OPSITE 
waterproof dressing. Participants were provided with extra dressings and advised on 
dressing care. Steri-strips were removed approximately after 1 week. A new incision 
was made for each biopsy on both sides of abdomen. 
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Adipose tissue biopsy 
 
 
 
 
                
 
 
 
             
 
 
Figure 2.1: Adipose tissue biopsy procedure on one of our study subjects (pictures 
taken with consent). A Site of incision injected with local anaesthetic (red arrow), 
site of old healed biopsy (blue arrow) from 1st visit, B Incision measuring 
approximately 1 cm is made using a size 11 sterile scalpel. C Extracting adipose 
tissue using Adson’s 15 mm forceps and a scalpel, D Intact adipose tissue removed 
from the site and the tissue is snap frozen immediately in liquid nitrogen. 
 
A	 B	
C	 D	
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2.5 Hyperglycaemic clamp  
 
Rationale for hyperglycaemic clamp  
Glucose homeostasis is dependent on pancreatic beta cell response to plasma 
glucose and sensitivity of body tissues to insulin. Hyperglycaemia stimulates insulin 
secretion which in turn causes cellular uptake of glucose leading to fall in plasma 
glucose concentrations. This sends a negative feedback signal to beta cells to 
prevent further insulin release. During in-vivo studies in normal physiological 
circumstances, this glucose–insulin feedback loop impedes quantification of beta 
cell response. The use of hyperglycaemic clamp technique allows to maintain a 
steady plasma glucose at a chosen hyperglycaemic plateau within narrow limits and 
this breaks glucose–insulin feedback loop. Maintaining a hyperglycaemic plateau 
controls the stimulus to beta cells and this allows to compare the beta cell sensitivity 
reliably in different subject populations337.  
The effect of GIP on insulin secretion is dependent on plasma glucose 
concentrations. Studies comparing euglycaemic and hyperglycaemic clamps showed 
that endogenous GIP or exogenous administration of GIP enhanced insulin release 
only with mild to moderate hyperglycaemia but not during euglycaemic clamps338. 
The effect of GIP induced insulin secretion was also not inhibited by 
hyperinsulinaemia339. Although a steady state of glucose can be maintained in 
hyperinsulinaemic-euglycaemic clamps endogenous insulin secretion cannot be 
assessed accurately in different glucose tolerant states; whereas with 
hyperglycaemic clamp technique the insulin responses to identical glucose stimulus 
can be compared in glucose tolerant and intolerant states340. 
Hyperglycaemic clamp technique 
All experiments in our first study with GIP/placebo infusions were conducted under 
hyperglycaemic clamp conditions. Several hyperglycaemic clamp protocols 
described in the literature276,337,339,341,342 were reviewed and based on these principles 
we prepared an in-house protocol for hyperglycaemic clamp based on body weight 
to aim for a blood glucose » 8 mmol/l.  This was done as a two-step procedure by 
rising the glucose acutely in the first 5 minutes with a bolus of 20% glucose 
followed by variable rate of 20% glucose infusion.   
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Step 1-  Priming dose glucose infusion  
Blood glucose levels were raised acutely in the first 5 minutes with priming dose of 
glucose based on body weight at 120mg/kg. For example, in a subject weighing 70 
kg, the priming dose of glucose required is 8400 mg (8.4 g) in the first 5 minutes 
Calculations for total volume of 20% glucose in first 5 minutes and examples for 
priming dose based on weight is shown in in appendix A. 
 
Step 2- Variable rate glucose infusion for maintenance  
After the first 5 minutes of priming dose of glucose the infusion is switched to lower 
rates of variable 20% glucose infusion between 1mg/kg/min to 15mg/kg/min or 
higher aiming to achieve a steady state glucose of 8 mmol by 30 minutes. After 30 
minutes of glucose infusion, GIP (2pmol/kg/min) or placebo was started and 
continued for the next 4 hours. Hyperglycaemic clamp using variable rate of glucose 
was a continued throughout the experiment (4 hours) aiming for glucose levels as 
close as possible to 8mmol. The calculations for variable rate glucose infusion for 
each subject is determined based on subject’s weight using excel software. An excel 
sheet specific to each subject was printed and used prior to starting each experiment.  
An example of infusion rate based on weight is shown in appendix A. Small volume 
blood was taken from existing cannula and blood glucose level was measured every 
5 minutes from an YSI glucose analyser (YSI UK Ltd) on-site until the end of 
GIP/placebo infusion. The changes to variable rate infusion were determined by 
these blood glucose measurements aiming for glucose level of 8 mmol/l with a 
narrow limit of 0.5 mmol/l deviation either sides. 
 
2.6 GIP product 
GIP was sourced from Polypeptide Laboratories in Strasbourg, France and sterile-
filtered by Stockport Pharmaceuticals (Stepping Hill Hospital, Stockport, UK). 
Certificate of sterile filtered GIP product is shown in appendix B.  We used the GIP 
dose of 2 pmol.kg.-1min-1 (dissolved in 0.9% saline) based on dose infused in 
previous studies38,343,344. Concomitant GIP infusion at either a low (1pmol/kg/min) 
or a high infusion rate (4 pmol/kg/min) in  healthy subjects during a hyperglycaemic 
clamp (7.8 mmol/l) showed no significant changes in insulin secretory responses345. 
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2.7 Biochemical analysis  
2.7.1 Glucose, insulin and metabolic profile 
 
Glucose Blood glucose concentrations during hyperglycaemic clamp were measured 
using YSI 2300 STAT glucose analyser (YSI U.K Ltd, Fleet, Hampshire, U.K) on 
site in the research unit. Plasma glucose concentration was measured from fluoride 
oxalated tubes using a Cobas 8000 modular analyser (Roche diagnostics, USA) at 
the biochemistry department at University Hospital Aintree, Liverpool. 
Insulin Serum insulin was measured by Enzyme Linked Immuno-Sorbent Assay 
(ELISA) using the Invitrogen Human Insulin ELISA kits (Invitrogen, Fisher 
Scientific Ltd Loughborough, U.K). The assay uses monoclonal antibodies directed 
against distinct epitopes of insulin with detection range of 0.17 to 250 uIU/ML. 
Metabolic profile Glycated haemoglobin, fasting lipid profile and liver function 
were measured from baseline blood samples in the biochemistry department at 
University Hospital Aintree, Liverpool.  HbA1c was determined by using high 
performance liquid chromatography method (Ha 8140, Menarini Diagnostics, 
Berkshire, UK). Fasting lipid profile (total cholesterol, HDL & triacylglycerols) was 
measured by homogeneous enzymatic, colorimetric method using the Cobas 8000 
modular analyser (Roche diagnostics, USA).  
HOMA-IR Homeostatic model assessment (HOMA-2) was used to estimate insulin 
resistance from fasting plasma glucose and insulin concentrations)346.  
Adipo-IR   Adipose tissue insulin resistance (Adipo-IR) was calculated as a product 
of fasting NEFAs (mmol/L) x fasting insulin (pmol/L)347. 
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2.7.2 Non-Esterified Fatty Acids (NEFAs)  
NEFAs were measured at Alder Hey Children’s Hospital, Liverpool using Randox 
kit on a Biostat BSD 570 analyser (Randox laboratories Ltd, London). The 
enzymatic reaction involved in the assay relies upon acetylation of Co-enzyme A by 
the NEFA in the presence of enzyme acyl CoA synthetase. The acyl- CoA produced 
from this reaction is oxidized by added acyl CoA oxidase with generation of 
hydrogen peroxide in the presence of enzyme peroxidase. This permits the 
condensation of 4-aminoantipyrine and N-ethyl-N-(2 hydroxy-3-sulphopropyl) m-
toluidine into a purple coloured product which is measured calorimetrically. 
 
 
2.7.3 Plasma gut hormones 
 
GIP Intact GIP was measured at the University of Copenhagen, Denmark; this           
N terminal directed assay is specific for the intact N-terminus of GIP showing little 
cross reactivity and reduces overestimation of biologically active peptide348.  
 
GLP-1 Active glucagon-like peptide-1 (GLP-1) was determined using commercial 
enzyme-linked immunoassay (ELISA) kits from Millipore, Billerica, USA. The 
standard curve range for GLP-1 ELISA was 2-100 pmol/L, inter and intra-assay 
precisions were 8 ± 4.8 % and 7.4 ± 1.1% respectively. 
 
Ghrelin Active ghrelin was determined using commercial ELISA kits from 
Millipore, Billerica, USA. The standard curve range for ghrelin ELISA was 10-2000 
pg/ml, inter and intra-assay precisions were 9.6-16.2 and 6.5-9.5% respectively. 
 
DPP-IV The assay for DDP-IV was done using an in-house method adapted from 
methodology developed at the University of Ulster301. DPP-IV activity was 
determined by a fluorometric method measuring 7-amino-4-methyl-coumarin 
(AMC) liberated from a DPP-IV substrate, Gly-Pro-AMC. The intra and inter-assay 
coefficients of variation of this assay were 2.1% and 6.9% respectively. 
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2.7.4 Plasma adipokines 
 
TNF R-2 Tumour Necrosis Factor Receptor 2 (TNF R2) is a marker of TNF-α 
activity. TNF-R2 was measured using a commercially available ELISA kit (Human 
sTNF RII/TNFRSF1B Quantikine ELISA Kit, DRT200, R&D Systems UK). It is a 
solid phase sandwich ELISA immunoassay with a sensitivity of 2.3pg/mL, with an 
intra-assay precision of 2.6 to 4.8 CV% and inter-assay precision of 3.5 to 5.1 CV%.  
MCP- 1 Human MCP-1 was measured using commercial ELISA kit (Quantikine 
Human MCP-1 kit DCP00, R&D Systems UK) This is a solid phase ELISA 
designed to measure MCP-1 in cell culture supernates, serum, plasma, and urine. 
The assay range is 31 to 2000 pg/ml, with an intra-assay precision of 4.9 to 7.8 
CV% and inter-assay precision of 4.6 to 6.7 CV%.  
 
Osteopontin   Human osteopontin was measured using commercial ELISA kit 
(Quantikine D0ST00, R&D Systems UK) This is a solid phase ELISA designed to 
measure osteopontin in in cell culture supernates, serum, plasma, urine and human 
milk. The assay range is 0.3 to 20ng/ml. with an intra-assay precision of 2.9 to 4 
CV% and inter-assay precision of 5.4 to 6.6 CV%.  
 
Adiponectin Human adiponectin was measured using a commercially available 
ELISA kit (Human Adiponectin ELISA, EZHADP-61K, Merck Millipore UK). The 
sensitivity of this assay is 1.5ng/mL, with an intra-assay precision of 1.0 to 7.4% 
and inter-assay precision of 2.4 to 8.4%.  
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2.8 Adipose Tissue analysis 
 
2.8.1 Subcutaneous adipose tissue (SAT) biopsy lipid content  
Lipid content /triacylglycerol (TAG) was quantified by measuring free glycerol 
output following overnight lipase treatment at 37ºC (Sigma). The values were 
normalized according to protein content.  All samples were done in duplicate. 
Lysates were prepared by homogenization of fat biopsies in a buffer containing: 
50mM TrisHCL pH=7.5, 150mM NaCl, 1% Triton X-100, and standard protease 
inhibitor cocktail (Complete Mini protease inhibitor cocktail, Roche Diagnostics, 
Germany). The procedure involves enzymatic hydrolysis of triglycerides in SAT to 
glycerol and free fatty acids. The glycerol produced is then measured by coupled 
enzymatic reactions using the free glycerol reagent (Sigma-Aldrich, Saint Louis, 
USA) measures free glycerol.  
 
2.8.2 SAT gene expression of lipid enzymes (LPL, ATGL and HSL) 
• RNA purification: Total RNA was extracted from less than 100mg of adipose 
tissue using the RNeasy Lipid Tissue Mini Kit (Qiagen Ltd, UK). The integrity of 
each RNA sample was checked by Agilent Bioanalyzer (Agilent Technologies, Palo 
Alto, California, USA). 
• RNA quantification: RNA (1µl) was diluted in DEPC-treated water (199µl) and 
mixed by brief vortexing before quantification using a spectrophotometer (BioSpec-
mini, Shimadzu Corp., Japan). A260/A280 ratio of their dilutions between 1.3 and 
1.6 were deemed suitable for use. 
• Reverse transcription: First strand complementary DNA (cDNA) synthesis was 
performed using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). For each 
reaction, 1 µg of RNA were mixed with the Reaction Mix (4 µl), Enzyme Mix (2 µl, 
both provided by the kit) and H2O, in a 20 µl reaction system, as suggested in the 
manufacturer’s instructions (Life Technologies). 
• qPCR: Real-time quantitative PCR was conducted in triplicate using a BIORAD 
CFX-connect real time PCR instrument (BioRAD laboratories) using pre-validated 
TaqMan probes (Life Technologies). 
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2.8.3 SAT gene expression of adipokines  
(TNF-a, MCP-1, Osteopontin and adiponectin) 
• RNA isolation: Total RNA isolation from all adipose tissue samples was carried out 
using TRIzol (Life Technologies) per manufacturer’s protocol. Adipose tissue was 
grounded to powder in liquid nitrogen and homogenised using 1ml of Trizol lysis 
method in a 2ml eppendorf tube. This was followed by additions of chloroform-
isoamyl alcohol, isopropanol and centrifuged at 12,000 g for 15 minutes at 4oC. 
Ethanol was removed and pellets were then re-dissolved in 20µl of RNAase free 
water (Sigma).   
• Reserve transcription: Complementary DNA was synthesised from 200ng of total 
RNA per sample using First standard buffer (Invitrogen), DTT and dNTPs 
(Invitrogen) followed by addition of Superscript II Reverse transcriptase 
(Invitrogen) RNAase free water (Sigma), RNA inhibitor (Invitrogen) This 20µl 
sample mixture was then incubated at 42oC for 1 hour after which the resulting 
cDNA product was diluted 20 times using RNAase free water. cDNA was placed at 
-20oC and ready to use when required for real-time quantitative PCR (qPCR). 
 
• Real-Time Quantitative PCR (qPCR):  Reactions were performed using the 
BioRad SSOAdvanced™ Universal SYBR® Green Supermix qPCR Mastermix Kit 
(BioRad). A reaction mixture of 12µl was made up for each sample by addition of 
5µl of SYBR Supermix, 5µl of cDNA and 1µl each of forward and reverse primers 
respectively. Reactions were run on a BioRad CFX qPCR System (BioRad) with 
three technical replicates per each cDNA sample.  
 
Further details on gene expression methods, housekeeping genes and primers are 
shown in appendix C. 
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2.9 Study protocols (in brief) 
 
Study 1: A randomised double blinded cross-over study involving a hyperglycaemic 
clamp (glucose 8.0 mmol/l) with a 240 min GIP infusion (2pmol kg-1 min-1) or 
normal saline. The details of study design, protocol and subject characteristics are 
discussed in chapter 3. Twenty three Caucasian men sub-divided into four groups 
were studied on two separate occasions with a minimum of 1 and a maximum of 3 
weeks between visits. Using a computer-generated randomisation model, subjects 
were randomly assigned to either GIP or placebo infusion on their initial visit and 
received the alternate infusion on their subsequent visit. Intravenous infusion of 
GIP/placebo was continued from 30 minutes after initiation of hyperglycaemic 
clamp until 240 minutes. 10 ml blood samples were taken at baseline (prior to 
hyperglycaemic clamp) and at 15, 30, 60, 120, 180 and 240 minutes following the 
initiation of the infusion (GIP/placebo). Subcutaneous adipose tissue (SAT) biopsies 
were obtained at baseline and after 240 min of the GIP/placebo infusion. 
 
Study 2: A prospective, observational study in patients with drug naive T2DM 
commencing metformin as monotherapy. Details of study design and protocol are 
discussed in chapter 6.  Eight subjects (6 male and 2 female) with obesity and new 
diagnosis of T2DM were studied prior to and after at least 3 months of metformin 
monotherapy. Patients had a total of 3 visits to the investigation unit. Each subject 
was studied for 6 hours following a standard mixed meal, before and after at least 3 
months of metformin monotherapy (mean dose 1.75 g daily). Blood samples were 
taken in the fasted state and at 11 further time points (15, 30, 60, 90, 120, 150, 180, 
210, 240, 300 and 360 minutes) after consumption of a standard mixed meal for 
measurement of gut hormones. Metformin was started after the first visit. Subjects 
attended for the 2nd visit six weeks following initiation of treatment with metformin 
for a repeat HbA1c measurement, lifestyle advice and metformin dose titration as 
per clinical requirement. The protocol on visit 1 was repeated on visit 3 which was 
at least three months after metformin treatment (range 3 to 7 months). 
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2.10 Statistical analysis 
 
One-way ANOVA 
One-way analysis of variance (ANOVA) and Tukey’s t-tests were performed to 
compare participant demographics and baseline biochemical parameters between the 
four groups in the first study. Changes in plasma adipokines during GIP/placebo 
infusion studies compared to baseline values were assessed using ANOVA and 
Dunnett’s multiple comparison tests. 
 
Area under the curve (AUC) 
Area under the curve (AUC) was calculated by trapezoidal rule using GraphPad 
Prism software to give an integrated measure of responses for insulin and NEFA 
concentrations over 4-hour period of GIP/placebo infusion in study-1 and for gut 
hormones after a mixed meal in study-2. In Study-1, Paired t-tests were performed 
on insulin and NEFA AUC0-4hr for subjects within each group (lean, obese, obese 
IGR and obese T2DM) to explore if AUCs differed with GIP versus placebo 
infusions.  In study-2 paired t tests were performed on hormone AUCs pre and post 
metformin treatment.  
 
Linear mixed-effects model 
A linear mixed-effects model was used to model insulin secretion and NEFA 
concentrations using three time points (baseline, 120 minutes and 240 minutes) in 
study-1. A two-way interaction between treatment and group was included within 
the model to investigate whether the effect of GIP infusion in comparison to the 
placebo infusion differed between groups. Results are expressed in estimated 
average unit changes in insulin and NEFAs during GIP vs. placebo infusion.  
 
Pearson correlation coefficient 
A Pearson product-moment correlation coefficient was computed to assess the 
relationship between insulin AUC and other variables (fasting plasma glucose, 
HOMA-IR and Adipo-IR) during GIP and placebo infusions in study-1. The same 
test was used to assess the relationship between degree of NEFA reduction and other 
variables (fasting plasma glucose and Adipo-IR) during GIP and placebo infusions. 
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Paired T tests 
Changes in SAT lipid content and gene expression are presented as a fold change 
values after GIP/placebo infusions compared to their respective baseline 
measurements on the same day.  Paired t-tests were performed on these fold changes 
to explore whether the change over the two-time points differed between GIP and 
placebo. Fold changes were log transformed before analysis. P value of < 0.05 (two-
tailed) was considered significant. Student’s t test was used for paired data with 
normal distribution and Wilcoxon signed-rank test when paired data were not 
normally distributed.  
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Chapter 3 
 
The effects of acute GIP infusion on insulin secretion  
in lean, obesity and type 2 diabetes 
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3.1 Introduction  
The two Incretin hormones GIP and GLP-1, together enhance glucose dependent 
insulin secretion and account for the incretin phenomenon. GLP-1 levels are reduced 
in patients with T2DM and therefore augmenting with GLP-1 is effective in the 
treatment of T2DM. In the last decade, stable GLP-1 receptor agonists (GLP-1RAs) 
available as self-administered subcutaneous injections are a preferred treatment 
choice for obese individuals with T2DM. In contrast, GIP concentrations are either 
normal or increased in patients with T2DM but interestingly its’ incretin activity is 
blunted and the reasons for this phenomenon remain unclear38. GIP’s role in the 
treatment of T2DM has also been explored in recent years. Long-acting GIP 
receptor agonists are currently being researched as prospective therapeutic agents in 
T2DM. Diminished insulinotropic activity and  unfavourable pharmacokinetics with 
rapid degradation of GIP by dipeptidyl-peptidase-IV (DPP- IV) are potential 
limitations for development of a stable agonist52.  
 
3.2 Hypothesis and aims 
It is unclear if the insulinotropic activity of GIP diminishes with obesity, 
hyperglycaemia and insulin resistance eventually leading to a blunted effect in the 
diabetic state or if this is only observed as a consequence of an established diabetic 
state. We hypothesised that insulinotropic activity of GIP may gradually diminish 
from normoglycaemic to hyperglycaemic states.  
The aim of this study was to explore the effects of acute GIP infusion on insulin 
concentration in lean, obese and in impaired glucose regulation states. To investigate 
these effects, we studied plasma insulin concentrations during acute GIP infusions 
under hyperglycaemic clamp conditions in lean, obese, obese subjects with impaired 
glucose regulation (IGR), and obese subjects with T2DM. This study was part of a 
bigger study assessing the effects of GIP infusions on adipose tissue metabolism 
(described in chapter 4). Our methodology did not include exploration of molecular 
mechanisms underlying the blunted insulinotropic effect of GIP in T2DM.  
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3.3 Subjects and methods 
We studied 23 Caucasian men, age 49 ± 12.3 years (mean ± SD) categorised into 
four groups according to BMI/glucose regulation: i) lean (n=6), ii) obese (n=6),      
iii) obese with impaired glucose regulation [obese IGR] (n=6) and iv) obese with 
(treatment-naive) T2DM [obese T2DM] (n=5). Group categories based on BMI and 
glucose regulation are discussed in detail in chapter 2, section 2.2. 
   
Study design (Figure 3.1) 
Each subject participated in a double-blind, crossover study involving a 
hyperglycaemic clamp (plasma glucose 8.0 mmol/l). After overnight fasting, 
subjects were infused with either GIP (2 pmol.kg. -1min-1, in 0.9% saline) or placebo 
(0.9% saline alone) using a computer-generated randomisation model in their first 
visit and received the alternate infusion on their second visit 1-3 weeks apart (Figure 
3.1). Both the investigator conducting the experiments and the subject were blinded 
to the treatment given. 
 
Study protocol (Figure 3.2) 
After anthropometric measurements, intravenous cannulae were inserted into both 
antecubital fossae, for blood sampling and infusions (GIP/placebo). Plasma glucose 
concentration ~8.0 mmol/l was maintained during a hyperglycaemic clamp as 
described in detail in chapter 2.  The intravenous infusion of GIP/placebo was 
continued from 30 minutes after initiation of hyperglycaemic clamp until 240 
minutes (Figure 3.2). 10 ml blood samples were taken at baseline (prior to 
hyperglycaemic clamp) and at 15, 30, 60, 120, 180 and 240 minutes following the 
initiation of the infusion (GIP/placebo) and measured for glucose and insulin. Blood 
samples at baseline, 120 and 240 minutes were measured for GIP concentrations. 
Adipose tissue biopsies were taken at baseline and immediately after GIP/placebo 
infusions on contralateral sides. Samples were stored at -80 oC and later analysed for 
lipid content, gene expression of lipid metabolism enzymes and adipokine gene 
expression (discussed in chapter 4 and 5). General methods on blood sample 
collection, processing, storage and analysis are discussed in detail in chapter 2, 
section 2.3. 
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Study design 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Study design showing four groups of subjects in a randomsed cross over 
study undergoing GIP and placebo infusions under hyperglycaemic clamp 
conditions 1 to 3 weeks apart. 
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Study protocol 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Study protocol showing duration of hyperglycaemic clamp (blue 
horizontal bar) aiming for glucose ~ 8mmol/l and the duration of GIP/placebo 
infusions and the time points for blood sampling and SAT biopsies. 
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3.4 Statistical Analysis 
 
Participant demographics, baseline biochemical parameters and blood glucose 
concentrations during the hyperglycaemic clamp are expressed as mean ± SD; all 
other results are expressed as mean ± SEM.  One-way analysis of variance 
(ANOVA) and Tukey’s t-tests were performed to compare participant demographics 
and baseline biochemical parameters between the four groups in this study.  
 
Area under the curve (AUC) for insulin concentrations over 4-hour period of GIP/ 
placebo infusion (AUC0-4hr) was calculated by trapezoidal rule using GraphPad 
Prism software. Paired t-tests were performed on insulin-AUC0-4hr for individual 
subjects within each group (lean, obese, obese IGR and obese T2DM) to explore if 
insulin-AUC differed with GIP versus placebo infusions. Tukey’s multiple 
comparisons test was used to compare the insulin-AUC across the four groups.  
Pearson product-moment correlation coefficient was computed to assess the 
relationship between insulin AUC and other variables (fasting plasma glucose, and 
HOMA-IR) during GIP and placebo infusions.  
 
A linear mixed-effects model was used to model insulin concentrations using three 
time points (baseline, 120 minutes and 240 minutes). A two-way interaction 
between treatment and group was included within the model to investigate whether 
the effect of GIP infusion in comparison to the placebo infusion differed between 
the groups. Variables were considered to be significant at the 5% significance level. 
Results are expressed in estimated average unit changes in insulin during GIP vs. 
placebo infusion. 
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3.5 Results 
 
3.5.1 Baseline characteristics and biochemical parameters 
Participant demographics 
Waist circumference and percentage body fat mass were significantly higher in 
obese, obese IGR, obese T2DM compared to the lean group. The duration of 
diabetes in obese T2DM group was 7 ± 5.5 months (mean ± SD), mean HbA1c of 54 
± 8.5 mmol/mol (7.1 ± 0.8 %) and all participants were naive to oral or injectable 
diabetes medications.  
 
Plasma glucose and insulin concentrations  
As expected, mean fasting glucose was higher in obese IGR and obese T2DM 
groups compared to the two other groups. Fasting insulin and HOMA-IR were 
significantly higher in obese, obese IGR and obese T2DM groups vs. the lean group. 
Adipo-IR was significantly higher in obese IGR vs. lean group and in obese T2DM 
group vs. lean and obese groups (Table 3.1). 
 
Metabolic parameters 
All subjects in obese IGR and obese T2DM groups had metabolic syndrome based 
on International Diabetes Federation 2006 criteria 349 with most consequently treated 
for hypertension and dyslipidemia: angiotensin convertase enzyme (ACE) inhibitors 
or angiotensin receptor blockers (three subjects in obese IGR group, five subjects in 
obese T2DM group), beta-blockers (two obese IGR, 2 obese T2DM) and calcium 
channel blocker (one obese T2DM). Three subjects in each of the above two groups 
were on statins. Two subjects in the obese group had metabolic syndrome (one on 
ACE inhibitors and one a fibrate). No lean subjects had metabolic syndrome or 
received any regular medication. The mean fasting NEFAs were higher in obese 
IGR and T2DM groups vs. the normoglycaemic groups but the difference was not 
statistically significant (Table 3.1). 
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Table 3.1 
 
 
 
 
 
 
Table 3.1: Baseline demographics, anthropometric and biochemical parameters (mean ± 
SD) in four groups of subjects. P value for statistically significant difference vs. Lean 
group is indicated as * (<0.05); ** (<0.01); *** (<0.001); **** (<0.0001) and p value for 
significant difference vs. obese group is indicated as ∆ (<0.05).  ≠Non-Esterified Fatty 
Acids (NEFA), ¥Homeostasis Model Assessment-Insulin resistance (HOMA-IR), 
§Adipose tissue insulin resistance (Adipo-IR). 
 
 
 
 
 
 
      Lean 
     (n=6) 
   Obese 
   (n=6) 
 Obese IGR 
   (n=6) 
  Obese T2DM 
     (n=5) 
Age (years) 35 + 7  47 + 12  57 + 8* 57 + 8 * 
BMI (kg/m2) 24 ± 1  40 ± 8** 37 ± 5*  45 ± 13***  
Waist Circumference (cm) 94 ± 5 129 ± 19** 124 ± 14** 140 ± 17*** 
Body fat mass (%) 18 ± 3 38 ± 6**** 31± 16**** 46 ± 6**** 
Systolic BP (mmHg) 131 ± 15 136 ± 14 141 ± 3 135 ±12 
Diastolic BP (mmHg) 78 ± 8 73 ± 5 72 ± 6 76 ± 14 
Alanine transaminase (U/L) 21 ± 6 27 ± 21 30 ± 17 24 ± 11 
Fasting cholesterol (mmol/l) 5.2 ± 0.7 5.0 ± 0.3 3.9 ± 0.6* 4.3 ± 1.0 
HDL (mmol/L) 1.3 ± 0.3 1.1 ± 0.1 0.9 ± 0.2* 0.8 ± 0.1* 
LDL (mmol/L) 3.4 ± 0.9 3.2 ± 0.5  2.5 ± 0.8 2.8 ± 0.9 
Triacylglycerols (mmol/l) 1.1 ± 0.1 1.5 ± 0.3 1.9 ± 1.5 1.5 ± 0.5 
Fasting plasma glucose 
(mmol/l) 
5.3 ± 0.3 5.1 ± 0.9 6.0 ± 0.7 6.8 ± 1.1* ∆ 
Fasting Insulin (µIU/ml) 11.9 ± 2.6  30.5 ±14.4*  38.3± 12.5**  36.9 ± 9.1** 
Fasting NEFAs≠ (µmol/L) 352 ± 118 312± 123 421± 115 494 ± 150 
HOMA-IR¥  1.6 ± 0.3 3.8 ± 1.8* 4.8 ± 1.4** 4.9 ± 1.2** 
Adipo-IR§ (mmol/L/pmol/L) 24.5 ± 8.1   54 ± 23.7 95.9 ±37.8** 115.7 ± 51.2**∆ 
HbA1c (mmol/mol)        -       -  44 ± 2.3  54 ± 8.5 
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3.5.2 Biochemistry changes during GIP and placebo infusions  
Blood glucose  
The blood glucose concentrations (mean ± SD) during the 4 hour hyperglycaemic 
clamp were similar across the four groups: lean, 8.02 ± 0.02 (GIP) vs.8.17 ± 0.14 
mmol/l (placebo); obese, 8.0 ± 0.07 (GIP) vs. 8.17 ± 0.07 mmol/l (placebo); obese 
IGR group, 8.08 ± 0.11 (GIP) vs. 8.11 ± 0.06 mmol/l (placebo) in and obese T2DM 
group, 8.35 ± 0.15 (GIP) vs. 8.46 ± 0.18 mmol/l (placebo). Blood glucose 
concentrations at every 15 minutes during infusions for the four groups are shown in 
Figure 3.3. 
 
The volume of 20% glucose (mean ± SEM) infused to maintain the hyperglycaemic 
clamp during GIP vs. placebo infusions in the four groups were: lean, 1124 ± 155 
mls (GIP) vs.   631 ± 152 mls (placebo); obese, 926 ± 150 (GIP) vs. 462 ± 106 mls 
(placebo) obese IGR group, 725 ± 139 (GIP) vs. 398 ± 34 mmol/l (placebo) in and 
obese T2DM group, 508 ± 72 (GIP) vs. 323 ± 14 mls (placebo). 
 
Plasma GIP concentrations 
Fasting plasma GIP concentrations were similar across the four groups for both 
visits. Higher GIP concentrations were achieved during GIP infusions and levels 
peaked during 2 hours and tapered towards the end of infusion (Figure 3.4). 
	
3.5.3 Serum insulin concentrations during GIP vs placebo infusions 
The insulin concentrations (mean ± SEM) at baseline (prior to hyperglycemic 
clamp) and at further six time points (15, 30, 60, 120, 180 and 240 minutes) during 
GIP and placebo infusions for all the four groups are shown in Figure 3.5 A-D. 
Serum insulin concentrations were higher within 15 minutes of GIP infusion 
compared to placebo in all four groups. This difference was sustained throughout the 
GIP infusion period in lean, obese and obese IGR groups. In obese T2DM group, 
insulin concentrations increased slightly with GIP infusion during initial 30 minutes 
compared to placebo which was not significant. For the rest of the duration of the 
infusion, there was no difference in insulin concentrations between GIP and placebo 
infusions.  
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Figure 3.3: Blood glucose concentrations (mean ± SD during 4 hour infusions of GIP 
vs. placebo (with hyperglycaemic clamp »8 mmol/l) are shown in A lean individuals,  
B obese, individuals, C obese individuals with IGR, D obese individuals with T2DM. 
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Figure 3.4: Plasma GIP concentrations (mean ± SEM) during 4 hour infusions of GIP 
vs. placebo (with hyperglycaemic clamp) are shown in A lean individuals, B obese, 
individuals, C obese individuals with IGR, D obese individuals with T2DM.   
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Figure 3.5: Serum insulin concentrations (mean ± SEM) during 4 hour infusions of 
GIP vs. placebo (with hyperglycaemic clamp) on Y-axis are plotted against time on 
X-axis for each group: A lean individuals, B obese individuals, C obese individuals 
with IGR, D obese individuals with T2DM. Baseline blood sampling was taken at 
the time point -30* minutes (on X axis). 
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Effects of GIP vs placebo infusions on insulin concentrations  
To assess the overall effect on insulin concentrations during GIP versus placebo 
infusion individually for different groups, statistical analysis was performed using a 
linear mixed-effects model with insulin concentrations at three time points (0, 120 
and 240 minutes). Results are expressed in estimated average unit changes in insulin 
during GIP vs. placebo infusion.  
 
The amount by which insulin concentration increases when receiving GIP differed 
across the groups, holding all other variables constant, these results were non-
significant between obese and obese IGR groups compared to lean group. 
Comparing insulin secretion during GIP versus placebo within each group, there 
was approximately 63, 70 and 121 µIU/ml increase in insulin concentrations when 
receiving a GIP infusion in lean, obese and obese IGR groups respectively. In obese 
T2DM group, there was only a 9µIU/ml increase in insulin concentration with GIP 
compared to placebo infusion (Table 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2: Unit increases in insulin concentrations (linear mixed-effects model), 
with GIP infusion compared to placebo infusion over 240 minutes in four groups of 
subjects in the study, confidence intervals (CI) and p values. 
 
 
 
 
 
 
Increase in insulin 
concentration (µIU/ml) 
GIP vs. placebo 
95% CI p-value 
 
Lean 
 
63 
 
10 to 115 
 
0.019 
Obese 70 18 to 12 0.009 
Obese IGR 121 68 to 173 <0.001 
Obese T2DM 9 - 49 to 67 0.76 
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Integrated insulin concentrations (AUC) during GIP vs placebo infusions  
 
Area under the curve for insulin concentrations (Insulin AUC0-4hr) was calculated 
from insulin measurements at the 7 time points as an integrated measure of insulin 
concentrations during the 4 hour GIP and placebo infusions. As GIP infusions 
enhanced the insulin secretion in the first three groups, the mean AUC0-4hr of insulin 
concentrations was higher with GIP infusion compared to placebo in lean, obese and 
obese IGR groups. Whereas in T2DM group, AUC0-4hr of insulin during GIP 
infusion and placebo infusions were not different (Figure 3.6). Although the mean 
insulin AUC0-4hr with GIP infusion was higher in obese group than all other groups, 
the difference was not statistically significant compared to insulin AUC with 
placebo infusion. When Insulin AUC during the GIP infusion alone is compared 
between the four groups but, it was not significantly different in lean, obese and 
obese IGR groups except for the obese T2DM group.  
 
Insulin AUCs in subjects within the four groups 
The distribution of insulin AUC0-4hr for individual subjects within each group during 
placebo and GIP infusions are shown in box plots (Figure 3.7). The insulin AUCs 
were significantly higher with GIP infusion compared to placebo in lean and obese 
IGR groups with a clear difference in the insulin AUCs for most subjects between 
the two infusions.  Whereas in the obese group, although the insulin AUCs were 
higher with GIP infusion in most subjects, some of the subjects also mounted a 
higher insulin secretion during placebo infusion (with hyperglycaemic clamp) 
making this difference less significant. The insulin AUC with GIP infusion in obese 
T2DM group was significantly lower compared to the other 3 groups and no 
different compared to placebo in the same group.  
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Figure 3.6:  A Mean insulin AUC0-4hr ± SEM for GIP vs placebo infusions in four 
groups presented as bar charts (white bar, placebo; black bar, GIP). P values 
presented as *<0.05, **<0.005. B AUC of insulin concentrations with placebo 
compared to GIP infusion over 240 minutes in all four groups, confidence intervals 
(CI) and p values. 
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Figure 3.7: Insulin AUC0-4hr (µIU/ml/min) in individual subjects during 4-hour 
infusions of GIP versus placebo in each group are presented in box plots with a 
median line. Whiskers represent the individuals with minimum and maximum 
insulin-AUC concentrations in the four groups: A Lean, B Obese, C Obese IGR and 
D Obese T2DM.  The p values are represented by * <0.05 and ** <0.005. 
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Correlation between insulin concentrations and fasting plasma glucose 
There was a negative correlation between AUC of insulin and fasting plasma 
glucose levels during GIP infusions (Figure 3.8) for all the subjects in the study 
(n=23). There was no such correlation with placebo infusion. These results indicate 
that there is a gradual decline in insulin secretions with GIP infusions in individuals 
with higher fasting plasma glucose level and this has a linear relationship. 
 
 
 
 
 
                 
  
 
 
 
 
 
Figure 3.8: Correlation between fasting plasma glucose (mmol/l) plotted on y axis 
against Insulin AUC (uIU/ml/min) on x axis for all subjects in the study (n=23) 
during A GIP infusion and B placebo infusions. C Pearson’s correlation coefficients, 
95% confidence intervals and two tailed p values.  
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3.6 Discussion 
 
In this study, we demonstrate that GIP infusion in a fasting state under 
hyperglycaemic clamp conditions stimulated insulin secretion in the lean, obese and 
obese subjects with IGR, whereas its insulinotropic action was significantly 
impaired in obese patients with T2DM. These results were consistent with findings 
reported by other studies previously. Additionally, our results showed that the 
integrated insulin concentrations (AUC) during GIP infusions correlated negatively 
with fasting plasma glucose for all subjects in the study. Thus, indicating a gradual 
decline in insulin secretion with GIP infusions in individuals with higher fasting 
plasma glucose levels. We also observed that the insulinotropic action of GIP did 
not differ significantly in normoglycaemic lean, obese and obese IGR subjects.  
 
In the obese group, the mean insulin AUC with GIP infusion was higher than all 
other groups, but difference in insulin AUC was not statistically significant 
compared to placebo infusion within the same group. This is probably because 
individuals in obese group had higher fasting insulin concentrations and further 
increments in insulin secretion in response to hyperglycaemia during placebo 
infusion (with hyperglycaemic clamp) making the overall difference less significant. 
In the obese IGR group, who also had higher fasting insulin concentrations, the 
insulin secretion during placebo infusion (with hyperglycaemic clamp) was not as 
high as compared to obese group. This is an expected lower insulin response to 
hyperglycaemia in IGR group but interestingly this difference is compensated 
during GIP infusion achieving comparable insulin concentrations to the obese group. 
 
Younger subjects were shown to have increased insulinotropic activity to GIP in a 
study350. Subjects in our lean group were younger compared to obese and obese IGR 
groups but the insulin AUC during GIP infusions were comparable between these 
groups considering the baseline insulin concentrations are different in the three 
groups. There was no correlation between age and insulin AUC for all our subjects.  
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The incretin effect is known to be diminished in T2DM. The insulinotropic activity 
of both incretin hormones (GLP-1 and GIP) is impaired in diabetes states 25. Many 
studies have reported reduced concentrations of GLP-1 after a mixed meal in T2DM 
subjects26,28,29. However increasing concentrations of GLP-1 through exogenous 
infusion normalises hyperglycaemia suggesting insulinotropic activity of GLP-1 is 
retained in T2DM39,351. In contrast to GLP-1, GIP secretion is not impaired in 
T2DM. Many studies showed either normal or higher levels of GIP in individuals 
with T2DM 9,352. GIP secretion may vary with age obesity and metabolic status. A 
meta-analysis showed higher BMI (>30 kg/m2), younger age (<60 years) and low 
HbA1c level (<53 mmol/mol) to be associated with higher GIP secretion in response 
to oral glucose tolerance test (OGTT)33. Despite normal levels in T2DM, GIP does 
not enhance insulin secretion and even exogenous infusions of GIP have a blunted 
insulinotropic activity in individuals with T2DM38,343,353,354. Similar effects of GIP 
on insulin secretion were observed even with supra physiological doses of GIP345,355.  
 
Both GLP-1 and GIP share similar insulin signalling pathways inside the pancreatic 
β cell. Although there is loss of efficacy in both incretin hormones in T2DM, GLP-1 
retains insulinotropic action in T2DM indicating that the common signalling 
pathways remain intact in T2DM. The reasons for the diminished GIP’s action on 
pancreatic β cell in individuals with T2DM remains unclear. Several underlying 
mechanisms may contribute to this phenomenon. Decline in β-cell function in 
T2DM could itself play a major role in diminishing the GIP induced insulin 
secretion and reduce the overall incretin effect. Activation of GIPR is important for 
GIP’s physiological action and this is somehow glucose dependent, with GIPR 
expression shown to be down regulated in response to chronic hyperglycaemia111. 
The blunted incretin effect may in part be due to reduced islet cell expression of GIP 
receptors (GIPR) secondary to chronic hyperglycaemia although, this has not been 
clearly demonstrated in humans.  In a study involving 93 subjects undergoing GIP 
infusions under hyperglycaemic clamp conditions, the insulinotropic activity of GIP 
progressively decreased with near complete loss of efficacy in patients with T2DM 
and overt hyperglycaemia25.  
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Studies in rats showed GIP receptor down regulation as a potential mechanism for 
GIP insensitivity/resistance in pancreatic beta cell. In Vancouver diabetic Zuker 
fatty rats GIP did not stimulate glucose-induced insulin secretion during in-vivo 
experiments or from the perfused rat pancreas and isolated perfused rat islets. The 
insulinotropic response of GLP-1 remained intact. In these experiments GIP failed 
to stimulate cAMP production in isolated and incubated rat islet cells. GIP receptor 
mRNA expression was also shown to be downregulated in the islets of these 
animals112. Peroxisome proliferator–activated receptor ƴ (PPARƴ) is thought to 
regulate GIPR transcription in pancreatic β-cells. Pancreatic PPAR ƴ knockout 
(PPAR-/- ) mice demonstrated  hyperglycaemia with normal β-cell mass but with 
reduced  GIPR expression356.  
 
Another important mechanism for reduced incretin effect in T2DM involves a 
transcription factor 7-like 2 (TCF7L2) protein that regulates GIPR and GLP-
1receptor (GLP-1R) and reduced levels of TCF7L2 in T2DM correlate with down 
regulation of GIPR and GLP-1R357. TCF7L2 previously known as TCF4 is a novel 
gene identified in the last decade and its variants are associated with susceptibility of 
developing T2DM358-360. TCF7L2 polymorphisms are considered to make a bigger 
contribution to the development of type 2 diabetes than any other genetic marker361. 
Common variants of TCF7L2 gene were associated with increased risk of T2DM in 
studies with large number of subjects of different ethnicity360,362-364. TCFL2 
polymorphism associated T2DM may be linked to reduced incretin mediated insulin 
secretion365. Depleting TCF7L2 in isolated islets cells resulted in increased beta cell 
apoptosis and reduced beta cell proliferation and overexpression of TCF7L2 
protected islets from glucose and cytokine induced apoptosis. These findings 
suggest that beta cell function and survival are regulated through interaction 
between TCF7L2 and GLP-1R/GIPR expression and signaling in T2DM366.   
 
In contrast to TCF7L2 regulation that involves both incretin receptors, signalling 
from GIPR alone but not GLP-1R controls the expression of transcription factor 7 
(TCF7), a member of TCF family367.  TCF7 in turn encodes a protein known as T-
cell specific transcription factor-1 (TCF1) that links GIPR signalling to control 
secretion of insulin and the survival of beta cells. Experiments in mice with selective 
ablation on GIPR in pancreatic beta cells had distinctly lower TCF-1 expression and 
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higher sensitivity for apoptosis367. This data indicates GIPR-TCF1 axis may have a 
significant role in preservation of pancreatic beta cell mass. Furthermore, disruption 
to GIPR-TCF1 axis may be another potential mechanism for GIP resistance in 
T2DM which is independent of the common signalling pathways for GIPR and 
GLP-1R which may still be intact in T2DM. This may explain the differential 
response with GLP-1 and GIP on insulin secretion and diminished insulin secretion 
even with supra-physiological doses of GIP. 
 
Genetic defects of GIPR were proposed as another mechanism for GIP resistance in 
T2DM. Reduction of b-cell mass and progressive deterioration in glycaemic control 
was seen in transgenic pigs expressing a dominant-negative glucose-dependent 
insulinotropic polypeptide receptor368; such findings did not correlate in humans 
with T2DM. These concepts are difficult to prove in humans as it is currently not 
possible to quantify the effects of GIP infusions on GIPR expression in pancreatic β 
cell in human with in-vivo experiments. 
 
GIP resistance in T2DM appears to be reversible with glucose normalisation. Down 
regulation of GIP receptor mRNA in T2DM Zucker fatty rats was almost completely 
reversed after 2 weeks of phlorizin treatment and normalization of 
hyperglycaemia369. Another study showed GIP and GLP-1 receptor expression was 
reduced in hyperglycaemic rats after a 90% partial pancreatectomy. This was shown 
to be reversed on treating hyperglycaemia with phlorizin370. In human subjects with 
T2DM and poor glycaemic control, intense insulin treatment and near normalization 
of glucose levels was shown to reverse the insulinotropic activity of GIP276. 
Similarly, improved glycaemic control with 12 weeks of DPP4 inhibitor as an add 
on treatment to metformin showed an improved beta cell response during 
hyperglycaemic clamp experiments371. Most subjects with T2DM in our study had 
stable glycaemic control with a mean HbA1c of 54 ± 8.5 mmol/mol however we still 
observed significantly impaired insulin secretion with GIP in this group. 
Nonetheless the studies described above demonstrate that reducing hyperglycaemia 
improves insulinotropic activity of both GIP and GLP-1. 
 
 
 113 
All experiments in our study were performed under hyperglycaemic clamp 
conditions to achieve comparable hyperglycaemia and to mimic post-prandial 
increases in GIP and insulin. The peak GIP concentrations achieved in our study 
during GIP infusions were comparable to levels achieved in other studies191.  During 
experiments with GIP infusions, we observed that the plasma GIP concentrations 
were consistently reduced by the end of experiments (on 240-minute sample) in all 
subjects. This is probably due to degradation of exogenous GIP by native DPP-IV or 
due in-homogenous mixing of GIP with normal saline in the infusate leading to 
reduced GIP concentrations towards the end of experiments.  
 
Studying four distinct groups (with differing BMI and glucose tolerance) facilitates 
evaluation of the differential effects of GIP in insulin sensitive and resistant 
individuals. However, we acknowledge limitations including small group sizes and 
the degree of obesity: there was limited pilot data in humans prior to initiation of 
this study therefore a power calculation was not done for the study. BMI in our 
obese T2DM group was high but comparable to obese and obese IGR groups. We 
acknowledge that results may differ in less obese subjects. 
 
In summary, the diminished insulinotropic effects of GIP in T2DM may be 
explained by multiple mechanisms involving beta cell dysfunction, down regulation 
of GIPR as a consequence of chronic hyperglycaemia and disruption to GIPR 
specific signaling in beta cells. This blunted effect appears to be partially reversed 
on reducing hyperglycaemia. Although our study was not aimed to identify the 
underlying mechanisms for GIP resistance in T2DM, we observed that overall 
insulin secretion as measured by AUC correlated negatively with fasting glucose 
levels during GIP infusions for all our subjects. This indicates chronic 
hyperglycaemia may influence GIP induced insulin secretion which may be a 
gradual effect during the transition from mild hyperglycaemia to development of 
T2DM with these effects more pronounced with onset of T2DM.  
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Effects of GIP on non-esterified fatty acid (NEFA) 
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4.1 Introduction  
 
GIP in addition to insulinotropic activity has other important extra-pancreatic 
metabolic functions with receptors expressed in such tissues as bone, brain, stomach 
and adipose tissue, where it may modulate post-prandial lipid metabolism 21. In 
animal models of obesity-induced insulin resistance, genetic and chemical 
disruption of GIP signaling protects against the deleterious effects of high fat 
feeding by preventing lipid deposition, adipocyte hypertrophy and expansion of 
adipose tissue mass, and reducing triacylglycerol deposition in liver and skeletal 
muscle, maintaining insulin sensitivity52,135. Thus if GIP has a potential pro-
adipogenic effect, selective GIP antagonists may be beneficial in treating obesity 
and type 2 diabetes mellitus (T2DM)87. 
 
GIP concentrations are increased with high fat diet88,96-98. Given that dietary fat 
consumption chronically stimulates the production and secretion of GIP, inducing K 
cell hyperplasia89, higher GIP concentrations may reflect consumption of an energy 
dense, high-fat diet. Early rodent studies demonstrated that a GIP infusion, during an 
intraduodenal lipid infusion, decreased plasma triacylglycerol levels187 while GIP 
has been shown to enhance insulin-induced fatty acid incorporation in rat adipose 
tissue186. Thus, GIP action mediated through the adipocyte GIP receptor, is anabolic 
in adipose tissue promoting fat deposition. 
 
It is important to distinguish between direct effects of GIP on fatty acid metabolism 
and indirect effects based on its insulinotropic action. Acute GIP infusion in lean 
healthy males (with hyperinsulinaemia and hyperglycaemia mimicking carbohydrate 
ingestion) increases adipose tissue blood flow, triacylglycerol (TAG) hydrolysis and 
NEFA re-esterification thus promoting triacylglycerol deposition189,196. In healthy 
obese men, acute GIP infusion reduced expression and activity of 11β 
hydroxysteroid dehydrogenase type 1 (11β-HSD1), a fat-specific glucocorticoid 
metabolism enzyme that may enhance lipolysis in subcutaneous adipose tissue 
(SAT)178. Thus, from the available animal model and human data, GIP appears to 
have a key regulatory role in lipid metabolism and adipose tissue.  
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To date, very few studies have investigated the effects of GIP on human adipose 
tissue and none have involved subjects with T2DM although the reported presence 
of functional GIP receptors on adipocytes strongly suggests GIP modulates human 
adipose tissue metabolism92,99.  However, a therapeutic benefit of inhibiting GIP 
action in adipose tissue in obesity-related disorders is clear due to its potential in 
limiting fat accretion.  
 
4.2 Hypothesis and aims 
 
Following on from the previous chapter, we hypothesised that GIP would have an 
anabolic action in SAT promoting NEFA re-esterification, which we speculated may 
be mediated either by enhancing lipoprotein lipase (LPL) expression/activity (a 
lipogenic enzyme)91,171, or by reducing adipose tissue triacylglycerol lipase (ATGL) 
and hormone sensitive lipase (HSL) expression/activity, two key lipolytic enzymes. 
We postulated that this effect may be different according to obesity status or glucose 
tolerance. Thus, we set out to determine the acute, in-vivo effects of intravenous GIP 
on NEFA concentrations, and i) TAG content in SAT and ii) gene expression of the 
key lipid regulating genes, lipoprotein lipase (LPL), adipose tissue triglyceride 
lipase (ATGL) and hormone sensitive lipase (HSL) in SAT, in obese individuals 
with different categories of glucose regulation (normoglycaemic, IGR and T2DM) 
versus lean, normoglycaemic controls.  
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4.3 Subjects and methods 
General methods are discussed in detail in chapter 2 (Methods). Details on subject 
groups, participant characteristics, study design and protocol are described in 
chapter 3, section 3.3. Only male subjects were studied to minimise the influence of 
sex steroids on lipid metabolism (e.g. considering menstrual cycle, menopause or 
hormone replacement therapy). Blood samples were taken at baseline (prior to 
initiation of hyperglycaemic clamp and at further six time points (described in 
chapter 3) for measurement of plasma NEFA concentrations.  
 
SAT biopsies Subcutaneous adipose tissue (SAT) biopsies were obtained at baseline 
and after 240 min of the GIP/placebo infusion on the contralateral site. Adipose 
tissue samples (50-150 mg wet weight) were collected and snap frozen in liquid 
nitrogen and stored at -80o C. Adipose tissue was quantified for SAT-TAG content 
by measuring free glycerol output following overnight lipase treatment. The gene 
expression of the key lipid regulating genes LPL, ATGL and HSL was measured by 
RNA extraction and real time quantitative PCR techniques. The details of 
subcutaneous adipose tissue biopsy procedure and the techniques of adipose tissue 
analysis are discussed in detail in chapter 2 (Methods), sections 2.4 and 2.8 
respectively. 
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4.4. Statistical analysis 
 
Area under the curve (AUC0-4hr) for NEFA concentrations over 4-hour period of GIP 
and placebo infusions were calculated by trapezoidal rule using GraphPad Prism 
software. Paired t tests were performed on NEFA-AUC0-4hr for individual subjects 
within each group (lean, obese, obese IGR and obese T2DM) to investigate if 
NEFA-AUC differed with GIP versus placebo infusions. Tukey’s multiple 
comparisons test was used to compare the NEFA-AUC across the four groups. 
Pearson product-moment correlation coefficient was computed to assess the 
relationship between degree of NEFA reduction and other variables (fasting plasma 
glucose and Adipo-IR) during GIP and placebo infusions. 
 
A linear mixed-effects model was used to model NEFA concentrations using three 
time points (baseline, 120 minutes and 240 minutes). Main effects for the four 
different groups and the treatment effect are included along with a two-way 
interaction between treatment and group. This allows that the overall effect of GIP 
infusion in comparison to the placebo infusion can be assessed individually for 
different groups. Results are expressed in estimated average unit changes in NEFAs 
during GIP vs. placebo infusion. 
 
Change in SAT triacylglycerol (TAG) and gene expression of adipokines are 
presented as fold changes from baseline to the measurements from adipose tissue 
immediately after GIP/Placebo infusions.  Paired t-tests were performed on these 
fold changes to explore whether the change over the two-time points differed 
between GIP and placebo. Fold changes were log transformed before analysis.          
P value of < 0.05 (two-tailed) was considered significant. 
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4.5 Results  
 
4.5.1 Participant details and metabolic parameters 
As described in the previous chapter, 23 individuals completed the study protocol in 
four sub-groups. The details of sub groups, baseline characteristics and metabolic 
parameters for all subjects are described in chapter 3, section 3.5 and in table 3.1. 
The blood glucose and GIP concentrations during hyperglycaemic clamp and the 
changes in insulin concentrations during GIP and placebo infusions are described in 
section 3.5.2 of the previous chapter. There were no significant alterations in serum 
triacylglycerol (TAG) concentrations with either GIP or placebo in any of the four 
groups (data not shown). 
 
4.5.2 Changes in Plasma Non-Esterified Fatty Acids (NEFAs)  
NEFA concentrations (mean ± SEM) at baseline (prior to hyperglycemic clamp) and 
at further six time points (15, 30, 60, 120, 180 and 240 minutes) during GIP and 
placebo infusions for all the four groups are shown in Figure 4.1 A-D. NEFA 
concentrations reduced from a higher baseline fasting level in all individuals during 
both GIP and placebo infusions with hyperglycaemic clamp. Greater reductions in 
NEFAs were seen during the first one hour. The degree of NEFA reduction however 
did not differ between GIP and placebo infusions in lean and obese groups whereas 
this difference was significant in obese T2DM group and a similar trend seen in 
obese IGR group although not statistically significant. 
 
Effects of GIP and placebo infusions on plasma NEFA concentrations 
To assess the overall effect of NEFA reduction during GIP and placebo infusions 
individually for different groups, statistical analysis was performed using a linear 
mixed-effects model with NEFA concentrations at three time points (0, 120 and 240 
minutes). Results are expressed in estimated average unit changes in NEFA during 
GIP vs. placebo infusion.  
 
The amount by which NEFA concentrations decreased during GIP infusions differed 
across the groups, holding all other variables constant, these results were non-
significant between the groups. Comparing NEFA reduction during GIP versus 
placebo infusions within the groups, there was approximately 82.6 µmol/L reduction 
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in NEFAs in obese T2DM group from baseline to 240 minutes with GIP infusion 
compared to placebo (95% CI, -139, 26; p = 0.004) In lean, obese and obese IGR 
groups the decreases in NEFAs with GIP infusions were not statistically different to 
placebo (Table 4.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1: Unit decreases in NEFA concentrations (linear mixed-effects model) 
during GIP infusion compared to placebo infusion over 240 minutes in all four 
groups, 95 % confidence intervals (CI) and p value. 
 
 
 
 
 
 
 
 
 
Decrease in NEFA 
Concentrations (µmol/l)  
GIP vs. Placebo 
95% CI p value 
Lean  7.9 -59 to 44 0.763 
Obese  31.2 -82 to 20 0.234 
Obese IGR 11.4 -63 to 41 0.668 
ObeseT2DM 82.6 -139 to -26 0.004* 
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Figure 4.1: The plasma concentrations of NEFA (mean ± SEM) during 4 hours of 
GIP vs. placebo infusions (with hyperglycaemic clamp) on Y-axis are plotted 
against time on X axis in each group:  A lean individuals, B obese individuals, C 
obese individuals with IGR, D obese individuals with T2DM. Baseline blood 
sampling was taken at the time point -30* minutes (on X axis). 
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Integrated NEFA concentrations in plasma (NEFA–AUC) 
Area under the curve for NEFA concentrations (NEFA-AUC- 0-4hr) was calculated 
from NEFA measurements at 7 time points during GIP and placebo infusions. 
Comparing AUCs within each group, the mean NEFA-AUC (0-4hr) in obese T2DM 
group was significantly lower with GIP infusion compared to placebo (41992 ± 
9843 vs 71468 ± 13605 µmol/L/min). The NEFA concentrations in obese IGR group 
also appeared to be lower with GIP compared to placebo infusion but difference in 
the mean AUC0-4hr was not statistically significant.  Whereas the mean AUC0-4hr for 
NEFAs in lean and obese groups were not different during GIP and placebo 
infusions (Figure 4.2). 
 
NEFA -AUCs in subjects within the four groups 
The distribution of NEFA-AUC0-4hr for individual subjects within each group during 
placebo and GIP infusions are shown in box plots (Figure 4.3) The NEFA-AUCs 
were very similar in all the lean subjects with both GIP and placebo infusions. 
Whereas in the other three groups majority of individuals had lower NEFA-AUC 
with GIP infusion compared to placebo but a statistically significant difference was 
only seen in the obese T2DM group. 
 
4.5.3 Relation between NEFA reduction (∆NEFA) and metabolic parameters 
 
∆NEFA and fasting plasma glucose 
The degree of reduction in NEFA (∆NEFA) with GIP infusion in all subjects (n=23) 
correlated positively with fasting plasma glucose suggesting that subjects with 
higher fasting plasma glucose had greater reductions in NEFA during GIP infusion. 
Such correlation was not seen with placebo infusion (Figure 4.4 A-B). 
 
∆NEFA and Adipo IR 
The degree of reduction in NEFA (∆NEFA) with GIP infusion in all subjects (n=23) 
correlated positively with Adipo-IR suggesting that subjects with higher Adipo-IR 
had greater reductions in NEFA during GIP infusion. Such correlation was not seen 
with placebo infusion (Figure 4.4 C-D). 
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Figure 4.2:  A Mean NEFA AUC0-4hr ± SEM for GIP vs placebo infusions in four 
groups presented as bar charts (white bar - placebo; black bar - GIP). B AUC of 
NEFA concentrations with placebo compared to GIP infusion over 240 minutes in 
all four groups, confidence intervals (CI) and p values, *represents p <0.05. 
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Figure 4.3 Box plots showing the distribution of NEFA-AUC0-4hr (µmol/L/min) 
values for individual subjects within each group during 4-hour infusions of GIP 
versus placebo. The line within the box plots represents the median value and 
whiskers represent the minimum and maximum values of NEFA-AUC for 
individuals within each group: A Lean, B Obese, C Obese IGR and D Obese T2DM.  
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Figure 4.4: A, B Correlation between NEFA reductions (∆NEFA) [umol/l] and fasting 
plasma glucose (mmol/l) on all subjects in study (n=23) during GIP vs. placebo infusion.          
C, D Correlation between ∆NEFA and adipo-IR(mmol/L/pmol/L) during GIP vs. placebo 
infusion for all subjects. Pearson correlation coefficients (r2) and two tailed p values (p) are 
shown in each graph. 
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4.5.4 Change in Subcutaneous Adipose Tissue (SAT) lipid content 
The change in SAT triacylglycerol (TAG) content after 240 minutes of GIP vs. 
placebo infusion relative to respective baselines on each visit for the four groups are 
shown in Figure 4.5. In obese T2DM group, the SAT-TAG content increased by 
nearly 1.8-fold from baseline with GIP infusion compared to 0.86-fold with placebo 
(p=0.043). There was no significant difference in TAG content in lean, obese and 
obese IGR groups (Figure 4.5). The lipid content was measured as glycerol/protein 
(ug/mg). The concentrations of glycerol (normalised to protein) in the four groups 
before and after the infusion of placebo and GIP are shown in table 4.2. 
 
4.5.5 Gene expression of key lipid metabolism enzymes in SAT 
Lipoprotein lipase (LPL) 
The changes in gene expression for the key lipid metabolism enzymes are presented 
as fold changes relative to baseline on the same day after GIP vs placebo infusions. 
In T2DM group, there was an increased trend in LPL gene expression with GIP 
infusion although not statistically significant (Figure 4.6A and table 4.3). In the 
other three groups the changes in LPL mRNA expression with GIP and placebo 
were comparable. In lean group, the mean LPL expression with placebo was very 
high as data was skewed due to an exaggerated response observed in one individual.  
 
Adipose tissue triglyceride lipase (ATGL)  
In T2DM group, ATGL expression was 1.5-fold higher with GIP infusion compared 
to 1.1-fold with placebo although not statistically significant (p=0.12). In the other 
three groups the changes in ATGL gene expression with GIP versus placebo were 
comparable (Figure 4.6B and table 4.3). There was an exaggerated ATGL gene 
expression after placebo infusion for one subject each in lean and obese groups. 
 
Hormone sensitive lipase (HSL) 
The changes in HSL gene expression were very variable across the groups with the 
data showing no meaningful trends.  HSL expression with GIP did not differ 
significantly compared to placebo in all four groups (Figures 4.6C and table 4.3). 
There significant variations in HSL expression within each group without any 
meaningful trend in any of the groups. 
 127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: A Fold changes (mean ± SEM) in subcutaneous adipose tissue (SAT) 
triacylglycerol (TAG) content after 240 min of GIP vs. placebo infusion relative to 
the baseline on the same day in four groups. Bars at the level of dotted line drawn 
from 1.0 on Y axis indicate there is no change in lipid content compared to baseline. 
*represents p value <0.05.
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Table 4.2: Lipid content in SAT, presented as glycerol/protein (ug/mg), pre and post infusion of placebo and GIP. The fold change in lipid 
content during placebo vs GIP infusions, confidence intervals (CI) and p values are shown in the right side of the table. *represents p <0.05. 
 
 
 
 
 
 
 
 
 
 
Groups 
 
Glycerol / protein (ug)/mg in SAT (mean ± SEM) 
  
Fold change in SAT- Glycerol / protein 
relative to baseline (mean ± SEM) 
 
Placebo 
 
GIP 
 
 
Placebo 
 
 
GIP 
 
 
95% CI 
 
 
P value 
 
Pre-infusion 
 
Post-infusion 
 
Pre-infusion 
 
Post-infusion 
 
    
 
Lean 
 
 
124.86 ± 21.30 
 
 
124.58 ± 19.30 
 
120.31 ± 20.13 
 
116.99 ± 21.93 
 
1.08 ± 0.16 
 
1.03 ± 0.18 
 
-0.5 to 0.6 
 
0.84 
Obese 
 
101.51 ± 15.26 96.71 ± 12.09 122.10 ± 23.03 96.45 ± 13.72 1.03 ±  0.14 0.93 ± 0.19 -0.43 to 0.62 0.65 
Obese IGR 
 
95.65 ± 5.69 99.71 ± 10.41 84.51 ± 8.43 91.33 ± 10.51 1.05 ± 0.12 1.12 ± 0.14 -0.56 to 0.4 0.73 
T2DM 
 
90.89 ± 14.58 80.04 ± 17.93 73.01 ± 15.64 123.31 ± 26.49 0.86 ± 0.10 1.78 ± 0.38 0.1 to 1.8 0.043* 
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   Figure 4.6: Fold changes (mean ± SEM) in SAT gene expression after 240 min of GIP vs. placebo infusion relative to baseline on the same day     
   presented as bar charts for A LPL B ATGL and C HSL in four groups (lean, obese, obese individuals with IGR and obese individuals with T2DM.
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           Table 4.3 Change in SAT gene expression presented as mean fold change ± SEM for LPL, ATGL and HSL after 240 min of GIP vs.  
            placebo infusion relative to baseline on the same day in lean, obese, obese individuals with IGR and obese individuals with T2DM.
Fold change (mean ± SEM) in SAT gene expression relative to respective baselines on each visit 
 
                                              LPL                   ATGL                       HSL 
Groups Placebo GIP               P value Placebo GIP               P value Placebo GIP               P value 
 
Lean 
 
1.8 ± 0.4  
 
1.2 ± 0.2  
 
0.38 
 
1.6 ± 0.3  
 
1.3 ± 0.2  
 
0.71  
 
1.7 ± 0.6  
 
1.2 ± 0.2  
 
0.42  
Obese 1.2 ± 0.1  1.3 ± 0.1  0.49 1.3 ± 0.2  1.3 ± 0.2  0.96  1.9 ± 0.6  1.8 ± 0.3  0.93  
Obese IGR 0.9 ± 0.1  1.1 ± 0.2  0.64 1.1 ± 0.1  1.2 ± 0.2  0.90  0.9 ± 0.1  1.5 ± 0.3  0.16  
Obese T2DM 0.9 ± 0.1  1.4 ± 0.2  0.27 1.1 + 0.1  1.5 ± 0.1  0.12  1.1 ± 0.2  1.0 ± 0.2  0.62  
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4.6 Discussion 
 
In this study, we demonstrate that acute GIP infusion, during fasting, under 
hyperglycaemic conditions, reduced serum/plasma NEFAs, concomitantly 
increasing SAT triacylglycerol (TAG) content in obese patients with T2DM. This 
anabolic effect was not observed in the lean, obese or obese patients with IGR. In 
contrast, while GIP stimulated insulin secretion in the lean, obese or obese patients 
with IGR, its insulinotropic action was not observed in obese patients with T2DM. 
Thus, in obese patients with T2DM, there is a dissociation of the effects on GIP on 
beta cells and adipocytes, with blunted insulinotropic but preserved lipogenic 
actions respectively.  
 
Activation of the GIP receptor (GIPR) is somehow glucose dependent, with GIPR 
expression down regulated in response to hyperglycaemia111. In patients with T2DM 
the blunted incretin effect (involving both incretin hormones, GLP-1 and GIP) may 
in part be due to reduced islet cell expression of GIP receptors (GIPR) secondary to 
chronic hyperglycemia25,38,343,353 although this has not been demonstrated in 
humans. The physiological role of GIP in adipose tissue in T2DM remains unclear 
although adipose GIPR expression may be similarly down regulated in insulin 
resistant human subjects and may represent a compensatory mechanism to reduce fat 
storage in insulin resistance, considering the interference of NEFAs on insulin signal 
transduction60,61. However, energy dense, high fat diets in obese individuals with 
T2DM could result in exaggerated fat storage (through exaggerated GIP release) 
even in the absence of adequate insulin secretion. Although we did not measure 
GIPR, the lipogenic action of GIP at the adipocyte appears to be more pronounced 
in T2DM. Studies in patients with NAFLD suggests elevated  GIP secretion is also 
associated with intra-hepatocellular lipid deposition372.  
 
Several factors may explain the differential ability of GIP to lower plasma NEFA 
concentrations and increase SAT lipid content in obese T2DM subjects vs. other 
patient groups. In lean, obese and obese individuals with IGR, where insulin 
secretion is potently stimulated and adipose tissue insulin sensitivity is preserved 
(lower Adipo-IR), insulin independently suppressed lipolysis, lowering NEFAs 
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perhaps leaving GIP’s effects trivial. However, in T2DM when insulin secretion is 
impaired and adipose tissue is insulin resistant (high Adipo-IR), the effect of GIP 
assumes greater importance, promoting lipid accumulation in adipocytes. This is 
consistent with animal data. GIP does not promote fat accumulation in adipocytes 
with normal insulin sensitivity, with GIPR-/- mice showing similar adiposity to wild-
type on control diet135. However, under conditions of diminished insulin action, 
using IRS1 deficient mice, when the effects of GIP are examined (by disrupting GIP 
signaling, GIP−/− vs. GIPR+/+) GIP was shown to promote SAT and VAT expansion 
and decrease fat oxidation with greater SAT and VAT mass and lower fat oxidation 
in IRS-1−/−GIPR−/− vs. IRS-1−/−GIPR+/+ mice 255.  
 
A few human studies examined the metabolic effect of an acute GIP infusion in lean 
and obese individuals but none reported in people with T2DM. In studies to date, the 
effects of GIP have been examined under different experimental conditions to those 
here, for example during concomitant intra-lipid infusion and/or with 
hyperinsulinaemic-hyperglycaemic clamp conditions. These data demonstrated that 
in lean people, GIP in combination with hyperinsulinaemia and hyperglycemia, 
increased adipose tissue blood flow, glucose uptake, and NEFA re-esterification, 
thus resulting in increased abdominal SAT TAG deposition189,196. The same group 
showed that in obese and IGR subjects GIP infusion did not have the same effect on 
adipose tissue blood flow or TAG deposition in adipose tissue191. However, the 
independent contributions of insulin vs. GIP to these metabolic effects are difficult 
to dissect and GIP per se appeared to have little effect on human subcutaneous 
adipose tissue in lean insulin sensitive subjects, with an effect only apparent when 
GIP was co-administered with insulin during hyperglycemia. Thus, it there would 
appear that there are direct and indirect effects of GIP.  
 
During nutrient excess lipogenesis is stimulated via lipoprotein lipase (LPL), 
hydrolysing circulating lipoprotein-derived triacylglycerols and promoting NEFA 
esterification into TAG and storage within lipid droplets of adipose tissue. During 
periods of fasting, mobilisation of NEFAs from fat depots relies on the activity of 
key hydrolases, including hormone-sensitive lipase (HSL) and adipose triglyceride 
lipase (ATGL). In SAT, insulin stimulates NEFA esterification and inhibits  
lipolytic process 137. Most of the animal studies have shown that GIP potentiates the 
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role of insulin in regulation of LPL, and NEFA incorporation into the adipose        
tissue 91,135,170,186. In cultured subcutaneous human adipocytes, LPL gene expression 
and activity were enhanced by GIP through activation of protein kinase B (PKB) 
followed by reduction in phosphorylation of Liver kinase B1 (LKB1) and AMP-
activated protein kinase (AMPK)115,171. Trying to determine the molecular 
mechanism by which SAT-TAG content changed, we measured SAT mRNA 
expression of LPL, ATGL and HSL; surprisingly, we observed no significant 
changes in expression to account for altered serum NEFAs or SAT TAG content. 
This may represent a time-course phenomenon (changes in gene expression with 
GIP in human adipose tissue may occur over a longer interval). This speculation is 
consistent with the slow temporal onset of the molecular responses in adipose tissue 
in animal studies171,247. GIP infusion may affect enzyme activity rather than gene 
expression and therefore results of ATGL and HSL may vary if phosphorylation was 
measured. To better appreciate the physiological effects of GIP administration on 
human SAT, stable isotope studies to determine dynamic changes in fat metabolism 
with serial tissue biopsies are required.  
 
All studies were performed under hyperglycaemic clamp conditions to achieve 
comparable hyperglycaemia and to mimic post-prandial increases in GIP and 
insulin. The peak GIP concentrations achieved in our study during GIP infusions 
were comparable to levels achieved elsewhere191. We believe the changes in NEFAs 
and SAT lipid content in our obese T2DM are more likely due to the effects of GIP, 
particularly in the absence of excess insulin secretion. However, the increase in lipid 
content (1.8-fold mean change) with GIP infusion in T2DM group appears to be 
excessive. It is likely that the adipose tissue sample we analysed in this group is 
probably not representative of the whole SAT. Individual variation in results within 
this group have also contributed to a higher mean change in the lipid content in this 
group (Table 4.2). Reductions in NEFA correlated positively with fasting glucose 
and Adipo-IR in all the subjects across the four groups suggesting the effects of GIP 
are more pronounced in hyperglycaemic and insulin resistant states. We recognise 
that higher ∆NEFA would be expected in subjects with higher fasting NEFA levels 
however correlation with Adipo-IR was only seen with GIP but not with placebo 
infusion (Figure 4.4). Although higher GIP peaks were noted in our T2DM group, 
levels were not statistically different from obese and IGR groups.  
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Studying four distinct groups (with differing BMI and glucose tolerance) facilitates 
evaluation of the differential effects of GIP in insulin sensitive and resistant 
individuals. However, we acknowledge limitations including small group sizes and 
the degree of obesity: there was limited pilot data in humans prior to initiation of 
this study and subsequently published human studies on GIP infusion had small 
number of subjects189-191. Findings from our study may differ in less severely obese 
individuals. Subjects in our obese and obese T2DM groups had very high BMI but it 
was not significantly different between these two groups.  Therefore, the effects of 
GIP on NEFA reductions and SAT-TAG content we observed in obese T2DM group 
cannot be attributed to severe obesity alone.  
 
We invited only male subjects to participate in this study to avoid the confounding 
effects of sex steroid fluctuations due to menstrual cycle, menopause and hormone 
replacement therapy in female subjects. The relationship between sex steroids and 
adipocyte biology is well characterized. It was shown previously that an inverse 
correlation exists between serum oestradiol and LPL activity373. LPL activity is 
lower under dermal patches of 17-b-oestradiol374 but increased following topical 
administration of progesterone patches375. Some of our subjects were treated for 
hypertension and hyperlipidaemia. Unrecognised interactions between anti-
hypertensive or lipid modifying medication and effects of GIP cannot be excluded.   
 
In conclusion, we demonstrate that in obese patients with T2DM, acute GIP infusion 
in a fasting state, during hyperglycaemia, lowers serum NEFA and increases the 
SAT lipid content despite reduced insulinotropic activity. In lean, obese and obese 
with IGR, despite the intact insulinotropic response to GIP no lipogenic effect was 
observed. This anabolic effect of GIP further exacerbates obesity and insulin 
resistance.  
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Chapter 5 
 
The influence of GIP on adipokine gene expression 
and secretion: effects in obesity and type 2 diabetes 
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5.1 Introduction 
 
GIP has an important role in adipose tissue metabolism. In the previous chapter, we 
demonstrated that GIP enhanced systemic NEFA clearance, increasing its 
incorporation into TAGs in SAT in obese subjects with T2DM. This occurred 
despite diminished insulin secretion in this group. GIP may influence SAT 
metabolism through multiple mechanisms. In recent years, animal studies suggest 
that GIP may enhance the secretion of pro-inflammatory adipokines and perhaps 
suppress secretion of anti-inflammatory adipokines, promoting adipose tissue 
inflammation.  
 
Obesity is characterised by low-grade inflammation, with the balance between 
secretion of pro and anti-inflammatory adipokines tipped in favour of the 
development of insulin resistance and type 2 diabetes199. Amongst various pro and 
anti- inflammatory adipokines involved in adipose tissue inflammation, there is now 
evidence to suggest that the expression of some of the adipokines in adipose tissue 
may be influenced by GIP. Earlier studies in GIPR knock out (Gipr–/) mice showed 
increased adiponectin expression in SAT and systemic secretion after 3 weeks of 
high fat diet when compared to wild type mice. These findings  may suggest that 
high fat feeds leading to increased GIP levels may suppress the expression and 
secretion of the anti-inflammatory adipokine, adiponectin in normal physiological 
circumstances208.  
 
GIP induced mRNA expression of pro-inflammatory adipokines IL-6, and TNF-a  
in human subcutaneous pre-adipocytes175,253.  GIP may also influence secretion of 
other inflammatory adipokines such as MCP-1 and osteopontin. Intraperitoneal GIP 
injections in mice increased MCP-1 expression and macrophage infiltration in 
adipose tissue252. GIP was shown to enhance osteopontin expression in primary 
rodent adipocytes236. Human adipocytes with a genetic variant of GIPR (with 
diminished function) had reduced osteopontin levels and better insulin sensitivity 
suggesting a role for GIP in regulation of osteopontin production in adipose 
tissue237. Resistin, another pro-inflammatory adipokine, is thought to play a key role 
in the GIP induced enhancement of lipoprotein lipase (LPL) activity.  Adipocytes of 
resistin knockout mice showed reduced GIPR expression and compromised GIP 
 137 
signalling pathways (PKB/LKB1/AMPK) that enhanced LPL activity171,184. 
Currently there is no evidence to suggest changes to resistin gene expression or 
secretion with GIP. 
 
There is insufficient evidence in humans to suggest that GIP has any effect on 
adipokine gene expression or secretion apart from one study in humans that showed 
an increase in MCP-1 gene expression and secretion with acute GIP infusions230. In  
a previous study from our unit, acute GIP infusions in obese individuals with type 2 
diabetes did not alter plasma IL-6, leptin, adiponectin, ghrelin and obestatin levels 
but IL-6 was supressed significantly with acute GLP-1 infusions 220. 
 
 
5.2 Hypothesis and aims 
 
We hypothesised that GIP may increase the expression and secretion of pro-
inflammatory adipokines and reduce the expression and secretion of the anti-
inflammatory cytokine, adiponectin in SAT. To investigate the putative pro-
inflammatory properties of GIP in human SAT, we studied the effects of acute GIP 
infusions versus placebo on the gene expression and plasma concentrations of 
adipokines TNF-a, MCP-1, osteopontin and adiponectin that were shown to be 
influenced with GIP treatment in animal models and in-vitro studies. We also 
explored whether the effects of GIP differed with obesity and with impaired glucose 
regulation. 
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5.3 Subjects and methods 
 
General methods are discussed in detail in chapter 2 (Methods). Details on subject 
groups, participant characteristics, study design and protocol are described in 
chapter 3, section 3.3. Blood samples at baseline (taken prior to hyperglycaemic 
clamp), 120 minutes and 240 minutes were measured for key adipokines TNF 
receptor 2 (TNF R2), MCP-1, adiponectin, and osteopontin. 
 
SAT biopsies Subcutaneous adipose tissue (SAT) biopsies were obtained at baseline 
and after 240 min of the GIP/placebo infusion on the contralateral site. Adipose 
tissue samples (50-150 mg wet weight) were collected and snap frozen in liquid 
nitrogen and stored at -80o C and later the gene expression of key adipokines TNF-
a, MCP-1, osteopontin and adiponectin were determined pre and post GIP/placebo 
infusions by real time qPCR techniques. The details of subcutaneous adipose tissue 
biopsy procedure and the techniques of adipose tissue analysis are discussed in 
detail in Chapter 2 (Methods), sections 2.4 and 2.8 respectively. 
 
5.4 Statistical Analysis 
 
Plasma Adipokine concentrations 
One-way analysis of variance (ANOVA) with Dunnett’s multiple comparison tests 
were performed to compare the changes in plasma adipokines at 120 minutes and 
240 minutes from their baseline during GIP and placebo infusions in the four 
groups.  Mean difference in these changes and p values were determined. P value 
(two tailed) <0.05 was considered to be statistically significant. 
 
Adipokine gene expression 
Fold change in gene expression after 240 minutes of GIP and placebo infusions 
compared to their respective baseline measurements on the same day were 
calculated (post infusion gene expression ÷ pre-expression values).  Fold changes in 
gene expression were log transformed before analysis and paired t-tests were 
performed to explore whether the change over the two-time points differed between 
GIP and placebo. P value of < 0.05 (two-tailed) was considered significant. 
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5.5 Results 
 
5.5.1 Participant details and metabolic parameters 
The details of participants, sub groups, baseline characteristics and metabolic 
parameters for all subjects are described in chapter 3, section 3.5 and in table 3.1. 
The blood glucose and GIP concentrations during hyperglycaemic clamp during GIP 
and placebo infusions are described in chapter 3, section 3.5.2. 
 
5.5.2 Plasma adipokine concentrations 
TNF R2, MCP-1, osteopontin and adiponectin were measured at baseline and at 
further two time points (120 min and 240 minutes) during GIP and placebo infusion. 
Baseline adipokines (fasting concentrations) were compared between the four 
groups (lean, obese, obese IGR and obese T2DM). Changes in adipokine 
concentrations during GIP vs placebo infusions were compared for all subjects 
together (n=23) to see if there was an overall difference between GIP and placebo 
infusion. Adipokine concentrations at three time points during GIP versus placebo 
infusions in each of the four groups were also compared separately.  
 
Fasting plasma adipokine concentrations in four groups 
Adipokine concentrations measured at baseline (fasting) prior to initiation of 
hyperglycaemic clamp for subjects in four groups are shown in Figure 5.1. Mean 
fasting plasma concentrations of TNF-R2 and MCP-1 were significantly different in 
all the four groups based on multiple comparison tests. In comparison with the lean 
group (control) the fasting concentrations of TNF-R2, MCP-1 and osteopontin were 
significantly higher in obese T2DM. There was no significant difference seen in 
fasting adiponectin levels between the four groups.  
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Plasma adipokine concentrations during GIP vs placebo infusion  
TNF-R2  
In the lean group, there was a reduction in TNF R2 concentrations from baseline to 
120-minute time point during placebo and GIP infusions (adjusted p value =0.02) 
but this difference was not significant at the end of infusion at 240 minutes. In other 
three groups reduction in TNF- R2 from baseline was observed only during placebo 
infusion at 120 minutes but not during GIP infusion (p= 0.01), (Figure 5.2 A-D). 
MCP-1  
There was no significant change in MCP-1 concentrations from baseline compared 
to both time points (120 and 240 minutes) during GIP or placebo infusion in any of 
the groups (Figure 5.2 E-H). 
Osteopontin  
There was no significant change in osteopontin concentrations from baseline to both 
time points (120 and 240 minutes) during GIP or placebo infusion in any of the 
groups (Figure 5.3 A-D). 
Adiponectin  
In all the groups, plasma adiponectin concentrations show a reduced trend at 120 
minutes during both placebo and GIP infusions but no change at 240 minutes 
compared to the baseline level post infusion. Results were not statistically 
significant due to wide variation in individual responses. (Figure 5.3 E-H). 
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Figure 5.1 Baseline (fasting) plasma adipokine concentrations (Mean ± SEM) in 
four groups. Statistically significant difference in baseline concentrations between 
obese T2DM group and lean group represented are by * (p <0.05) and ** (p <0.01). 
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Plasma TNF R2 and MCP-1 concentrations during GIP vs placebo infusions  
 
                                
                                
--------------------------------------------------------------------------------------------------------- 
                                
 
                                
   
 
Figure 5 2: Plasma TNF-R2 and MCP-1 concentrations (mean ± SEM) during 4 hour infusions of 
GIP vs. placebo (with hyperglycaemic clamp) A-D TNF-R2 concentrations in all four groups and        
E-H: MCP-1 concentration in all four groups.  
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Plasma osteopontin and adiponectin concentrations during GIP vs placebo 
infusions  
 
                                    
             
                                               
------------------------------------------------------------------------------------------------------ 
     
                               
                          
 
 
Figure 5.3: Plasma osteopontin and adiponectin concentrations (mean ± SEM) during 4 hour 
infusions of GIP vs. placebo (with hyperglycaemic clamp) A-D osteopontin concentrations in all four 
groups and E-H: adiponectin concentration in all four groups.                                                                                                                                                                                                                                                                        
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5.5.3 Adipokine gene expression in SAT 
 
Gene expression of key adipokines TNF-a, MCP-1, adiponectin and osteopontin are 
expressed as relative expression values obtained by normalisation to three 
housekeeping genes (ribosomal 18s, Beta 2 micro-globulin and glyceraldehyde 3-
phosphate dehydrogenase). There was no significant difference in baseline (fasting) 
adipokine expression for any of the adipokines in all four groups (Table 5.1). For 
each adipokine, the gene expression results for individuals within each group (lean, 
obese, IGR and T2DM) are presented in a box plot distribution for both placebo and 
GIP infusions days. Change in gene expression from baseline to the post infusion 
value is presented as fold change and these values were used to compare the effects 
of GIP versus placebo on gene expression.  
 
Adipokine gene expression at baseline (fasting state) 
 
Table 5.1 Baseline adipokine gene expression (mean ± SEM) in SAT in the four 
groups. P value is derived from one-way ANOVA comparing four groups indicating 
the overall difference in baseline concentrations between the four groups. 
 
 
 
 
Adipokine 
 
 
Lean 
(N=6) 
 
Obese 
(N=6) 
 
Obese IGR 
(N=6) 
 
Obese T2DM 
(N=5) 
 
 
P 
value 
 
 
TNF-a 
 
 
0.57 ± 0.1 
 
0.82 ± 0.1 
 
0.78 ± 0.2 
 
0.92 ± 0.2 
 
0.4 
 
MCP-1 
 
 
0.69 ± 0.1 
 
 
0.46 ± 0.04 
 
0.59 ± 0.1 
 
0.54 ± 0.1 
 
0.5 
 
Osteopontin 
 
0.87 ± 0.2 
 
 
0.39 ± 0.1 
 
0.64 ± 0.3 
 
0.72 ± 0.2 
 
0.5 
 
Adiponectin 
 
 
0.61 ± 0.2 
 
1.04 ± 0.3 
 
1.01 ± 0.1 
 
1.01 ± 0.1 
 
0.3 
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TNF-a gene expression in SAT 
Baseline TNF-a gene expression (mean ± SEM) was lower in lean subjects but it 
was not statistically different from the other three groups (Table 5.1) Gene 
expressions pre and post infusion of placebo and GIP (2 separate days) for 
individuals in each group are shown in Figure 5.4 A-D. Comparing within each 
group, TNF- a expression in lean and obese individuals were similar with GIP or 
placebo infusions. Whereas in obese IGR and obese T2DM groups, the TNF-a 
expressions post GIP infusion are higher in most subjects compared to their 
respective baseline (pre) values and higher compared to the post placebo infusion 
values (Figure 5.4 C, D). 
The changes in TNF-a gene expression (mean ± SEM fold change) from baseline to 
the end of infusion for placebo vs GIP visits are shown for the four groups in Figure 
5.4 E. The gene expression did not change with GIP or placebo infusions in lean and 
obese groups. Whereas in the obese T2DM group, the change in gene expression 
was significantly higher with GIP infusion compared to placebo (3.5 ± 1.7-fold vs 
0.8 ± 0.1fold respectively). Similar trend was seen in obese IGR group although the 
results were not statistically significant.  
 
MCP-1 gene expression in SAT 
Baseline MCP-1 gene expression (mean ± SEM) was similar in all the four groups 
(Table 5.1). Gene expressions pre and post infusion of placebo and GIP for 
individuals in each group are shown in Figure 5.5. Comparing within each group, 
MCP-1 expression was higher in most lean and obese individuals with GIP infusion 
compared to their respective baseline (pre) values and higher compared to the post 
placebo infusion expression (Figure 5.5 A, B).  
The changes in MCP-1 gene expression (mean ± SEM fold change) from baseline to 
the end of infusion for placebo vs GIP visits in all the four groups are shown in 
Figure 5.5E. The change in gene expression was significantly higher with GIP 
infusion compared to placebo in lean and obese groups (lean: 2.6 ± 0.5 vs. 0.9 ± 0.3-
fold p=0.02; obese: 2.4 ± 0.6 vs.1.4 ± 0.4) respectively. Interestingly such difference 
with GIP infusion was not observed in the obese IGR and obese T2DM groups. 
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TNF-a gene expression in SAT 
 
                         
                         
 
 
 
Figure 5.4: TNF-a gene expression for individual subjects pre and post infusion of placebo and GIP                  
(2 separate days) is presented in box plots in A lean subjects, B obese subjects, C obese individuals with 
IGR and D obese individuals with T2DM. Horizontal line in the boxplot represents the median value and 
whiskers represent the minimum and maximum values of gene expression. E Fold changes (mean ± 
SEM) in TNF-a gene expression in subcutaneous adipose tissue (SAT) after 240 min of GIP vs. placebo 
infusion relative to the baseline on respective days are presented as bar charts in the four groups.  
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MCP-1 gene expression in SAT 
 
                      
 
                        
 
 
 
 
Figure 5.5: MCP-1 gene expression for individual subjects pre and post infusion of placebo and GIP (2 
separate days) is presented in boxplots in A lean subjects, B obese subjects, C obese individuals with 
IGR and D obese individuals with T2DM. Horizontal line within each boxplot represents the median 
value and whiskers represent the minimum and maximum values of gene expression, F represents a data 
point outside axis limit. E Fold changes (mean ± SEM) in MCP-1 gene expression in subcutaneous 
adipose tissue (SAT) after 240 min of GIP vs. placebo infusion relative to the baseline on respective days 
are presented as bar charts in the four groups.   
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Osteopontin gene expression in SAT 
Baseline osteopontin gene expression (mean ± SEM) was not statistically different 
in the four groups (Table 5.1) Gene expressions pre and post infusion of placebo and 
GIP for individuals in each group are shown in Figure 5.6 A-D. Comparing within 
each group, there was no significant difference in gene expression from baseline 
(pre) to post infusion with GIP or placebo in most subjects. One subject each in 
obese IGR and obese T2DM groups had exaggerated gene expression response after 
placebo infusion that skews the data. 
 
The change in osteopontin gene expression (mean ± SEM of fold change) from 
baseline to the end infusion for placebo vs GIP visits in all the four groups are 
shown in figure 5.6 E. There was no significant change in gene expression in all the 
groups. Although the fold change with placebo in obese IGR and obese T2DM 
groups appears to be higher, the data is skewed due to exaggerated response in 
individual subjects in each group and therefore results are not significant. 
 
Adiponectin gene expression in SAT 
 
Baseline adiponectin gene expression (mean ± SEM) was slightly lower in lean 
group but not significantly different from the other three groups (Table 5.1). Gene 
expressions pre and post infusion of placebo and GIP for individuals in each group 
are shown in Figure 5.7 A-D. Comparing within each group, adiponectin expression 
showed wide variation in lean and obese individuals with no overall change in 
expression from baseline (pre) to post infusion with GIP or placebo). In obese IGR 
and obese T2DM subjects, the adiponectin expressions were similar in both these 
groups and there was no change after GIP or placebo infusions. 
 
The change in adiponectin gene expression (mean ± SEM of fold change) from 
baseline to the end infusion for placebo vs GIP visits in all the four groups are 
shown in figure 5.7 E. There was no significant change in gene expression in obese, 
obese IGR and obese T2DM groups. Although there appears to be a difference in the 
lean group between GIP and placebo, the variations in individual responses to GIP 
in this group skew the data and therefore this difference was not statistically 
significant. 
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Osteopontin gene expression in SAT 
 
 
                                  
 
                                  
 
 
     
 
Figure 5.6: Osteopontin gene expression for individual subjects pre-and post infusion of placebo and 
GIP (2 separate days) is presented in boxplots in A lean subjects, B obese subjects, C obese individuals 
with IGR and D obese individuals with T2DM. Horizontal line within each boxplot represents the 
median value and whiskers represent the minimum and maximum values of gene expression for each 
group, F represents a data point outside axis limit. E Fold changes (mean ± SEM) in osteopontin gene 
expression in subcutaneous adipose tissue (SAT) after 240 min of GIP vs. placebo infusion relative to the 
baseline on respective days are presented as bar charts in the four groups.  
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Adiponectin gene expression in SAT 
 
 
                                 
                                  
 
 
 
 
 
Figure 5.7: Adiponectin gene expression for individual subjects pre and post infusion of placebo and 
GIP (2 separate days) is presented in A lean subjects, B obese subjects, C obese individuals with IGR 
and D obese individuals with T2DM. Horizontal line within each boxplot represents the median value 
and whiskers represent the minimum and maximum values of gene expression for each group, E Fold 
changes (mean ± SEM) in adiponectin gene expression in subcutaneous adipose tissue (SAT) after 240 
min of GIP vs. placebo infusion relative to the baseline on respective days are presented as bar charts in 
the four groups.  
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5.6 Discussion 
 
The effects of GIP on plasma and SAT adipokine expression has not been studied 
before in human subjects with T2DM. In this study, as expected, the baseline plasma 
concentrations of TNF-a, MCP-1 and osteopontin were significantly higher in the 
obese T2DM group compared to the lean control group222,376-381 but the anticipated 
lower plasma adiponectin concentration in the IGR or T2DM participants was not 
observed with no significant differences between the four groups382,383. However, in 
response to GIP, there were no significant changes in the concentration of any of the 
plasma adipokines in any of the groups. In SAT, we showed that gene expression of 
TNF-a in SAT of obese T2DM subjects increased significantly after GIP infusion 
compared to placebo and similar trends were seen in obese subjects with IGR with 
no change in lean and obese normoglycaemic subjects. In contrast, MCP-1 gene 
expression was higher with GIP infusion in lean and obese but was not different in 
IGR or T2DM. There was no change in osteopontin and adiponectin gene expression 
with GIP or placebo infusions in any of the groups.  
At present, there is little literature regarding the in vivo effects of GIP on adipokines 
in human SAT with no evidence to support whether these effects of GIP differ 
according to insulin sensitivity. From earlier results, it is known that SAT retains 
sensitivity to GIP’s actions in T2DM subjects despite the loss of insulinotropic 
activity. The results we observed in gene expression of TNF-a and MCP-1 with GIP 
infusions are interesting as the groups which had higher gene expression of these 
two inflammatory adipokines were not consistent and there seems to be a difference 
in these gene expressions with GIP in normoglycaemic and hyperglycaemic states.  
IL-6 and TNF-a are well studied adipokines in adipose tissue inflammation and 
their concentrations are increased in obesity and insulin resistant states.  Studies in 
animal models and cell cultures showed consistent increases in IL-6 with 
GIP175,253,384. TNF-a induces insulin resistance through multiple mechanisms that 
involve altered regulation of NEFA, Glut4 proteins and defects in insulin receptor 
signalling212,213.  Previous in-vitro studies have shown that changes in TNF-a 
expression with GIP treatment were inconsistent. Whilst some studies showed GIP 
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to increase in TNF-a expression along with IL6 and MCP-1248,253, others showed 
either no change175,385 or reduced expression and inflammation with GIP 
treatment385,386.  
Studies exploring the molecular mechanisms suggest these actions of GIP are 
mediated through pathways involving Protein Kinase-A (PKA) nuclear factor κB 
(NF-κB) and hypoxia inducible factor-1a (HIF-1a)175,252. GIP was also shown to 
induce lipolysis which increases inflammatory cytokines, a process inhibited by 
insulin177. In insulin deficient states, lipolysis releases NEFAs that are re-esterified 
in the presence of GIP and this vicious cycle of lipolysis and pro-inflammatory 
adipokine expression may contribute to insulin resistance in adipose tissue. GIP was 
shown to increase pro-inflammatory adipokine IL-6 secretion in the presence of 
other cytokines such as IL-1β, TNFα and lipopolysaccharides which release 
inflammatory cytokines175,248 indicating GIP action may be more prominent in low 
grade inflammatory states. 
We speculate that GIP induced TNF-a expression in obese T2DM subjects observed 
in our study could potentially be due to the reasons that pro-inflammatory effects of 
GIP may be prominent in insulin deficient subjects compared to normoglycaemic 
healthy individuals where anti-inflammatory effects of Insulin may override the pro-
inflammatory effects of GIP387,388. In mice models insulin was shown to inhibit 
TNF-a and improve endothelial function389. Furthermore, T2DM is a low grade 
chronic inflammation state and GIP may have an enhanced action in the presence of 
other inflammatory adipokines.  We are unable to explain the lack of such changes 
in other inflammatory adipokines to fully support this concept. 
MCP-1 is a key regulator chemokine involved in migration and infiltration of 
monocytes and macrophages221.  A single human study in normoglycaemic obese 
individuals showed acute GIP infusions had increased gene expression and plasma 
concentrations of MCP-1 and MCP-2 230. These results are similar to the findings we 
observed in obese and lean individuals in our experiments. The above study used a 
different methodology (euglycaemic clamps and hyper-insulinemic hyperglycaemic 
clamps) but used similar concentrations of GIP infusions (2pmol.kg-1.min-1) as in 
our study. In the same study GIP also increased MCP-1 expression in co-cultures of 
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3T3L1 adipocytes. There are no studies so far evaluating these effects of GIP in 
individuals with T2DM.  
TNF R1 and TNF R2 are the two distinct receptors that mediates the biological 
effects of TNF-a on adipose tissue390,391. We measured TNF R2 in plasma which is 
a widely expressed receptor for TNF-a and is homologous to the archetypal TNF-a. 
TNF R2 is expression is higher in obesity and insulin resistant states and is reliably 
measured in plasma392,393. We did not observe any significant changes in adipokines 
secretion in plasma. It is possible that the 4-hour time frame may have not been 
sufficiently long for the inflammatory changes in adipose tissue to be translated into 
changes in the circulation.  
Most studies that evaluated GIP effects on adipose tissue inflammation were done in 
normoglycaemic animal models and on pre-cultured adipocytes. Studying human 
subjects with T2DM enabled us to evaluate the differential effects of GIP in 
normoglycaemic and hyperglycaemic individuals with altered b cell function. All 
experiments were done under hyperglycaemic clamp conditions that induces 
hyperinsulinaemia. The effects of insulin on adipokine expression is a major factor 
when assessing the independent effects of GIP. We also acknowledge the limitations 
in accurately assessing the effects of GIP due to small group sizes in our study. We 
are unable to comment on the underlying mechanisms for change in TNF-a  as our 
methodology was not aimed to explore the molecular mechanisms of GIP’s pro-
inflammatory action. Unfortunately, the effects of GIP on IL-6 gene expression 
could not be assessed in our experiments at the time of this study due to technical 
difficulties with primers we used that could not be optimised to appropriate 
conditions to carry out qPCR.   
In summary GIP appears to have pro-inflammatory effects in SAT with most of the 
evidence derived from animal models and in vitro studies. These effects of GIP may 
not be conspicuous in normoglycaemic state with normal b cell function but may be 
pronounced in insulin deficient states. It remains unclear if modulation of pro-
inflammatory effects of GIP leading to modulation of adipokine secretion would 
further translate into exacerbation of insulin resistance and development of T2DM. 
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Chapter 6 
 
Effects of treatment with metformin on incretin 
system and gut hormones in obese patients with 
T2DM  
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6.1 Introduction 
 
The incretin effect in type 2 diabetes mellitus (T2DM) is reduced due to diminished 
insulinotropic activity of both incretin hormones (GLP-1 and GIP)25.	Restoration of 
normoglycaemia in T2DM may partially reverse the diminished insulinotropic 
activity276. Hypoglycaemic agents may enhance the secretion of incretins or improve 
their efficacy. Whilst the newer class of dipeptidyl peptidase-IV (DPP-IV) inhibitors 
developed specifically for this purpose approximately 10 years ago are now widely 
used in T2DM, the older and well established drug, metformin also appears to have 
an influence on the incretin axis. The glucose-lowering effect of metformin is 
thought to be mediated through reduced hepatic glucose output, increased peripheral 
glucose uptake and enhanced intestinal utilisation of glucose278-280.  
 
In the last decade, there is emerging evidence that metformin treatment in 
animals281,283 and in humans (obese individuals without T2DM and individuals with 
T2DM) increases GLP-1 concentrations288-291,293,295. There is little evidence on 
changes to circulating GIP concentrations with metformin treatment and no 
evidence so far on how metformin treatment may influence actions of GIP at the 
adipose tissue level. Prior to this current study, published research had evaluated the 
short-term effects of metformin treatment (up to four weeks) and the acute effects 
(after a single dose of metformin) on GLP-1 and DPP-IV activity in patients with 
T2DM289,291-293,295. At the time of this study, there was limited data to support that 
these effects are sustained with longer term treatment.  
 
Metformin improves glycaemic control with less weight gain compared to some of 
the other oral anti-hyperglycaemic treatments in patients with T2DM303. Although 
the mechanisms behind this are poorly understood, metformin has been shown to 
reduce food intake in obese subjects with and without diabetes mellitus304,305.   The 
effects of metformin treatment on appetite regulatory hormones are less well 
studied.  Ghrelin is a potent orexigenic (appetite stimulant) hormone secreted from 
the gastric fundus which plays an important role in the hypothalamic regulation of 
energy homeostasis 73. The role of metformin on modulation of ghrelin levels in 
patients with T2DM remains unclear. Studies in this area so far have shown 
conflicting results306-309.  
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6.2 Hypothesis and aims 
We hypothesised that metformin treatment may affect the incretin system by altering 
the incretin hormone concentrations which may contribute to its additional glucose-
lowering properties.  The previously reported anorectic effects of metformin that 
leads to improvement in glycaemic control and weight loss may be related to 
changes in ghrelin levels. 
Our aim was to study the effects of treatment with metformin (minimum 3 months) 
on endogenous GIP, GLP-1 concentrations, DPP-IV activity and active ghrelin 
concentrations in obese patients with T2DM. 
 
6.3 Subjects and Methods 
 
Study design  
This was a prospective observational study in patients with drug naive T2DM 
commencing metformin as monotherapy. We studied eight subjects (6 males and 2 
female) age 58.7 ± 2.6 years with obesity and new diagnosis of T2DM. None of 
these subjects were on treatment for T2DM at the start of this study. Each subject 
was studied for 6 hours with blood sampling at multiple time points following a 
standard mixed meal, before and after at least 3 months of metformin monotherapy. 
 
Study protocol (Figure 6.1) 
All participants had 3 visits (Figure 6.1) to the investigations unit in Clinical 
Sciences Centre, University Hospital Aintree, Liverpool. A detailed history was 
taken on the first visit and anthropometric assessments were done on all three visits. 
 
Visit 1 
On their 1st visit, an intravenous cannula was inserted and fasting blood samples 
were collected into EDTA, lithium heparin and serum separator tubes for later 
measurement of DPP-IV activity, GLP-1 and ghrelin. Blood collection tubes had 50 
microliters aprotinin, to prevent degradation by DPP-IV and other proteolytic 
enzymes. Details on sample collection processing and storage are described in 
chapter 2 (Methods). 
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After collection of blood samples in the fasted state (time = 0 minutes), patients 
were asked to consume a mixed meal calculated to provide approximately 600 kcal 
(cereals, toast, flora, jam and orange juice). The energy load of the meal was 
calculated to be 23% fat, 13% protein and 64% carbohydrate. Blood samples were 
taken for later measurement of DPP-IV activity, GLP-1 and ghrelin at 15, 30, 60, 90, 
120, 150, 180, 210, 240, 300 and 360 minutes after consumption of the test meal. 
The postprandial peak of GLP-1 concentrations is usually seen between 60 to 120 
minutes, we sampled blood for a longer duration to see if the observed effects were 
sustained and to detect any changes in the other variables (DPP-IV and ghrelin). 
Participants marked their hunger score and desire to eat on a visual analogue scale 
(0-100) in the fasted state and at every hour after a mixed meal. A buffet lunch was 
provided at the end of the experiments and total calorie intake during this lunch was 
recorded. 
 
Following visit 1, patients were commenced on metformin tablets, starting initially 
at 500 mg daily, and the dose titrated upwards over a period of six to eight weeks to 
the dose that produced satisfactory metabolic control or titrated to the maximum 
dose tolerated by the patient. The maximum dose for metformin given was 1000 mg 
three times daily. Subjects with gastrointestinal side effects during the period of 
upward titration of the dose were instructed to return to the dose previously tolerated 
for a further two weeks, and then an increase in the dosage was re-attempted if 
tolerated.  During this time, all patients were instructed to continue with their diet as 
previously recommended. 
 
Visit 2 
Six weeks following initiation of treatment with metformin, participants were 
asked to attend the investigational unit for a 2nd visit. At this stage blood samples 
were taken to measure HbA1c.  Lifestyle advice was offered (as in routine 
clinical practice), compliance with medication was assessed and further dose 
titration was recommended as appropriate.  
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Visit 3 
All subjects attended for their 3rd visit at least three months (range 3 to 7 
months) after the initiation of metformin monotherapy, and the procedures of 
visit 1 were repeated in an identical manner. Telephone contact was maintained 
with all subjects between visits 1 and 3 to monitor compliance with medication 
and to offer advice on problems with medication tolerance. 
 
 
 
  
	
	
							
	
 
 
 
 
 
 
 
 
 
   
 
 
Figure 6.1 Study design showing 3 visits for each participant and the study protocol 
during each of these visits. 
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6.4 Statistical Analysis 
 
Hormone profiles at multiple time points after a standard mixed meal were 
compared with baseline fasting concentrations using One-ANOVA and Dunnett’s 
multiple comparison tests. 
 
Area under the curve (AUC) was calculated for all the variables measured at 12 time 
points over a period of 6 hours to give an integrated measure of responses. AUC was 
calculated by the trapezoidal rule using GraphPad Prism software. AUCs pre and 
post metformin treatment (visit 1 and visit 3) were compared using Student’s t test 
for paired data and Wilcoxon signed-rank test when paired data were not normally 
distributed. Mean observations at each time point pre and post metformin were also 
compared for all variables. P value of < 0.05 (two-tailed) was considered to be 
significant. 
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6.5 Results 
 
6.5.1 Participant demographics and metabolic parameters 
 
Eight subjects (6 male and 2 female) with a mean age of 58.7 years (range 47 to 69 
years) were recruited. Mean dose of metformin at visit 3 was 1.75 g daily (range 1 to 
3 g daily). As expected glycaemic control improved in all patients after at least 3 
months of metformin therapy (range 3 to 7 months). The mean HbA1c reduction 
was 13.5 ± 4 mmol/mol (p = 0.017) with metformin treatment but there was no 
significant change in body weight (Figure 6.2 and Table 6.1). 
 
 
			 					  
 
Figure 6.2: A HbA1c (mmol/mol) and B body weight (kg) before and after 3 months of 
metformin treatment for all subjects presented in box plots with median line. Whiskers 
represent minimum and maximum measures of Hba1c and weight. *p=<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1: Changes in glycaemic control and body weight after 3 months of metformin 
treatment. Variables are shown as mean ± SEM, NS denotes not significant. 
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6.5.2 Fasting hormone profiles pre and post metformin 
 
GLP-1 Following 3 months of metformin monotherapy, the mean fasting GLP-1 
levels were higher compared to the baseline but there was significant variation in 
GLP-1 levels in individual subjects and the results were not statistically significant 
(Figure 6.3A). [pre-metformin: 5.3 ± 2 vs. post metformin: 7.3 ± 3.4 pmoles/litre, 
(Mean ± SEM); P = 0.2.]. 
DPP-IV activity: The mean fasting DPP-IV activity was significantly lower after 3 
months of metformin treatment compared to the baseline (pre-metformin: 43.8 ± 3.6 
vs. post metformin: 36.7 ± 1.4 pmoles/min/ng; P = 0.012). Most individuals had 
lower fasting DPP-IV activity after metformin treatment (Figure 6.3 B). 
Ghrelin: The mean fasting ghrelin levels were not different before and after 
metformin treatment (pre-metformin: 42.4 ± 8.8 vs. post metformin: 47.1 ± 10.4 
ρg/ml; P = 0.6). (Figure 6.3C). 
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Figure 6.3 Fasting concentrations 
of plasma GLP-1, DPP-IV activity 
and ghrelin before and after 3 
months of metformin treatment for 
all subjects presented as box plots 
with median line. Whiskers 
represent minimum and maximum 
measures. *p=<0.05.  
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6.5.3 Postprandial hormonal profile after a standard test meal 
 
GLP-1: The mean GLP-1 concentrations measured at 12 time points after the test 
meal were consistently higher after 3 months of metformin monotherapy compared 
with the pre-metformin visit (Figure 6.4 A). The GLP-1 concentrations increased 
within 30 minutes after the standard mixed meal (post metformin) but 
concentrations at all time points were not significantly different from 
baseline/fasting state. Mean AUC0-6hr of GLP-1 was significantly higher on 
metformin (pre: 1750.8 ± 640 vs. post: 2718.8 ± 1182.3 pmoles/litre/min;                     
P = 0.017) [Figure 6.4 B].  
 
DPP-IV activity: The mean DPP-IV activity measured at all time points after the 
test meal were consistently lower after 3 months of metformin monotherapy 
compared with the pre-metformin visit (Figure 6.5 A). The DPP-IV concentrations 
at any of the time points were not significantly different from baseline/fasting state. 
Mean AUC0-6hr of DPP-IV activity was lower post metformin but this did not reach 
statistical significance (pre: 14099.4 ± 989 vs. post metformin 11988.2 ± 737.8 
pmoles/min/ng; P = 0.1). 
 
Ghrelin: Ghrelin concentrations measured at 12 time points after the test meal 
before and after 3 months of metformin monotherapy were very variable between 
the two visits and did not show any meaningful trend. At all-time points 
concentrations of ghrelin were not significantly different from baseline/fasting state. 
(Figure 6.6 A). There was no significant difference in mean AUC0-6hr of ghrelin 
following treatment with metformin compared with baseline (pre: 18425.9 ± 2436 
vs post: 18787.6 ± 2485 ρg/ml/min, P = 0.9). 
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Figure 6.4: A Mean GLP-1 ± SEM (pmol/L) for all subjects at 12 time points after a 
standard mixed meal pre and post metformin treatment. B AUC of GLP-1 for all 
subjects before and after 3 months of metformin treatment are presented in box plots 
with median line. Whiskers represent minimum and maximum AUC measures of 
GLP-1. 
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Figure 6.5: A Mean DPP-IV activity ± SEM (pmol/min/ng) for all subjects at 12 
time points after a standard mixed meal pre and post metformin treatment. B AUC 
of DPP-IV activity for all subjects before and after 3 months of metformin treatment 
are presented in box plots with median line. Whiskers represent minimum and 
maximum AUC measures of DPP-IV activity. 
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Figure 6.6: A Mean ghrelin ± SEM (pg/ml) of all subjects at 12 time points after a 
standard mixed meal pre and post metformin treatment. B AUC of DPP-IV activity 
for all subjects before and after 3 months of metformin treatment are presented in 
box plots with median line. Whiskers represent minimum and maximum AUC 
measures of ghrelin. 
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6.5.4 Scores on visual analogue scales and total calorie intake 
 
All subjects marked their scores of hunger and their desire to eat on a visual 
analogue scale (0-100) on the two visits (pre and post metformin treatment). There 
was no difference in the scores on visual analogue scales pre and post metformin 
(Figure 6.7 A, B). Total calorie intake during a buffet lunch at the end of the 
experiments did not differ between pre and post metformin visits (Figure 6.7 C). 
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mixed meal A Hunger scores,      
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(Kcal) intake during buffet lunch 
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6.6 Discussion 
 
In this study, we have shown that three or more months of metformin monotherapy 
in obese patients with T2DM is associated with a significant increase in postprandial 
active GLP-1 concentration, which is maintained for up to six hours after a standard 
meal. We also observed an increased trend in fasting GLP-1 levels although the 
difference was not statistically significant. DPP-IV activity was significantly lower 
in the fasting state after 3 months of metformin therapy. Postprandial DPP-IV 
activity seemed to be lower after metformin treatment but this difference was not 
statistically significant. Reduced fasting DPP-IV may have contributed to the 
enhanced post prandial GLP-1 secretion in our study. However, our methodology 
was not aimed at exploring the underlying mechanisms of increased GLP-1 
secretion. Glycaemic control improved as expected but no significant weight change 
occurred during this period despite the observed increased postprandial GLP-1 
responses. There was no difference in participants’ visual analogue score of hunger 
or their desire to eat on pre and post metformin visits. Furthermore, there was no 
difference in calorie intake during a buffet lunch before and after metformin 
treatment. 
 
The results from our study are consistent with the other human studies in the past 
that showed increased post prandial GLP-1 levels with metformin treatment in non-
diabetic lean and obese subjects289,292,293 and in obese subjects with T2DM292. 
Metformin treatment in these studies was for a shorter duration ranging from 4 days 
to 4 weeks. At the time of our study there was dearth of evidence on the effects of 
longer term metformin treatment on incretins and gut hormones in T2DM.  One 
study undertaken in non-diabetic women with polycystic ovarian syndrome (PCOS) 
showed increased AUC of both GIP and GLP-1 after a 75g oral glucose tolerance 
test in lean women (BMI < 25 kg/m2). A similar trend was seen in obese women 
(BMI» 32 kg/m2) with PCOS but the results were not statistically significant.  
 
Larger studies published recently strengthen the concept of metformin enhanced 
GLP-1 concentrations. Data taken from a large cross sectional study of 836 people 
with recent diagnosis of T2DM aimed at investigating predictive bio markers of 
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glycaemic deterioration and phenotyping (DIRECT study) showed fasting GLP-1 
levels to be significantly higher in patients treated with metformin compared to 
those on life style modification277. A randomised double blind placebo controlled 
trial (CAMERA study) on effects of metformin on cardiovascular disease in patients 
without diabetes (n=86) showed that metformin treated subjects consistently had 
higher fasting GLP-1 levels at 6, 12 and 18 month intervals compared to those on 
life style measures alone (n=87) 277.  A randomised cross over trial using delayed 
release metformin showed that 5-day treatment period resulted in significant 
increases in GLP-1 and PYY concentrations299. Other smaller studies in subjects 
with T2DM published in recent years after our study, have shown varied results with 
some studies suggesting metformin enhanced GLP-1 concentrations but had no 
effects on GIP concentrations296-298. Whereas studies of patients with T2DM on 
combination treatment with metformin and sitagliptin (DPP-IV inhibitor) showed 
higher GIP and GLP-1 concentrations with the combination or sitagliptin alone but 
not with metformin alone294,300.  
 
The precise mechanism(s) through which metformin increases GLP-1 
concentrations in the plasma remain unclear. Although improved glycaemic control 
and reduced metabolic risk factors may partially restore the diminished incretin 
effect in T2DM, data from the DIRECT study suggested that GLP-1 concentrations 
were higher in metformin treated patients despite adjusting for HbA1c, fasting 
glucose and lifestyle factors, suggesting an independent effect of metformin in 
addition to the glucose lowering properties. Treatment with delayed release 
metformin showed similar levels of glucose reduction and enhanced GLP-1 and 
PYY secretion compared to immediate release metformin despite 60% reduction in 
systemic exposure to metformin with the delayed release preparation.  This suggests 
a local action of metformin in the distal ileum mediated by gut hormone secretion 
which may contribute significantly to its glucose lowering effects299,394. DPP-IV 
inhibition by metformin has been proposed as another mechanism that enhances 
GLP-1 levels301,302. We also observed in our study a reduction in fasting/baseline 
DPP-IV activity although a causal relationship with the raised post-prandial GLP-1 
levels cannot be established. Cuthbertson et.al395 demonstrated that in patients with 
T2DM  under fasting conditions, a single dose of subcutaneous GLP-1 (7-36) amide, 
in combination with 1 gram of metformin,  resulted in reduced DPP-IV activity and 
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increased plasma active concentrations of the injected GLP-1 (7-36) amide than 
when GLP-1 was injected alone, suggesting metformin increases GLP-1 via 
inhibition of DPP-IV.  
Results from other studies contradict the DPP-IV inhibition concept and favour the 
notion that metformin directly enhances the synthesis of GLP-1. One previous study 
showed a dose dependent increase in active GLP-1 levels even in DPP-IV-deficient 
F344/DuCrj rats after treatment with metformin, suggesting a mechanism 
independent of DPP-IV inhibition281. Another study that employed in vitro methods 
demonstrated that metformin did not alter GLP-1 degradation suggesting that it did 
not act through DPP-IV inhibition396. Migoya et al397 showed that in healthy 
individuals without T2DM, 2 days of treatment with metformin (1 gram per day 
orally)  increased the total and active GLP-1 concentrations but had no effect on the 
other incretin hormone, glucose dependent insulinotropic polypeptide (GIP). 
Furthermore, it has been demonstrated that metformin treatment increases pre-
proglucagon gene (Gcg) expression in the large intestine of mice leading to 
increased total GLP-1 concentration397. Another recent study in mice has shown that 
metformin enhances expression of the GLP-1 receptor through peroxisome 
proliferator-activated receptor-α (PPAR-α)398. 
GLP-1 is rapidly degraded by the enzyme DPP-IV secreted from endothelial 
capillaries of the intestinal mucosa. Nearly 75% of GLP-1 is inactivated before it 
enters the systemic circulation399. There are arguments for and against GLP-1 
mediation as the sole or major therapeutic action of DPP-IV inhibition399,400. It has 
been proposed that endogenous GLP-1 exerts immediate local effects in the gut and 
hepatic portal bed to stimulate hypothalamic neural pathways for insulin secretion, 
which occurs before degradation by DPP-IV. Therefore DPP-IV inhibition only 
protects the endocrine route but not the important neural pathways for insulin 
secretion399. The synergistic action of metformin and DPP-IV inhibitor combination 
therapy in T2DM is recognised to result in superior glycaemic control compared 
with the cumulative individual maximal monotherapies401. Given the potency of 
DPP-IV inhibitors in reducing the serum DPP-IV activity by more than 80%, a small 
degree of further inhibition by metformin may not completely explain the superior 
glycaemic control46. Moreover, lack of postprandial rise in active GLP-1 is a 
 170 
recognised problem in patients with T2DM402. Therefore, the ability of metformin to 
enhance endogenous GLP-1 secretion and the unidentified benefits of DPP-IV 
inhibition in addition to enhancing GLP-1 in the circulation would seem as a 
favourable explanation for this synergism. 
 
There were no significant changes in ghrelin levels before and after metformin 
treatment in our study. These results are in contrast to a previous study from our 
research unit which demonstrated that patients with T2DM on metformin 
monotherapy exhibit a prolonged fall in ghrelin concentrations after a mixed meal 
compared with matched controls on diet alone307. The study described above was a 
cross-sectional study and ghrelin levels were not studied pre and post metformin 
treatment in the same group of patients which may account for some of this 
variation. Similarly, another study has shown that four months of treatment with 
metformin but not pioglitazone reduced ghrelin levels after a glucose load despite 
similar reductions in HbA1c in both groups308. However, subjects in that study had 
longer duration of diabetes and the majority were already on sulphonylureas. Other 
studies have shown contradictory results suggesting an increase in ghrelin levels 
after metformin treatment306,309. Douge et al306 showed that ghrelin levels increased 
after 6 weeks of metformin treatment in obese patients with T2DM  but this was not 
accompanied by changes in hunger and fullness scores. There were variations in the 
individual responses to ghrelin in our study; we are therefore unable to comment on 
any trends in ghrelin levels in individuals on metformin therapy.   
  
The strengths of our study include testing the effects of long term metformin 
treatment on a clinically appropriate patient group (obese patients with drug naive 
T2DM) and increased frequency of blood sampling after a standard meal. Although 
the postprandial peak of GLP-1 concentration is usually seen between 60 to 120 
minutes, we sampled blood for a longer duration to see if the observed effects were 
sustained and to detect any changes in the other variables (DPP-IV and ghrelin). We 
did not measure GIP due to lack of reliable GIP assay locally at the time of this 
study and there was insufficient evidence from many studies to suggest any changes 
in GIP concentrations with metformin treatment in T2DM. The small sample size 
and the significant variation among individuals in the postprandial responses of 
GLP-1, ghrelin and DPP-IV activity are possible limitations. However, a previous 
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study with a sample size of 8 was shown to have 90% power to detect a 25% 
difference in DPP-IV activity at the 5% significance level 302. Having a placebo arm 
may have strengthened our study further, however we felt it would be unethical to 
withhold treatment in any of our subjects given their HbA1c result.   
 
In summary, three months or more of metformin monotherapy in obese patients with 
T2DM is associated with significantly increased postprandial GLP-1 levels and 
reduced fasting DPP-IV activity. Previous studies have suggested no significant 
changes in GIP concentrations. The pleotropic effects of metformin on the entero-
insular axis may represent yet another important mechanism underlying its glucose 
lowering properties. 
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Chapter 7 
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7.1 Summary of results  
 
Study 1 
We demonstrate that acute GIP infusion in a fasting state under hyperglycaemic 
clamp conditions stimulated insulin secretion in the lean, obese and obese subjects 
with IGR, whereas its insulinotropic action was significantly impaired in obese 
patients with T2DM, consistent with results from previous studies. Additionally, the 
integrated insulin concentrations (AUC) during GIP infusions correlated negatively 
with fasting plasma glucose for all subjects in the study, indicating a gradual decline 
in insulin secretion with GIP infusions in individuals with higher fasting plasma 
glucose levels. 
 
GIP infusion reduced plasma NEFAs, concomitantly increasing SAT triacylglycerol 
(TAG) content in obese patients with T2DM. This anabolic effect was not observed 
in the lean, obese or obese patients with IGR. In contrast, while GIP stimulated 
insulin secretion in the lean, obese and obese patients with IGR, its insulinotropic 
action was not observed in obese patients with T2DM. The reduction in NEFA 
concentration with GIP correlated with adipose tissue insulin resistance for all 
subjects. There were no significant gene expression changes in key SAT lipid 
metabolism enzymes.	Thus, in obese patients with T2DM, there is a dissociation of 
the effects on GIP on beta cells and adipocytes, with blunted insulinotropic but 
preserved lipogenic actions respectively. 	
	
Baseline plasma concentrations of TNF-a, MCP-1 and osteopontin were 
significantly higher in the obese T2DM group compared to the lean control group. 
The gene expression of TNF-a in SAT of obese T2DM subjects increased 
significantly after GIP infusion compared to placebo and similar trends were seen in 
obese subjects with IGR with no change in lean and obese normoglycaemic subjects. 
In contrast, MCP-1 gene expression was higher with GIP infusion in lean and obese 
but was not different in IGR or T2DM. There was no change in osteopontin and 
adiponectin gene expression with GIP or placebo infusions in any of the groups. 
Summary of results for study 1 are shown in Table 7.1. 
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Study 2 
Three or more months of metformin monotherapy in obese patients with T2DM is 
associated with a significant increase in postprandial active GLP-1 concentration, 
which is maintained for up to six hours after a standard meal. We also observed an 
increased trend in fasting GLP-1 levels although the difference was not statistically 
significant. DPP-IV activity was significantly lower in the fasting state after 3 
months of metformin therapy. Post prandial DPP-IV activity seemed to be lower 
after metformin treatment but this difference was not statistically significant. There 
was no change in ghrelin levels post metformin treatment. 
 
7.2 Limitations of studies 
We acknowledge the small number of subjects in each group. There was limited 
pilot data in humans prior to initiation of this study and subsequently published 
human studies on GIP infusion had similar number of subjects between 6-8 
participants per group189-191. Subjects other than controls had very high BMI 
therefore the findings may differ in less severely obese individuals with BMI < 40 
kg/m2. Only male subjects were recruited for GIP infusion studies to avoid the 
confounding effects of sex steroid fluctuations due to menstrual cycle, menopause 
and hormone replacement therapy in female subjects. Results may therefore vary in 
female subjects. Some subjects in obese IGR and T2DM group were on medication 
for hypertension and dyslipidaemia. Unrecognised interactions between anti-
hypertensive or lipid modifying medication and effects of GIP cannot be excluded.   
 
We acknowledge assessing the effects of GIP on glucagon secretion would have 
been a useful measure but we did not measure this as our experiments were 
conducted under hyperglycaemic clamps where glucagon is usually supressed. GIP 
infusion may affect enzyme activity rather than gene expression and therefore 
results of LPL, ATGL and HSL may vary if activity was measured. Unfortunately, 
the effects of GIP on IL-6 gene expression could not be assessed in our experiments 
at the time of this study due to technical difficulties with primers that could not be 
optimised to appropriate conditions to carry out qPCR.  In study 2, we did not 
measure GIP due to lack of reliable GIP assay locally at the time of this study and 
there is insufficient evidence from several studies on any changes in GIP 
concentrations with metformin treatment in T2DM. 
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Table 7.1 Summary of results for study-1 
 
 
Effects of GIP  
vs placebo 
 
 
Lean 
 
Obese 
 
Obese IGR 
 
Obese T2DM 
Plasma  
 
Insulin 
 
 
­ 
 
­ 
 
­ 
 
« 
 
NEFA 
 
 
« 
 
« 
 
« 
 
¯ 
 
Adipokines 
 
« 
 
« 
 
« 
 
« 
 
SAT  
 
Triacylglycerol 
content 
 
 
« 
 
« 
 
« 
 
­ 
 
Gene expression 
of SAT enzymes 
 
 
« 
 
« 
 
« 
 
« 
 
Gene expression 
of SAT adipokines 
 
 
­ MCP-1 
 
­ MCP-1 
 
« 
 
­ TNF-a 
 
	
Table 7.1: Summary of results on the effects of GIP vs placebo in four groups.           
« indicates no difference in effects compared to placebo.  
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7.3 Physiological role of GIP: an overview 
GIP is likely to have many different actions in multiple peripheral tissues. Although 
its’ principal action was thought to be in postprandial glucose regulation through 
insulin secretion, blocking GIP signalling surprisingly caused only a minor 
disturbance in glucose regulation with benefits on other metabolic profiles 
questioning its primary physiological role in the pancreas. Its role in adipose tissue 
metabolism has gained more understanding in the last two decades but most of the 
evidence is from animal studies. Although there is some evidence to suggest it is 
pro-adipogenic in humans, the results are not consistent in all subject groups and 
there are very few studies in humans to date. New evidence from animal studies 
suggests GIP may have beneficial effects in bone and brain but this concept is at a 
very early stage. In this section, I have discussed the role of GIP in specific tissues 
and the implications in healthy individuals compared to those with T2DM.  
 
Effects in pancreas: is this the primary physiological role of GIP? 
In healthy individuals, GIP mediates the bulk of incretin effect thus, playing an 
important role in post prandial glucose metabolism403. Both incretin hormones 
enhance insulin biosynthesis and b cell survival. Whilst GLP-1 retains its 
insulinotropic activity in people with T2DM, GIP has a blunted effect despite 
preserved secretion of GIP in these individuals. Interestingly, the effects of GIP 
differ from GLP-1 on glucagon secretion. We are now aware that GIP increases 
glucagon secretion in healthy individuals during fasting and hypoglycaemic 
conditions but not during hyperglycaemia118,119. Similar effects of GIP on glucagon 
were also observed in patients with type 1 diabetes404. Although glucagon secretion 
by GIP appears to be a protective mechanism to stabilise glucose in healthy 
individuals, it may worsen glucose intolerance in people with T2DM405. 
Additionally, GIP was shown to enhance another islet cell hormone known as 
pancreatic peptide (PP) secreted from PP cells which is also elevated along with 
glucagon in T2DM406. GIP therefore seems to have effects on multiple cells in 
pancreatic islets that can influence glucose metabolism. Whilst GIPR is down 
regulated in hyperglycaemic states with loss of GIP sensitivity in b cells for insulin 
secretion, the action of GIP in a cells and PP cells may be retained leading to 
increased glucagon and PP secretion and worsening of glucose intolerance in 
T2DM.  
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Studying the metabolic effects through GIP signal blockade helps to understand the 
overall contribution of GIP in glucose regulation. Most studies in GIPR knockout 
mice showed that glucose tolerance and insulin sensitivity had improved on high fat 
diet in contrast to what would have been expected with the loss of insulinotropic 
activity from GIP135,256,257,407. As the metabolic profile improves with inhibition of 
GIP signal, it is possible that the negative effects of GIP inhibition at pancreas are 
compensated by beneficial effects in other tissues leading to improved beta cell 
function and insulin sensitivity due to removal of triacylglycerols from pancreas, 
liver and muscle. Weight loss as a result of reduction in adiposity may also 
ameliorate insulin resistance. Data from these studies indicate that effects of GIP in 
pancreas may not be as vital as it was thought to be in the past. Whilst other glucose 
regulatory mechanisms and GLP-1 may compensate for glucose metabolism in 
healthy individuals, preventing GIP action in a and PP cells of pancreas would seem 
beneficial in T2DM with reduction in counter regulatory hormones. 
	
The effects of GIP in adipose tissue: Is it harmful or beneficial? 
Storage of energy deposits in adipose tissue is an adaptive mechanism of 
evolutionary importance. Perhaps the effects of GIP in adipose tissue was a 
protective mechanism during the times of under-nutrition and famine which may 
have become maladaptive with surplus dietary intake. The excess fat deposition by 
GIP seen in animal studies was only with high fat diets and not observed with 
normal diet. Demonstration of fat ingestion as the most potent stimulator of GIP 
secretion in animals89,98,99 and humans88,97 indicates a significant role for GIP in post 
prandial lipid metabolism. The effects of GIP on enhancing LPL activity seen in 
animal studies were not observed in the limited human studies. The most convincing 
evidence in humans is the effect of GIP on NEFA metabolism. Most studies 
(including our experiments) show a consistent reduction in plasma NEFA with GIP 
suggesting a re-esterification process in adipose tissue178,188-192.  If the source of 
NEFA reaching adipocyte endothelium for re-esterification is derived from diet, one 
would expect a reduction in plasma triacylglycerols in the post prandial state. 
However, in studies using meal experiments, surprisingly there was no reduction in 
plasma triacylglycerols levels with GIP infusions196,408. GIP mediated effects on 
lipid metabolism via peripheral lipid clearance in humans warrants further 
examination.   
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GIP may modulate other fat deposits that leads to excess liver and visceral fat 
deposits165,166. In support of this, results from a large cross-sectional study of Danish 
men demonstrated an association between higher stimulated levels of GIP (during a 
glucose tolerance test) and a metabolically unfavorable phenotype (higher visceral: 
subcutaneous fat distribution and a higher waist-hip ratio). This study also 
demonstrated that higher fasting GIP levels were associated with lower LDL 
cholesterol (men and women) and higher HDL in women. 167. Whilst clearance of 
LDL by GIP from circulation is beneficial in reducing the lipotoxicity, unhealthy 
distribution of fat in in visceral adipose tissue potentially mediated by GIP would 
have long term deleterious effects. 
 
It is possible that GIP acts as a regulator of fat deposits. In addition to its lipogenic 
action, it is thought to increase lipolysis and induce inflammatory adipokines174-176.  
These lipolytic effects of GIP are enhanced with insulin deficiency177. In healthy 
individuals under normal diet, these counter regulatory effects of GIP in adipose 
tissue may be balanced without excess fat deposition. In individuals with chronic 
excess high fat consumption and obesity the balance may tilt more towards 
increased fat deposition. In people with T2DM with lack of insulin secretion on high 
fat diets, GIP may lead to exaggerated fat deposition and inflammation (Figure 7.1). 
 
We know that visceral fat is a major source of NEFA and chronic elevations of 
NEFAs interfere with insulin signalling, inhibiting glucose uptake and glycogen 
synthesis60,61. Free fatty acid (NEFA) uptake is higher in visceral fat compared to 
subcutaneous fat409 and visceral fat deposits are more susceptible to lipolytic stimuli 
such as catecholamines410,411 and this lipolytic process is enhanced in the absence of 
insulin. Whilst clearance of NEFA from circulation by GIP may be beneficial, 
increasing subcutaneous and potentially visceral fat deposits with over-nutrition 
would result in fat storage in metabolically unfavourable sites.  These fat deposits 
can be a constant source of excess NEFA in circulation. We speculate that with 
consumption of energy dense high fat diet, the effects of GIP in adipose tissue may 
lead to a vicious cycle of fat storage and lipolysis releasing excess NEFA which 
further exacerbates insulin resistance and obesity (Figure 7.2). 
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Figure 7.1 In healthy people, GIP acts on its receptors on beta cells and adipocytes 
to promote insulin secretion (insulinotropic action) and lipid deposition (adipogenic 
action) (left figure). In obesity, with consumption of an energy-dense, higher fat 
diet, there is enhanced insulin secretion (which may help overcome peripheral 
insulin resistance) and increased lipid deposition (which will further enhance fat 
storage) (middle figure). In T2DM, the effects of GIP on beta cell are impaired with 
reduced insulin secretion; the effects on the adipocyte seem to be preserved further 
promoting lipid deposition (right figure). 
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Figure 7.2 Pro-adipogenic effects of GIP in subcutaneous and visceral adipose 
tissue (SAT/VAT) with high fat diet consumption leading to a vicious cycle of fat 
deposition and lipolysis exacerbating adiposity and insulin resistance. 
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Does GIP have beneficial effects in other tissues? 
The role of incretin hormones in bone physiology is a fairly new concept412.  GIP 
appears to have direct beneficial effects in bone with GIPR expressed in osteoblasts 
and osteoclasts127-129. To date there are very few studies that have evaluated the 
effects of GIP on human bone metabolism. Experiments in healthy male subjects 
showed that glucose when given orally leading to incretin secretion, the peaks in 
GIP were associated with turnover markers that indicate reduced bone resorption 413.  
Similarly, even exogenous GIP infusions in healthy males reduced circulating 
markers of bone resorption414. Polymorphisms in GIPR were associated with 
reduction in bone mineral density and increased fracture risk in post-menopausal 
women415. Treatment of mice with stable GIP analogues have shown to reduce 
osteoclast formation and bone resorption suggesting there may be potential benefits 
on bone with a GIP agonist treatment. Based on available data the beneficial action 
of GIP appears to be is mainly through reduction bone resorption. There may be 
some favourable effects of GIP on the brain but all the evidence is derived from 
animal models suggesting a role in neural progenitor cell proliferation 121. 
 
GIP: A friend or foe? 
GIP appears to be multi-dimensional in its action with positive and negative effects 
in many tissues. Whilst the insulinotropic action of GIP remains important in 
regulating glucose metabolism, the effects of glucagon stimulation in healthy 
individuals and people with T2DM needs further evaluation. The role of GIP in 
adipose tissue metabolism seem to differ in healthy and diabetes states as we have 
observed in our study. The pro-adipogenic effect of GIP is mostly by enhancing 
NEFA incorporation into adipose tissue. It is not completely clear if these effects of 
GIP are deleterious or may even have some benefits in reducing lipotoxicity. GIP 
also has lipolytic properties and may increase pro-inflammatory adipokines. These 
effects appear to be more pronounced with insulin deficiency. Recent studies 
suggest beneficial effects of GIP in bone and brain although the evidence in this area 
is still premature. In view of both beneficial and undesirable effects, targeting GIP 
either by blocking or enhancing its action is likely to compromise some of its 
important actions or cause deleterious effects making it difficult to manipulate this 
hormone in therapeutics. 
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7.4 Therapeutic potential of GIP 
 
Therapeutics of GIP is an interesting area as both GIP agonists and antagonists have 
been developed in the recent years and were used in animal models. These are 
discussed in detail in Chapter 1, section 1.3 and 1.4. Amongst the GIP agonists, the 
truncated analogue, GIP 1-30 appears to be effective in insulin secretion and was 
also shown to have longer term benefits in b cell preservation416. Single molecule 
drugs which are dual activators of GIP and GLP-1 receptors are also currently in 
development and have been shown to be beneficial and both glucose metabolism 
and weight reduction in animal models417,418.  
 
Contrary to the above, several observations in animal models support the concept of 
inhibition of GIP action to reduce dietary induced obesity along with improvement 
in metabolic parameters52 (discussed in Chapter 1 section 1.10). GIP antagonism 
could offer a potentially novel approach in the future for treatment of dietary 
induced obesity and its complications such as T2DM87. However, it is important to 
understand the actions of GIP on other vital organs like brain and bone in humans. 
Recent evidence from animal studies show that long term inhibition of GIP may 
have some adverse effects on cognitive function and bone remodelling.  
 
Studies evaluating the effects of GIPR knockout in other tissues  showed that Gipr–/–  
mice had impaired learning, reduced synaptic activity and neurogenesis419. 
Prolonged GIP receptor activation with GIP agonists had improved cognitive 
function and hippocampal synaptic plasticity in high fat fed mice420. GIPR knockout 
mice were observed to have earlier age related changes and altered bone turnover421. 
Alteration in trabecular bone volume and reduction in bone strength was also seen 
with GIP inhibition422,423. A study evaluated the effects of GIPR knockout in mice in 
multiple tissues and suggested that partial receptor knockout did not change glucose 
tolerance but reduced obesity with preservation of bone volume as opposed to 
reduction in bone volume with complete GIPR knockout407. Therefore, the intended 
improvements in metabolic profile by GIP antagonism may compromise the benefits 
in bone and brain tissues which needs further careful evaluation. 
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7.5 Future direction of GIP research 
 
 
Results presented in this thesis and recent evidence from other studies on the effects 
of GIP in humans raise additional questions that need to be addressed in future 
studies. It is now evident that the effects of GIP in human adipose tissue may vary 
with obesity and in T2DM. It is important to evaluate the effects of GIP in a larger 
group of patients with T2DM to establish whether the effects we observed on lipid 
deposition can be replicated. It is difficult to dissect the insulin independent effects 
of GIP in normal physiological circumstances therefore testing this concept in 
insulin deficient states would be of significant value.  The effects of GIP on 
glucagon secretion in T2DM which may alter glucose tolerance needs further 
evaluation.  
 
The pro-adipogenic effects of GIP were only seen in animals with high fat diet 
indicating GIP mainly alters post prandial lipid metabolism. The source of NEFA 
that undergo re-esterification in human studies is unclear. Studies using stable 
isotopes help to study the dynamic changes in lipid metabolism424. Tracers [U-13C] 
palmitate and 13C-carbon labeled substrates have been used to assess NEFA 
metabolism425,426. Future GIP infusion studies using tracer labelled test meals and 
subsequent mass spectrometry analysis of NEFA would give better understanding 
into the synthesis and uptake of NEFA in fasting and postprandial states. GIP may 
promote fat deposition in visceral adipose tissue and liver but this is not proven and 
therefore the use of isotope traces methods would also help to evaluate this aspect. 
 
In the light of GIP agonists and antagonists being considered as therapeutic agents 
for diabetes and obesity, the effects of GIP in central nervous system and bone 
metabolism in humans needs further evaluation. 
 
 
	
	
	
	
 184 
	
	
	
	
	
	
	
	
	
	
	
 
 
 
 
Appendices 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
 185 
Appendix A 
 
Hyperglycaemic clamp protocol 
 
 
Equipments required 
YSI Glucose analyser       
Pump for glucose infusion    
Pump for GIP/placebo infusion 
Consumables 
Green Veflons, Venflon dressing packs Chlorprep, BD –Q –syte, 3 way taps                         
Syringes 1 ml, 2ml, 5ml, 10 ml, 20 ml, infusion sets, 20% glucose (500 ml bags), 
0.9% normal saline (1000 ml bags) and GIP product in ampules  
Blood collection tubes (serum separator, EDTA, lithium heparin and fluoride 
oxalate). 
 
Aim: To maintain blood glucose concentration as close as possible to 8mmol with a 
narrow limit of 0.5 mmol/l on either side. 
 
Step -1 
Priming dose of glucose 120mg/kg to 130mg/kg in 5 minutes 
Example 1 
If 120mg/kg body weight is used for 70 kg man: 120x 70 /1000 = 8.4 g to be given 
in the first 5 minutes which is to be infused as 20% glucose. 
 
The calculations for the volume of 20% glucose to be given is as follows: 
Concentrated glucose is available as 20% glucose infusion in 500 ml volume bags 
1ml of 20% glucose = 0.2 gram of glucose  
5 ml of 20% glucose = 1gram of glucose  
8.4 g of glucose would require 8.4 x 5ml of 20% glucose = total 42 ml 
To give 42 ml of 20% glucose in 5 minutes the rate of infusion (ml/hr) to be set on 
the infusion pump is 42 x 12 ml/ hour = 504 ml/hour  
Final formula   
Rate 20 % glucose of infusion (ml/hr) = (120 x wt (kg) /1000) x 5 x 12 (ml/hr)   
 
 186 
Examples of infusion rates in first 5 minutes for glucose load of 120mg/kg weight 
Participant’s weight 
in kg 
Glucose required in 
grams 
Millilitres of 
20% glucose in 
 5 minutes 
Rate of 20% 
glucose 
infusion in 
mls/hr 
 
60 7.2 36 432 
65 7.8 39 468 
70 8.4 42 504 
75 9.0 45 540 
80 9.6 48 576 
85 10.2 51 612 
90 10.8 54 648 
95 11.4 57 684 
100 12.0 60 720 
110 13.2 66 792 
120 14.4 72 864 
130 15.6 78 936 
140 16.8 84 1008 
150 18 90 1080 
160 19.2 96 1152 
170 20.4 102 1224 
180 21.5 108 1296 
190 22.8 114 1368 
200 24 120 1440 
 
 
 
Examples of infusion rates for first 5 minutes with higher glucose load of 130mg/kg 
is are shown below:  
 
Final formula for this would be (130 x wt (kg) /1000) x 5 x 12 (ml/hr)   
 
Participant’s 
weight in kg 
Glucose required 
in grams 
Millilitres of 
20% glucose in   
5 minutes 
Rate of 20% 
glucose infusion 
in ml/hr 
60 7.8 39 468 
65 8.45 42 504 
70 9.1 46 552 
75 9.75 49 588 
80 10.4 52 624 
85 11.0 55 660 
90 11.7 59 708 
95 12.3 62 744 
100 13.0 65 780 
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Step 2  
Variable 20% glucose infusion  
 
After 1st five minutes of high dose priming infusion, the rate of infusion is lowered 
to variable 20% glucose infusion from 1mg/kg/min to 15mg/kg/min or higher 
aiming to achieve a steady state glucose of 8 mmol/l by 30 minutes. At the end of 30 
minutes, GIP at 2pmol/kg/min or 0.9% saline (placebo) is started and continued for 
4 hours Simultaneously, the variable rate 20% glucose infusion is continued for the 
whole experiment aiming for a blood glucose close to 8mmol. 
 
Example 
For a 70-kg person at 1mg/kg/min will be 70mg/min at the rate of 21ml/hr 
and 15 mg/kg/min will be 1050mg/min, at the rate of 315mls/hr. 
 
Calculation on an excel sheet for variable glucose infusion based on weight are 
shown below for a subject weighing 70kg. 
 
Glucose Infusion Rate 
  
Infusion of 20% glucose (ml/hr) 
mg/kg/min mg/min mg/hr 
 1 70 4200 21 
1.5 105 6300 31.5 
2 140 8400 42 
2.5 175 10500 52.5 
3 210 12600 63 
3.5 245 14700 73.5 
4 280 16800 84 
4.5 315 18900 94.5 
5 350 21000 105 
5.5 385 23100 115.5 
6 420 25200 126 
6.5 455 27300 136.5 
7 490 29400 147 
7.5 525 31500 157.5 
8 560 33600 168 
8.5 595 35700 178.5 
9 630 37800 189 
9.5 665 39900 199.5 
10 700 42000 210 
10.5 735 44100 220.5 
11 770 46200 231 
11.5 805 48300 241.5 
12 840 50400 252 
12.5 875 52500 262.5 
13 910 54600 273 
13.5 945 56700 283.5 
14 980 58800 294 
14.5 1015 60900 304.5 
15 1050 63000 315 
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Appendix B 
 
GIP product- Certificate of analysis 
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Appendix C 
 
Additional details on gene expression qPCR techniques 
 
Methods for gene expression of lipid enzymes LPL, ATGL and HSL  
Total RNA was extracted from adipose tissue using RNeasy Lipid Tissue Mini Kit 
(Qiagen Ltd, UK) following the manufacturer’s instructions. cDNA was generated 
using SuperScript VILO cDNA Synthesis Kit (Invitrogen, UK). Quantitative PCR 
was performed using a Bio-Rad CFXConnect Real-time PCR system (Bio-Rad 
Laboratories Ltd., UK). The PCR reactions were performed in triplicate for each 
sample, each containing predesigned TaqMan Gene Expression Assays (optimized 
mixture of primers and probes) and TaqMan Gene Expression Master Mix, with the 
manufacturer’s instructions on the thermal cycling conditions (Applied Biosystems, 
UK).  
Negative controls omitting reverse transcriptase were included. These assays were: 
Hs00386101_m1 (pnpla2 encoding ATGL),  
Hs00193510_m1 (lipe encoding HSL),  
Hs00173425_m1 (lpl encoding LPL).  
Relative gene expression was quantified using ΔΔCq method normalized for the 
transcript level of a housekeeping gene β-actin (Hs99999903_m1). 
qPCR thermal cycling conditions used SAT gene expression of lipid enzymes                   
(Applied Biosystems, UK):  
• Hold 50°C, 2 min 
• Hold 95 °C, 10  
• 95 °C, 15 sec  
• 60 °C for 1min 
• Go to step 3 and repeat 39 cycles. 
qPCR thermal cycling protocol used SAT gene expression of adipokines 
(BioRAd) 
 
• 95oC for 3 minutes 
• 95oC for 30 seconds 
• 58oC for 30 seconds, temperature differed for different gene primer pairs. 
• 72oC for 30 seconds 
• The specificity of amplification reactions was confirmed by melt curve 
analysis.   
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Primer sets used for SAT gene expression of adipokines (TNF-a, MCP-1, 
osteopontin and adiponectin) 
Primer sets used with their respective annealing temperatures were:  
 
TNF-alpha:  
Forward: 5’CTCTTCTGCCTGCTGCACTTTG3’ 
Reverse: 5’ATGGGCTACAGGCTTGTCACTC3’ 
Annealing temperature: 62oC 
 
Osteopontin: 
Forward: 5′TTGCAGCCTTCTCAGCCAA3’ 
Reverse: 5′GGAGGCAAAAGCAAATCACTG3’ 
Annealing temperature: 65oC 
 
MCP-1: 
Forward: 5’TCAGCCAGATGCAATCAATGCC3’ 
Reverse: 5’GGTGGTCCATGGAATCCTGA3’ 
Annealing temperature: 62.5oC 
 
Adiponectin: 
Forward: 5’GACCAGGAAACCACGACTCA3’ 
Reverse: 5’CCTTAGGACCAATAAGACCTGGA3’ 
Annealing temperature: 58oC 
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Appendix D 
 
Visual analogue scale (VAS) 
 
 
 
PARTICIPANT:                                                 DATE:  
TEST DAY: Visit 1/ visit 3                                Time 
  
INSTRUCTIONS FOR PARTICIPANTS:Please read each question and then 
put a mark through the line that best represents how you are feeling in relation 
to that sensation at this moment.  
 
EXAMPLE: 
How TIRED do you feel at this moment?  
Not at all tired ________________________________________Extremely tired  
 
 
PLEASE ANSWER THE FOLLOWING QUESTIONS:  
How HUNGRY do you feel at this moment?  
Not at all hungry______________________________________Extremely hungry 
 
How STRONG is your desire to eat at this moment?  
Not at all strong_______________________________________Very strong 
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